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During infection, poxvirus makes host cells conducive for viral replication by causing 
host shutoff that is marked by global inhibition of host protein synthesis. Host shutoff facilitates 
the reallocation of cellular resources for viral replication and evasion of host antiviral immune 
responses. However, it poses a challenge for continuous synthesis of crucial cellular proteins and 
viral proteins that are important for viral replication. It is unclear whether and how viral and 
specific cellular proteins are selectively synthesized during poxvirus-induced host shutoff. 
In this dissertation, we elucidated that vaccinia virus boosts viral post-replicative protein 
synthesis by using the 5'-poly(A) leader at the 5'-UTR. Vaccinia virus has evolutionarily 
optimized the length of the poly(A) leader, and uninterrupted poly(A) leader is required for 
promoting poxvirus protein production. During vaccinia virus-induced shutoff, poly(A) leader 
stipulates viral post-replicative mRNAs an adaptive mechanism to translate efficiently. The 
poly(A) leader translation was not mediated by an internal ribosome entry site (IRES) mode, 
albeit poly(A) leader mediates cap-independent mode of translation. Through further 
investigation, we uncovered a cellular RNA-binding protein La-Related Protein 4 (LARP4) that 
was repurposed to augment vaccinia virus post-replicative mRNA translation. During VACV 
infection, LARP4 is enriched in the virus factory where VACV post-replicative mRNAs are 
translated. A decrease of LARP4 protein level reduces VACV replication, blocks post-replicative 
protein synthesis, and decreases 5'-poly(A) leader mediated translational advantage. Further 
studies showed that LARP4 is vital for the cap-independent mode of translation from poly(A) 
leader.  
We also showed that infection of vaccinia virus, the prototypic poxvirus, induced 
selective synthesis of cellular proteins involved in oxidative phosphorylation. Using 
  
simultaneous RNA-seq and ribosome profiling, we determined the mRNAs encoding proteins for 
oxidative phosphorylation complexes had increased relative translation efficiency. Indeed, 
vaccinia virus infection increased the activity of oxidative phosphorylation. Inhibition of 
oxidative phosphorylation function suppressed vaccinia virus replication significantly. Moreover, 
the mRNAs of oxidative phosphorylation have short 5'-UTRs with a less complex secondary 
structure that could confer oxidative phosphorylation mRNAs a translational advantage in 
vaccinia virus-infected cells during host shutoff. 
Together, these studies advanced our understanding of how vaccinia virus selectively 
synthesizes viral and cellular proteins for efficient viral replication during host shutoff. The 
findings may facilitate the development of novel anti-poxvirus strategies and the improvement of 
poxviruses as vaccine vectors and anti-cancer agents. 
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Chapter 1 - Introduction 
 Poxvirus 
 Viruses and the importance of virology 
Viruses (from Sanskrit visah and Latin vīrus, both meaning poison) are ubiquitously 
present microscopic infectious agents that require host cells in order to replicate (1). Viruses 
infect both eukaryotes (Animals, Plants, and Fungi) and prokaryotes (Archaea and Bacteria), 
utilizing host machineries to conduct different phases of the replication cycle, thus making them 
an obligatory intracellular parasite. Viruses have genomic material (DNA or RNA) inside a 
protein coat called a capsid and—in some cases—an extra layer of lipid envelope.  
The study of viruses (virology) is important not merely due to them being the most 
abundant lifeforms—with an estimated 1031 viruses on earth (2,3)—but also because viruses are 
imperative for maintaining the biogeochemical cycle by killing 20% of the microbial biomass 
daily in the ocean. Viruses through causing diseases in plants, animals, and humans drive the 
evolution of both host and virus (4). Virology contributes to knowledge regarding viruses and the 
cells they infect. In fact, the study of viruses provides an instrumental understanding of various 
basic mechanisms such as DNA replication, transcription, translation, RNA processing, and 
immunology, among others  (5–8). Throughout history, viral diseases have crippled the world 
and the greatest threat is currently posed by diseases from viruses such as HIV, Ebola, Nipah, 
measles, monkeypox, influenza, MERS-CoV, and Zika. Basic knowledge regarding these 
pathogens provides scientists with the tools necessary to develop vaccines against these deadly 
viruses and therapeutics for the diseases they cause. Insight into important fundamental aspects 
of viruses has also led to the development of beneficial applications of viruses as tools against 
non-infectious diseases including cancer, and anti-microbial resistance (AMR). Notable 
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examples include therapies such as oncolytic virotherapy against various cancers and phage 
therapy against AMR (9,10). The scientific capital gained from studying viruses will have 
broader applications in science and medicine, subsequently attributing to the discovery of new 
basic cellular mechanisms to broaden our horizon of knowledge.  
 Poxviridae virion structure and classification 
The virions of poxviruses are membrane-bound structures with diverse morphology, 
though they are mostly brick- or oval-shaped. The internal structures of virions consist of a 
walled dumbbell-shaped core flanked by lateral bodies. The size of the prototypic poxvirus-
vaccinia virus (VACV) virion is 360 x 270 x 250 nm (11). Furthermore, different forms of virion 
are produced that vary mainly in the outer membrane layers, including immature virion (IV), 
mature virion (MV), wrapped virion (WV), and extracellular enveloped virion (EV). IVs have a 
genome and core proteins encapsulated by a single membrane of crescent envelope. Further 
maturation of membrane proteins in IV form MV. When MVs acquire two extra membranes 
from the trans-golgi network, a WV with three membrane is formed. During egress, the outer 
membrane of the WV is fused with the outer plasma membrane to release two membraned EV 
(12).  
Poxviridae members have a broad host range that includes butterflies, moths, birds, 
sheep, cattle, crocodile, rabbit, swine, and humans. Based on this host range, they are classified 
into two subfamilies: Chordopoxvirinae and Entomopoxvirinae. Subfamily Chordopoxvirinae 
contains members infecting vertebrate hosts and are divided into 11 genera (Avipoxvirus, 
Capripoxvirus, Centapoxvirus, Cervidpoxvirus, Crocodylidpoxvirus, Leporipoxvirus, 
Molluscipoxvirus, Orthopoxvirus, Parapoxvirus, Suipoxvirus, and Yatapoxvirus). Members of 
the subfamily Entomopoxvirinae infect insect hosts and are classified into three genera based on 
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virion morphology, genome size, and host range (Alphaentomopoxvirus, Betaentomopoxvirus, 
and Gammaentomopoxvirus). Among the different genera of poxviruses, only Molluscipoxvirus, 
Orthopoxvirus, Parapoxvirus, and Yatapoxvirus genera can infect humans (12,13).  
Among the Poxviridae members that can infect humans, Orthopoxvirus is the most 
widely studied. The infamous variola virus (VARV)—the causative agent of smallpox—and 
monkeypox virus (MPXV)—the causative agent of monkeypox—belong to the Orthopoxvirus 
genus. Molluscum contagiosum virus (MOCV), belonging to the Molluscipoxvirus genus, causes 
a human skin disease called molluscum contagiosum (12). 
 Poxviridae genome and gene expression 
Poxviridae is a family of viruses that have a linear, non-segmented, double-stranded 
DNA genome with a unique feature of replicating in the host cell cytoplasm (12). The genome 
ranges from 130 to 375 kilobase pairs (kbp) in length with a hairpin loop at each terminus (14). 
To sustain cytosolic replication, transmission between hosts, and the evasion of the host immune 
system, approximately 150-300 proteins are encoded by the genomes of different poxviruses. 
They encode, among many others, enzymes responsible for viral DNA replication, transcription, 
mRNA modification-like capping, 2’O methylation, decapping, polyadenylation-, at least 15 
proteins for entry (4 for binding and 11 for fusion), and a plethora of immunomodulatory 
enzymes alongside protein kinases and proteases (15). Viral DNA replication, post-replicative 
gene transcription, translation, and virion assembly occur in distinct perinuclear compartments 
referred to as viral factories (VFs). VFs are specialized cytoplasmic foci formed by the 
accumulation of viral DNA from actively replicating virus that arise from a single poxvirus 
virion (16).  
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During infection, poxvirus virions attach and fuse with the cell membrane to release their 
core into the host cell cytoplasm (17,18). After the release of the core, poxvirus gene expression 
occurs in a temporal cascade manner (19,20). Immediately following the release of the core into 
the cytoplasm, early genes are transcribed, processed in the core, and diffused outside in the 
cytoplasm for subsequent translation by host ribosomes (21). Early genes encode for DNA 
polymerase, RNA polymerase, intermediate transcription factors, growth factors, and many 
immunomodulatory proteins (12). After early gene expression, core uncoating occurs followed 
by DNA replication in perinuclear spaces called VFs (22). The daughter strand of DNA is then 
used for the transcription of post-replicative genes (intermediate and late genes) (23). The 
intermediate gene encodes for late transcription factors, whereas late genes primarily encode for 
structural proteins—along with other core enzymes and early transcription factors—to be 
packaged in the virion (12). Virion assembly begins by the formation of a crescent around a 
dense mass of core protein known as the viroplasm (24). Maturation of this crescent is 
accompanied by the encapsidation of the IV genome form. Further proteolysis, the addition of 
membrane proteins to IV, and movement of IV outside VFs form MVs (25,26). MVs are the 
most abundant particle produced during infection. Some MVs are wrapped by a trans-Golgi-
derived membrane to form WVs (27), which travel to the cell surface via microtubules. The 
outer membrane of the WV fuses with the plasma membrane to release EV (12). 
 Diseases caused by poxvirus infection 
Poxviruses cause diseases in humans and other animals. VARV and MOCV exclusively 
infect humans, as the only known natural reservoir for these viruses are humans. Many other 
poxviruses can also infect humans though infections occurring via the zoonotic route from 
infected animals—monkeypox being a notable one. Tanapox virus and yabapoxvirus also cause 
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infections in humans and are transmitted via insect vector. Orf virus, pseudocowpox virus, 
bovine popular stomatitis virus, and seal parapoxvirus also infect humans via direct contact with 
occupational hazards. Lumpy skin disease virus (LSDV), myxoma virus (MYXV), and goatpox 
virus (GTPV) are some prominent poxviruses causing fatal diseases in their respective animal 
hosts, subsequently causing economic losses to global agribusiness. Prominent poxvirus-derived 
human diseases are discussed in the following section in greater detail (12). 
Smallpox 
Smallpox, which is caused by VARV, is the deadliest infectious disease in human 
history, killing 300-500 million people in the 20th century alone. Smallpox was transmitted by 
contact with infected individuals or contaminated objects, as well as inhalation of an airborne 
aerosol containing virus. Smallpox was endemic worldwide and was described as early as the 4th 
century in China. The fatality rate of smallpox ranged from 10-40%. From ancient times, 
continuous efforts were made to cure or prevent smallpox. One common prophylactic measure, 
known as “variolation”, was practiced in China by subcutaneously or intranasally inoculating 
smallpox scab material to unexposed individuals (28), which prevented future lethal VARV 
infection. 
In the late 17th century, English physician Edward Jenner observed that milkmaids who 
were exposed to cowpox virus (CPXV) during the milking process were protected from future 
VARV infection. This observation led him to conduct an experiment in 1796, where he 
inoculated material from the CPXV lesions of milkmaid to a boy susceptible to smallpox. After 
recovery from cowpox, the boy was challenged with VARV (29) and did not develop smallpox. 
This led to the discovery of a safe alternative process to variolation known as “vaccination”, with 
the cowpox material used for injections being the "vaccine”. The term comes from the Latin 
word vaccinae meaning "of or relating to cows”. 
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After Jenner’s findings, vaccine material for smallpox vaccination was obtained from 
poxvirus lesions from milkmaids as well as animals such as sheep, horses, and cows. This 
practice provided different vaccine materials to be mixed and potentially increased mutations in 
virus during transfer in different hosts. It seems that during this time, VACV emerged as the 
vaccine material. The original source of VACV remains debated, though recent findings indicate 
that horsepox virus (HPXV) is the most likely candidate (30). While Jenner used CPXV as a 
vaccine, the VACV that emerged from the practice of maintaining vaccine material provides an 
equal—if not higher—degree of effective protection from smallpox.  
In 1966, the World Health Organization (WHO) initiated a global vaccination campaign 
using VACV to eradicate smallpox. In 1980, the WHO announced the eradication of smallpox. 
Although smallpox is eradicated from nature, it still poses threats. In fact, in the early 21st 
century, a United States intelligence agency claimed that smallpox can potentially be used as a 
biological weapon (31). Presently, there remain two stocks of VARV in government laboratories 
in the USA and Russia (32). Unclaimed stocks of VARV have also been discovered in the past 
(33). Advancements in synthetic biology makes it possible for the de novo synthesis of VARV, 
as synthetic HPXV was recently generated from commercially synthesized DNA fragments (34). 
Hence, everyone must be vigilant about the possibility of smallpox re-emergence. 
Molluscum contagiosum 
Molluscum contagiosum is a cutaneous infection caused by MOCV, which causes 
painless round bumps on the skin and is mostly observed in children. In the US, there are 
200,000 cases per year, with this infection being implicated in 1 in 500 outpatient visits per year. 
MOCV is distributed throughout the world. The transmission of MOCV occurs by sexual contact 
as well as direct or indirect contact via shared towels. MOCV reinfection in other areas of the 
skin occurs frequently due to autoinoculation by scratching the original lesion. Unlike other 
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poxviruses, MOCV have a stringent constraint on replication. The reason researchers are unable 
to determine the molecular basis of such blockage is the inability to grow MOCV in tissue 
culture and the lack of an animal model (12).  
Monkeypox  
Monkeypox is a zoonotic disease caused by MPXV. It is endemic in Central and Western 
Africa. MPXV infects rodents and sometimes non-human primates; however, there has been 
zoonotic transmission to humans through cuts during the handling of bush meat, the inhalation of 
contaminated aerosol, or bites from infected animals. The natural reservoirs of MPXV are 
rodents; however, they were first discovered in 1958 when colonies of monkey were infected and 
thus, named monkeypox virus. The appearance of monkeypox disease is similar to smallpox, as 
records of human-to-human transmission exist. Although monkeypox in less fatal 
(approximately ~ 10%) than smallpox, there is neither proven treatment nor approved vaccine for 
monkeypox. However, smallpox vaccination can reduce the risk of monkeypox infection in 
humans and other animals. Since 1970, there have been numerous outbreaks in 10 countries in 
Africa, the USA, Israel, and the UK. The Democratic Republic of Congo has reported >1000 
cases of monkeypox annually since 2005, and, as per Nigeria, the outbreak remains uncontained. 
With outbreaks not being contained, the clinical similarity to smallpox, human-to-human 
transmission, and no proven treatment or vaccine, monkeypox represents a disease of grave 
concern since it can become an efficient human pathogen under favorable conditions (35,36).  
 Poxviruses as gene expression tools, vaccines vectors, and oncolytic agents 
The majority of research on orthopoxviruses has been performed on VACV, which is a 
member of the orthopoxviruses and shares genetic and antigenic similarities with other 
orthopoxvirus members, and is the reason why VACV was effectively used as a live vaccine to 
eradicate smallpox. This feat of eradicating smallpox is considered one of the greatest 
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achievements of vaccinology. Long after smallpox eradication, VACV remains intensively 
studied due to its role as a vector in vaccine development and cancer treatment—making its 
study imperative for biomedical research. VACV continues to be used in the laboratory as a tool 
to understand the basic virological properties of the orthopoxviruses and cells. VACV is a 
convenient and safe alternative to the more pathogenic viruses (e.g. VARV and MPXV); 
therefore, it is the most commonly studied orthopoxvirus (12).  
VACV may also be used in gene therapy, in the treatment of some cancers, and as a 
vector for rabies wildlife vaccines. Much of the work on oncolytic VACV development has 
focused on strains deficient for the viral thymidine kinase (TK) gene, many of which are further 
attenuated by the inactivation of additional virus genes, including viral growth factor (VGF) 
(37).  
VACV has many advantages over other expression systems, including the ease of 
isolating recombinant viruses, the broad host range, the ability to take large amounts of DNA, a 
high rate of protein expression, and its relative safety (38,39). All of these features make VACV 
a great tool for understanding the basic biology of cells, vaccine vectors, cancer therapeutics, and 
gene therapy agents  (38–40).  
 Poxvirus-induced Host shutoff 
Viruses are obligatory intracellular parasites that require a host cell to replicate. In many 
virus-infected cells, the synthesis of host macromolecules is adversely affected, whereas viral 
macromolecules are synthesized unsurpassed. This leads to the accumulation of viral proteins 
concurrently with a decline in global host protein synthesis, a phenomenon termed “host 
shutoff”. To induce host shutoff, the virus targets the various steps of gene expression: DNA 
synthesis, transcription, mRNA processing, and translation (41).  
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Viruses have a limited number of genes to perform replication. However, they do not 
possess genes for energy production and protein synthesis. Hence, all viruses are obliged to rely 
on host cells to co-share produced energy and translation machinery. In other words, competition 
exists between viruses and hosts to use the limited amount of energy molecules and cellular 
translation machinery available. This situation instigates the virus to induce rapid and profound 
decline in global host protein synthesis. Viruses encode proteins to induce host shutoff by 
affecting various steps of gene expression. Studies on virus-induced host shutoff to date have 
indicated that viruses allocate relatively fewer proteins to inhibit DNA synthesis and 
transcription; conversely, the viruses encode an arsenal of proteins to target mRNA processing 
and translation. One of the most energy-consuming processes in the cell is mRNA translation. By 
usurping host mRNA translation, viruses can gain competitive advantage over available energy 
and translational machinery, thereby enhancing the expression of viral mRNA to protein (42). 
During infection with a virus, host cells induce innate immune response as first line of 
defense, which then primes the adaptive immune response to clear any viral infection. Despite 
the host cell having an efficient, innate, and adaptive immunity-mediated antiviral response, 
viruses have evolved diverse strategies to impede, modulate, and evade such antiviral response. 
In addition to encoding multiple classes of immunomodulatory proteins, viruses also take 
advantage of host shutoff. The depletion of host proteins, including those involved in antiviral 
response, provides viruses with an additional strategy to counteract immune response. In addition 
to host shutoff and production of immunomodulatory proteins, poxviruses such as VACV have 
evolved strategies to diminish formation of pathogen associated molecular patterns (PAMPs) 
such as dsRNA and recognition of such PAMPs by host cell pattern recognition receptors (PRRs) 
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(43). The multiple strategies available to curb antiviral response allows for unchecked viral 
replication (41,44). 
Host shutoff must occur within the time frame of the virus replication cycle—for many 
viruses, this could be merely a few hours. Within such short period of time, a virus uses a myriad 
of tricks to induce host shutoff and divert cellular resources towards the synthesis of viral 
macromolecules. During infection, poxviruses such as VACV modulate host cells in a 
multifaceted manner. Immediately following infection, VACVs modify cytoplasmic cytoskeleton 
by making cells circular. Furthermore, VACVs make host cells conducive for viral replication by 
inhibiting host cell cytopathic effect, altering cellular metabolism, and inducing global host 
protein synthesis shutoff. Furthermore, to induce host shutoff, VACV infections cease the 
synthesis of all three major macromolecules in the flow of genetic information from host DNA 
through RNA to proteins. Some of the strategies used by various viruses are discussed in the 
following section, with a focus on poxvirus.  
 Cellular DNA synthesis inhibition and the induction of host DNA degradation  
DNA is the central genetic material that encodes information that proceeds to transcripts 
and proteins. Viruses have evolved means to modulate host DNA molecules. Some plant and 
animal viruses increase host DNA synthesis to induce tumorigenic growth that favors virus 
replication and spread. Members of the Geminivirus family, beet curly top virus (BCTV) and 
tomato golden mosaic virus (TGMV) induce host DNA synthesis to cause tumorigenic growth 
through the C4 and AL1 genes, respectively (45,46). Similarly, animal viruses have pleiotropic 
transforming proteins—E1A in adenovirus, E6/7 in papillomavirus, and large T antigen in simian 
virus—to prompt normal cells to transform into cancer cells   (46–48). In contrast, many other 
classes of viruses decrease host DNA synthesis or degrade them to induce host shutoff and 
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reallocate cellular resources for viral DNA synthesis. Notable examples include the virion-
associated protein of frog virus 3 (FV3), S1 gene of reovirus, ICP10 of herpes simplex virus type 
2 (HSV-2), and a small segment at 3’ end of vesicular stomatitis virus (VSV) genome inhibits 
host DNA synthesis via an unknown mechanism (49–52). Bacteriophage T4D-induced exo- and 
endodeoxynucleases degrade bacterial host DNA within 5 minutes post infection (54).  
Poxvirus infection induces a rapid decrease in host cell DNA synthesis and an increase in 
DNA degradation. To decrease host cell DNA synthesis, VACV infection declines host nuclear 
DNA polymerase activity as early as 2 hours post infection. Studies measuring 14C- or 3H-
labeled thymidine incorporation into host and viral DNA during VACV infection observed an 
immediate decrease in labeled thymidine incorporation in host DNA, whereas labeled thymidine 
incorporation in viral DNA increased until 3 hours post infection, corresponding to the time 
when viral DNA replication occurs (55,56). Heat-inactivated and UV-irradiated non-infectious 
VACV inhibited host DNA synthesis, indicating that protein(s) in the virion were responsible for 
the inhibition (56,57). Additionally, VACV encodes two DNases that hydrolyze single-stranded 
DNA. Exonuclease is active at pH 5 and endonuclease is active at pH 7.8, similar to the pH 
found in the nucleus, which might be a mechanism to selectively degrade host DNA present in 
nucleus (57–59). By negatively affecting the host DNA, which is a source of genetic information 
to synthesize host proteins, vaccinia virus induces host shutoff by operating at multiple levels.  
 Prevention of cellular RNA synthesis  
RNA is transcribed by three different DNA-dependent RNA polymerase enzymes in 
eukaryotic cells. Transcription by RNA polymerase I (RNAPI) synthesizes ribosomal RNAs 
(rRNAs), while RNA polymerase II (RNAPII) yields messenger RNAs (mRNAs), and RNA 
polymerase III (RNAPIII) produces transfer RNAs (tRNAs), small non-coding RNAs (snRNAs), 
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micro RNAs (miRNAs), 5S RNA (5S), and small nucleolar RNAs (snoRNAs) (61,62). 
Prevention of cellular mRNA synthesis provides viruses with the advantage of accessing cellular 
translation machinery unchallenged. Hence, viruses use different proteins to target enzymes, 
RNAPII, that synthesize mRNAs. Foot-and-mouth disease virus (FMDV) encodes 3C proteases 
that cleave histone H3, thus affecting the regulatory domain necessary for transcription (63). 
Influenza A virus (IAV) uses multiple strategies to diminish host transcription. Early during 
infection, IAV inhibits RNAPII elongation followed by RNAPII degradation later during 
infection. IAV infection also induces stress that leads to the failure of RNAPII termination at the 
polyadenylation signal (PAS), which negatively affects host mRNA (61–63). Like IAV, herpes 
simplex virus type 1 (HSV-1) also induces the failure of RNAPII to terminate at PAS by an 
unknown mechanism (67). Additionally, HSV-1 infection decreases RNAPII occupancy in two-
thirds of cellular genes (68). In fact, HSV-1 proteins ICP4 and ICP22 are known to negatively 
regulate RNAPII-mediated transcription initiation and elongation (66–68).  
VACV infection inhibits host cell RNA synthesis by selectively inhibiting RNAPII, 
which functions to catalyze the transcription of DNA to synthesize pre-mRNA (72,73). In 
previous studies, the rate of RNA synthesis was determined using 3H and 14C-uridine uptake 
experiments. These experiments demonstrated that, compared to the uninfected condition, a 60% 
and 90% reduction in uridine uptake during VACV infection occurred at 3 and 9 hours post 
infection, respectively (57,73). Unlike the inhibition of DNA polymerase activity, infectious 
VACV and the expression of early viral genes are required to inhibit RNAPII activity. 
Additionally, VACV infection induces the global degradation of host and viral mRNA, 
subsequently decreasing the half-life of host/viral mRNA during infection. However, the 
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inhibition of RNA synthesis was shown to be independent of RNA degradation (73), though the 
mechanism remains elusive. 
 Targeting various mRNA processing mechanisms  
mRNA that codes for protein are synthesized as pre-mRNA. Pre-mRNA synthesized 
during transcription undergo processing to form mature mRNA. Viruses encode proteins that 
block each of the steps involved in mRNA maturation, including mRNA processing-capping, 
polyadenylation or splicing, and the export of mRNA from the nucleus to cytoplasm. Viruses 
most frequently induces host mRNA degradation. 
Capping: During transcription, when the length of mRNA reaches 25-30 nucleotides, 7-
methylguanosine cap (m7G) is added to the 5′ end of the transcript, which protects the mRNA 
from 5’-3’ exoribonucleases such as Xrn1. Many viruses target the removal of the 5’ cap to 
induce mRNA degradation. Influenza virus cleaves 5’ caps and uses the cleaved oligonucleotide 
as a primer for its own transcription through a mechanism known as “cap snatching” (74). To 
perform cap snatching, polymerase basic protein 2 (PB-2) binds to host mRNA cap through an 
extensive conformation change, followed by the cleavage of cap from the host mRNA by the 
endonuclease in polymerase acidic protein (PA). PB-1 uses the cleaved cap as a primer for viral 
mRNA transcription (75). Hantavirus also performs cap snatching using its N protein, which 
binds to cellular mRNA cap and rescues capped mRNA fragments from P bodies post-mRNA 
degradation. The capped mRNA fragment is further processed by viral RNA-dependent RNA 
polymerase to be used as a primer for viral mRNA synthesis (76). Recently, African swine fever 
virus (ASFV) was shown to encode a decapping protein, ASFV-DP, which removes the m7G cap 
from both host and viral mRNAs (77). 
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To take advantage of cellular cap-dependent translation initiation mode, VACV mRNAs 
have a 7-methylguanosine (m7G) cap at the 5' end. VACV mRNAs capping is carried out in three 
reactions performed by viral enzymes. In this process, the newly synthesized transcript with a 5' 
triphosphate is cleaved to a diphosphate by RNA triphosphatase. Guanosine monophosphate 
(GMP) is then added by RNA guanylyl-transferase, and subsequently methylated at N7 position 
by RNA (guanine-N7) methyltransferase. VACV encodes the heterodimeric capping enzyme 
complex of D1/D12 protein. D1 functions as RNA triphosphatase and RNA guanylyltransferase, 
whereas D12 performs RNA (guanine-N7) methyltransferase activities (12). Capped viral 
transcripts promptly compete for the limited translational machinery and energy in the host cell. 
Additionally, VACV encodes VP39 protein (J3R), which adds a methyl group at the 2'-O 
position of the first transcribed nucleotide (cap 1) adjacent to the 5' cap (cap 0). Such 
modification is present in eukaryotic mRNA, but is usually absent in viruses (78). The host’s 
innate immune system recognizes hypomethylated viral RNA by interferon-induced proteins 
with tetratricopeptide repeats 1 (IFIT-1) to distinguish between self and non-self mRNA, thereby 
preventing non-self mRNA translation (79). By methylation at the 2'-O position of cap 1, VACV 
evades host immune response and boosts its mRNA translation (80). Another strategy that 
VACV uses is to completely remove the 5' cap or decap mRNA by two proteins (D9 and D10) 
expressed at the early and post-replicative periods of the viral replication cycle, respectively 
(81,82). The decapped mRNAs are then degraded by 5'-3' exonucleases such as Xrn1 (83,84). 
The decapping process leading to mRNA degradation is discussed further in mRNA degradation 
section.  
Splicing: The pre-mRNA contains coding exons and non-coding introns. During the 
maturation of pre-mRNA, the introns are removed and exons are joined through a process called 
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splicing. Viruses inhibit host gene expression by targeting splicing. HSV-2 encodes ICP27 
protein, which binds directly to pre-mRNA and prevents splicing (85). Unlike HSV-2, human 
immunodeficiency virus 1 (HIV-1) Vpr protein binds to spliceosome protein SAP145 to inhibit 
host pre-mRNA splicing (86). Blocking splicing will lead to mRNA with a premature stop codon 
or the disruption of the open reading frame, resulting in the production of aberrant proteins that 
are promptly degraded.  
VACV has been evolutionarily optimized to lack gene-containing introns; hence, splicing 
is dispensable for VACV. However, VACV targets host-splicing mechanism to induce host 
shutoff. The serine (S)/arginine (R)-rich protein (SR protein) family are an important protein 
family required for spliceosome assembly (87). SR proteins are hyper-phosphorylated at a serine 
residue that is required for its function (88). Like adenoviruses, VACVs can inactivate SR 
protein, thereby controlling the host cell's RNA splicing machinery. VACV hypo-phosphorylates 
SR protein, mediated by VACV phosphatase H1, to inhibit its function in splicing (89). A recent 
study demonstrated that CPXV infection significantly upregulates the proteins of RNA splicing 
at 2 hpi; however, during the course of infection (6 hpi and 10 hpi) many splicing factors are 
downregulated (90). Since splicing is not required for VACV, it can inhibit cellular splicing 
machinery to induce host shutoff without negatively affecting viral growth.  
Polyadenylation: Polyadenylation is the process of adding a stretch of adenine bases at 
the 3’ end of mRNA. It is an essential process for mRNA maturation that is tightly coupled with 
transcription termination. Polyadenylation protects mRNA from 3’-5’ exoribonucleases and 
assists in the optimal translation of mRNAs (91). Viruses have evolved methods to target the 
polyadenylation process to affect mRNA stability. Nonstructural protein 1 (NS1a) of IAV 
restricts the polyadenylation of nascent host mRNA by interacting with cleavage-
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polyadenylation specificity factor 30 (CPSF30) (92). CPSF are responsible for recognizing 
polyadenylation signal in pre-mRNA and cleave the pre-mRNA, followed by the 
polyadenylation of upstream cleaved product (93). In contrast to IAV’s strategy to block 
polyadenylation, Kaposi's sarcoma-associated herpesvirus (KSHV) hyper-adenylates host 
transcripts through SOX protein, which also leads to decreased transcript stability (94,95). 
To add a poly(A) tail at the 3' end of viral mRNA, VACV encodes the heterodimeric 
poly(A) polymerase complex of VP55/VP39 proteins early during infection. VP55 (E1L) protein 
functions as a catalytic component, whereas VP39 (J3R) protein acts as a processivity factor. 
During VACV infection, apart from catalyzing polyadenylation in viral mRNA VACV poly(A), 
polymerase polyadenylates cellular RNAs such as tRNA, small nuclear RNA (snRNA), and 
mRNA to form non-translating polyadenylated short sequences (POLADS) (96). In this cell-free 
protein synthesizing system, the addition of POLADS inhibits cellular mRNA synthesis by up to 
70%, while viral mRNA had minimal inhibition (94–96). The selective host protein synthesis 
inhibitory property of the POLADS is due to the poly(A) tail, as the increased length of the 
poly(A) tail in POLADS corresponds to increased inhibitory activity (96,98). Moreover, the 
addition of PABP reversed host cell mRNA translation inhibition by POLADS, suggesting that 
PABP becomes the limiting factor for host cell mRNA translation during VACV infection 
(96,98,99). Another interesting strategy that VACV uses to thwart the negative regulator for viral 
replication caused by host microRNA (miRNA) involves viral poly(A) polymerase (100). During 
VACV infection, VP55 protein becomes essential and adequate to polyadenylate host miRNA, 
thereby leading to its degradation and relieving its negative regulation on viral replication (100).  
mRNA export: mRNA translation occurs in the cytoplasm, thus the transcribed mRNA 
must be exported from the nucleus. Viruses target the export of host mRNAs by disrupting the 
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nuclear-cytoplasmic transport machinery. Rhinovirus 2A and 3C protease cleaves vital 
constituents of nucleocytoplasmic mRNA export machinery (101). IAV protein NS1 and VSV 
matrix protein downregulate and competitively bind Nup98 protein, respectively, which is 
required for mRNA export (102,103). Additionally, IAV's NS1 protein interacts with and 
sequesters key mRNA export machinery proteins (p15, E1B-AP5, Rae1, and NXF1) to form an 
inhibitory complex, thereby inducing mRNA export blockage (102). During poxvirus infection, 
no known inhibition of nuclear-cytoplasmic transport machinery has been reported to date.  
mRNA degradation: A common feature of many viruses is that they encode 
exoribonucleases and endoribonucleases to cleave host mRNA. Severe acute respiratory 
syndrome-Coronavirus (SARS-CoV) NSP1 protein, IAV PA-X protein, HSV virion host shutoff 
(VHS) protein, Epstein-Barr virus (EBV) BGLF5 protein, and KSHV SOX protein have exo- or 
endoribonuclease activities and decrease global host protein synthesis by decimating host 
mRNAs (101–105). 
VACV infection promptly induces host cellular RNA degradation. Cellular housekeeping 
genes for mRNA, such as ß-actin and α-tubulin mRNA, are progressively degraded over time 
during VACV infection, and they are almost entirely degraded by 10 hours post infection (109). 
Earlier studies postulated that RNA degradation during VACV infection could occur due to the 
following reasons: 1) Synthesis of viral RNases; 2) Rapid turnover of mRNA due to re-
compartmentalization of mRNA in morphologically altered infected cells; 3) Interferon-induced 
2′5′-oligoadenylate synthetase (OAS) through the activation of endonuclease RNase L, which 
does not discriminate between host and viral mRNA. Although the aforementioned postulates 
could be true, subsequent findings have demonstrated that VACV encodes two enzymes (D9R 
and D10R) with the Nudix hydrolases motif (81,82). Enzymes with the Nudix motif hydrolyze a 
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nucleoside diphosphate linked to any moiety X. Initial reports demonstrated that D9R and D10R 
negatively regulated gene expression independent of the promoter used. However, the expression 
of a gene under an encephalomyocarditis (EMC) virus leader sequence that underwent 5'-cap-
independent translation using IRES was not negatively affected by D9R and D10R 
overexpression (110). These significant findings demonstrated that D9R and D10R degraded the 
transcripts that are capped (m7GpppN) at the 5' end—a feature of both VACV and host mRNAs. 
In fact, by cleaving the 5'-cap, the Nudix motif of D9R and D10R presumably renders the 
mRNA for degradation by 5'-3' exonuclease Xrn1 (84). The importance of D9R and D10R is 
further accentuated by the fact that a homolog of D9R is found in all chordopoxviruses, whereas 
the D10R homolog is conserved in all known poxviruses (15). A recent study demonstrated that 
the depletion of cellular mRNA is a major contributor to VACV-induced host protein synthesis 
shutoff (111). Degradation of host mRNA leading to host shutoff is vital for VACV replication, 
as it not only usurps host innate immune response, but also reallocates the translation machinery 
to viral mRNAs. 
 Usurping host mRNA translation  
mRNA translation is the most energy-consuming process in the cell. Cellular mRNA 
translation has three major steps: initiation, elongation, and termination. During initiation, 
eukaryotic initiation factor 2 (eIF2) forms a ternary complex (TC) with initiator-methionine 
tRNA (Met-tRNAi) and GTP. Consequently, TC binds to 40S ribosome in complex with eIF1, 
eIF3, and eIF5 to form the 43S pre-initiation complex. A rate-limiting translation initiation step 
is then followed by the recruitment of a hetero-trimeric complex called eIF4F on mRNA. eIF4F 
consists of m7G cap-binding protein eIF4E, RNA helicase eIF4A, and scaffold protein eIF4G. 
eIF4E binding protein 1 (4EBP1) is a translation repressor that limits the availability of eIF4E to 
19 
form the eIF4F complex (112). Hyperphosphorylated (4 sites) 4EBP1 releases eIF4E for eIF4F 
complex formation. Once formed, the eIF4F complex binds m7G cap, and the scaffold protein 
eIF4G interacts with the poly(A) binding protein (PABP) bound to 3’ poly(A) tail to promote 
transient 5’-3’ communication known as the closed loop model. Subsequently, by binding to the 
eIF3 complex, eIF4G helps recruit 43S pre-initiation complex on the mRNA to form 48S pre-
initiation complex. The 48S pre-initiation complex then scans the mRNA in 5’→ 3’ direction 
until it reaches the start codon, usually AUG. Once the start codon is recognized, eIF5B mediates 
the hydrolysis of eIF2-bound GTP. This change prompts the joining of the 60S ribosome to 48S 
pre-initiation complex to form an elongation-competent 80S complex (113). This sophisticated 
process is followed by translation elongation, termination, and ribosome recycling. 
Since translation initiation is the rate-limiting step of translation, many viruses target 
different proteins involved in this process. The various proteins involved in translation initiation 
that are targeted by viruses are discussed in greater detail in the following paragraphs.  
eIF4F: The multi-subunit complex eIF4F is one of the primary targets for viruses to 
seize host translation. Viruses belonging to different families target all three proteins in the 
eIF4F complex. FMDV protease 3C cleaves both eIF4As to block host translation (114). HSV-1 
VHS protein binds to eIF4A—a RNA helicase—to gain close proximity to cleave and degrade 
host mRNAs (115), while various viral proteases target eIF4G to inhibit host translation. 
Proteases such as enterovirus (EV) 2A protease, HIV-1 protease, FMDV leader protease, and 
feline calicivirus 3C protease cleave eIF4G (113–116). Viral proteins such as rhinovirus 2A and 
rotavirus NSP3 bind eIF4G and displace PABP to prevent the closed loop conformation required 
for translation in many host mRNAs (120,121). Cap-binding protein eIF4E is a common target 
for many viruses to decline host translation. Adenovirus shutoff protein 100 K, tobacco mosaic 
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virus (TMV) VPg protein, Cripavirus, and influenza virus by unidentified proteins bind and 
recruit eIF4E to viral mRNA (119–122). Enteroviruses (EV) use a distinctive approach to target 
eIF4E, where virus-induced miR-141 suppresses eIF4E mRNA translation (126). Many viruses 
also target the phosphorylation state of translation repressor protein 4EBP1. 
Hyperphosphorylated 4EBP1 then releases eIF4E to mediate translation initiation. SV40 Small T 
Ag carries out the PP2A-dependent dephosphorylation of 4EBP1, whereas VSV M protein and 
reovirus p17 dephosphorylate 4EBP1 by inactivating Akt-mTOR (124–126). In doing so, viruses 
induce host shutoff since the majority of host mRNAs depend on eIF4F complex-reliant cap-
dependent translation.  
eIF1, eIF2, eIF3, and eIF5 multifactor complex: The multifactor initiation complex is 
formed when the N-terminus of eIF3 interacts concurrently with eIF5 and eIF1, and is further 
augmented by the interaction of eIF5 with the N-terminus of eIF2β (130,131). Viruses are known 
to alter the multifactor initiation complex function to induce host shutoff. Alphaviruses (Sindbis 
and Semliki Forest virus) induce the phosphorylation of eIF2α to block global host translation 
(132). eIF3 is multiprotein complex composed of 13 different proteins, and viruses bind to 
different proteins of eIF3 to decimate host mRNA translation. Measles N protein binds eIF3g, 
whereas rabies M protein binds eIF3h to negatively affect host translation (133,134). Similarly, 
SARS-CoV and infectious bronchitis virus (IBV) spike protein binds eIF3f to impair host mRNA 
translation (135). Enteroviruses encode 3C proteases cleave eIF5B, thus impairing translation by 
preventing eIF5B from interacting with eIF1A and the ribosome to accurately position met-
tRNA on the start codon of an mRNA (136). Some viruses, such as FMDV, use multiple modes 
to induce host shutoff. In addition to cleaving eIF4A and eIF4G, FMDV infection induces the 
cleavage of eIF3a, eIF3b, and PABP (114).  
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PABP: PABP binds to the 3’ poly(A) tail of an mRNA to enhance RNA stability, and 
this interaction is vital for translation initiation complex formation in the cytoplasm (137). Many 
viruses target PABP to induce host shutoff. Norovirus and enterovirus protease 3C cleave PABP 
to inhibit its function (138,139). HIV-1 protease, Rubella capsid protein, and influenza NS1 bind 
PABP and suppress translation (136–138). Rotavirus NSP3 displaces PABP from eIF4G and 
interacts with RoXaN to cause nuclear accumulation of PABP (121,143). Similarly, the SOX and 
K10 proteins of KSHV and HSV-1 UL47 protein bind PABP to cause nuclear accumulation and 
prevent its function in the cytoplasm (144,145). 
VACV uses distinct tactics to modulate the extremely synchronized and high energy 
consuming protein synthesis mechanism from cellular mRNAs. During VACV infection, prompt 
and selective inhibition of cellular protein synthesis occurs. Earlier findings have demonstrated 
that VACV infection results in the inhibition of protein synthesis via a surface tubular element 
(STE) displayed on the VACV membrane. However, VACV STE did not affect either cellular 
RNA or DNA synthesis. When the authors exposed cells to purified STE, a decrease in the 
polyribosome occurred, accompanied by an increase in the free ribosome pool. Although these 
observations suggest that STE negatively affects translation initiation, further studies are 
necessary to determine the exact mechanism (146). 
Another very remarkable factor present in virions that is implicated in inducing host 
shutoff is phosphorylated 11 kDa protein (147,148), which is encoded by F17R in Copenhagen 
strain (F18R in WR strain) (145–148). Purified 11 kDa/F17 protein from VACV virion and cell-
free extract from VACV-infected cells prevents methionyl-tRNA_fMet-40S initiation complex 
formation to induce host shutoff (147,148). The importance of this small protein is further 
augmented by the fact that preventing expression of F17 protein interrupts VACV 
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morphogenesis (149). It was recently demonstrated that F17 sequestering Rictor and Raptor 
dysregulates mTOR to counter antiviral response while retaining mTOR-mediated enhancement 
of viral protein synthesis (152). These findings indicate that F17 has multiple roles, from 
inducing host shutoff and countering antiviral response to enhancing viral protein synthesis 
during infection.  
Among the many approaches used to usurp host mRNA translation, VACV expresses 
protein 169 early during infection, and is confined in the host cell cytoplasm. In the cytoplasm, 
protein 169 impairs host protein synthesis, thereby facilitating the inhibition of host antiviral 
responses. Unlike other factors that induce host shutoff, protein 169 targets translation initiation 
by affecting both cap-dependent and cap-independent mechanisms. Although protein 169 is not 
vital to VACV replication and spread, it is required to regulate virulence, as VACV lacking 
protein 169 causes severe infections that induce stronger immune responses and are thus 
promptly cleared. By inducing host protein synthesis shutoff, VACV protein 169 suppresses host 
antiviral response and hence regulates virulence (153).  
Apart from these general mechanisms to induce host shutoff, VACV also targets some 
specific translation initiation factors. Translation initiation is thought to be the rate-limiting step 
during mRNA translation, as it is highly regulated via various translation initiation factors. 
VACV modulates translation initiation factors such as eIF4E, eIF4G that are part of the cap-
binding complex eIF4F. VACV infection phosphorylates eIF4E, though the broader implications 
of such modification are not well studied to date (154). However, it is well established in 
eukaryotes that higher eIF4E phosphorylation is associated with increased translation (151–154). 
Conversely, other studies have suggested that non-phosphorylated eIF4E have a higher affinity 
for a 5' cap in an mRNA than the phosphorylated eIF4E counterpart (159). Furthermore, 
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phosphorylated eIF4E is not mandatory for translation initiation (160), and cap-dependent 
translation is inhibited by phosphorylated eIF4E (161). If any of the latter situation is true during 
VACV infection, phosphorylation of eIF4E may be one of the mechanisms used to subvert the 
cap-dependent translation of host mRNA.  
VACV also sequesters eIF4E and eIF4G into foci near the virus factory, suggesting that 
the initiation factors are re-localized to enhance VACV mRNA translation (16,162). Recently, 
antiviral granules (AVGs) and RNA granules were found adjacent to and within viral factories 
(163,164). In fact, AVGs contain translation initiation proteins (eIF3h, eIF4E, and PABP), 
leading to speculation that such redistribution of translation initiation factors could be a 
mechanism to limit the availability of these factors for host mRNA translation (163).  
As discussed earlier, VACV poly(A) polymerase induced POLADS sequester PABP in 
order to make them inaccessible for host mRNA translation to induce host shutoff. The different 




Figure 1-1: Summary of VACV-induced host protein synthesis shutoff 
VACV targets and ceases synthesis of all three major macromolecules in central dogma of 
genetics, i.e. DNA, RNA and Proteins. To induce host shutoff, VACV inhibits DNA replication 
(Virion proteins), degrades host DNA (VACV DNases), inhibits transcription (Early protein/s) 
and splicing (H1 Phosphatase). Further, VACV hinders 43S preinitiation complex formation 
(F17), decreases polysome bound mRNAs (Surface Tubular Element) and inhibits both cap-
dependent and cap-independent mode of translation (VACV 169). Additionally, VP55/VP39 
heterodimeric poly(A) polymerase adds poly(A) tail to tRNA, snRNA and mRNAs to form 
POLADS. These POLADS sequesters PABP to negatively affect translation. Remarkably, the 
major contributor to host shutoff is host mRNA degradation that is carried out by sequential 
decapping by two viral decapping enzymes D9 and D10 followed by degradation by cellular 
Xrn1 5'-3' exonuclease. Using all these multiple strategies, VACV induces host shutoff. 
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Selective Protein Synthesis during Virus-induced Host Shutoff 
 Virus-induced global host shutoff is beneficial for viruses, as it helps evade host antiviral 
immune response. Additionally, shutoff also leads to the reapportion of cellular machinery and 
critical host processes to confer a replication advantage for the virus. Although shutoff provides 
advantages to the virus in regard to immune evasion and the reallocation of cellular resources, 
the selective synthesis of crucial cellular proteins and viral proteins is necessary to sustain virus 
replication. 
 Strategies employed by poxvirus to synthesize proteins during host shutoff 
 Many viruses have evolved various strategies to boost viral protein synthesis during host 
shutoff. Most viruses have acquired critical elements in mRNA to induce selective viral protein 
synthesis. A common element in viral mRNA is the internal ribosome entry site (IRES). Notable 
viruses that use IRES to mediate translation initiation via initiation factor independent mode 
include SARS, HCV, CSFV, HIV, and CrPV (165). Influenza B virus induces combined 
translation of both M1 and BM2 protein by the base pairing of mRNA with 18S ribosomal RNA 
to promote the re-initiation of translation (166). Adenovirus uses ribosome shunting to enhance 
viral mRNA translation, where the tripartite leader in the non-coding region of viral late mRNAs 
exhibits high complementarity with 18S rRNA, which promotes the ribosome shunting 
mechanism (167). Viruses are notorious for recruiting translation initiation factors to their 
mRNA to promote viral mRNA translation. Calicivirus VPg protein binds and recruits eiF3 and 
eIF4E to viral mRNA (168,169) and HSV-11 ICP27, while UL47 protein binds PABP (145). As 
such, this recruitment of initiation factor to viral mRNA stimulates its translation. During the 
replication cycle, viruses produce dsRNA that is sensed by innate immune molecule PKR, 
leading to self and downstream eIF2α phosphorylation (170). When eIF2α is phosphorylated, 
26 
global inhibition of translation initiation occurs (171). To avert this situation, viruses use various 
strategies to hinder PKR-mediated eIF2α-phosphorylation. Influenza NS1 HCMV's two related 
proteins (TRS1 and IRS1) sequester dsRNA and prevent PKR phosphorylation (172,173). 
HSV-1 US11, EBV SM, and KSHV ORF57 directly sequester PKR to thwart PKR activation 
(174,175). HPV E6 and HSV ICP34.5 protein regulate eif2α phosphatase to dephosphorylate 
eiF2α (176,177). 
 To mediate selective translation during poxvirus infection, VACV modulates many 
proteins that regulate translation initiation. VACV possesses cis-acting sequences and trans-
acting factors that may regulate selective viral mRNA translation. Selectively synthesized 
proteins and the evolutionarily optimized strategy used during VACV-induced host shutoff are 
discussed below.  
 VACV's strategies to modulate translation initiation factor  
eIF4F Complex: 
The eIF4F complex is composed of a cap-binding subunit (eIF4E), an RNA helicase 
(eIF4A), and a scaffold protein (eIF4G). Among these proteins, the activity of eIF4E is highly 
regulated by many factors that converge into two major signaling pathways: PI3K/AKT/mTOR 
and MAPK/ERK (178,179). 
eIF4E is repressed by hypo-phosphorylated eIF4E-binding proteins (4E-BPs) (180). 
Activation of PI3K/AKT/mTOR pathway leads to hyperphosphorylation of 4E-BP by mTORC1 
triggering the release of eIF4E and thereby, increasing the pool of eIF4E available for translation 
initiation (181,182). At the early time during infection, VACV induces surface β1-mediated 
PI3K activation leading to hyperphosphorylation of 4E-BP1 and subsequent release of 
cap-binding protein eIF4E (183,184). Hyperphosphorylated 4E-BP1 is consequently degraded by 
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proteasome during VACV infection (162). Activation of PI3K augments the formation of eIF4F 
complex enhancing VACV protein synthesis (184). Another poxvirus, Myxoma virus activates 
AKT by host range protein MT-5 (185,186). However, the role of AKT activation on a 
translation during MYXV infection is not studied yet. 
A second signaling pathway that regulates eIF4E is MAPK/ERK pathway. Activation of 
the MAPK/ERK pathway phosphorylates and activates MNK1/2. Activated MNK1/2, in turn, 
phosphorylates eIF4E at the Serine 209 residue (178,187), leading to an increase in translation 
initiation (151–154). VACV infection activates MAPK/ERK pathway stimulating 
phosphorylation of eIF4E by MNK1 (162). VACV protein synthesis was severely affected when 
cells were treated with MNK inhibitor CGP57380 and in MNK1 knocked out MEF cell line 
suggesting the importance of eIF4E phosphorylation by MNK1 (162,188).  The previous report 
showed that 40S-bound eIF3e (an indicator of 43S pre-initiation complex formation) is 
prerequisite for recruitment of eIF4E kinase MNK1 to eIF4G during VACV infection (154). 
Interestingly, phosphorylated eIF4E has lower affinity for 5' cap (159), and it is predicted that 
eIF4E phosphorylation occurs after 43S pre-initiation complex formation to promote the release 
of the eIF4F complex to initiate ribosome scanning (189). As discussed earlier, phosphorylation 
of eIF4E could have negative regulation in host translation initiation leading to dual purpose 
during VACV infection.  
eIF1, eIF2, eIF3 and eIF5 multifactor complex:  
VACV infection generates a huge amount of double-stranded RNA (dsRNA) due to the 
overlapping nature of viral transcripts. dsRNA is sensed by the host anti-viral defense 
mechanism through the N-terminal domain of protein kinase R (PKR). Upon dsRNA binding, 
PKR is activated by autophosphorylation reaction followed by phosphorylation of eIF2α leading 
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to global inhibition of translation in infected cells (190). VACV has developed multiple 
strategies to evade PKR activation. One of the strategies used by poxvirus to prevent PKR 
mediated eIF2α phosphorylation is to encode pseudosubstrates of PKR such as K3L in VACV, 
M156R in MYXV, C8L in swine poxvirus (187–189). These pseudosubstrates isolate PKR to 
prevent activation of downstream effector-phosphorylated eIF2α. Another approach poxvirus 
uses to deter, or delay PKR activation is by producing dsRNA binding protein, E3L in VACV 
and M029 in MYXV, that sequester dsRNA to make it inaccessible to PKR (194,195). Despite 
the presence of PKR antagonists, poxviruses also use different strategies to minimize the 
production of dsRNA. VACV D9 and D10 are decapping enzymes that keep the amount of 
virus-induced dsRNA at a minimum during infection, preventing the activation of PKR and 2’5’-
oligoadenylate synthetase (OAS)/RNase L-associated RNA decay that inhibits viral protein 
synthesis (83,84). VACV also takes advantage of the cellular 5’-3’ mRNA exonuclease Xrn1 to 
reduce the number of potential PKR and RNase L substrates (83,84).  
Selectively translated cellular proteins 
During VACV induced host shutoff, mRNA degradation is the major contributor; 
however, a small fraction of host transcripts are not affected. One study showed that interleukin 
6 signal transducer (IL-6ST) and Apurinic/apyrimidinic endonuclease 2 (APEX2) mRNA are 
constant, whereas, solute carrier family 4-member 3 (SLC4A3) mRNA abundance is marginally 
decreased (196). In contrast, pericentrin (PCNT2) and Wiskott-Aldrich syndrome protein 
(WASP) mRNA are upregulated (196). Later it was discovered that WASP is important for 
VACV infection in the host cell (197). However, the mechanism by which host factors such as 
WASP are selectively upregulated remains to be investigated. 
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Recent global, simultaneous RNA-seq and Ribosome profiling, analysis showed that, 
during VACV infection, mRNA encoding proteins for oxidative phosphorylation (OXPHOS) are 
translationally upregulated (111). OXPHOS are responsible for ATP production, and elevated 
ATP level is crucial for VACV infection (111,198,199). Previously, it was shown that VACV 
increases explicitly nicotinamide adenine dinucleotide dehydrogenase 4 (ND4) and 
cyclooxygenase-2 (COX2) protein levels, two mitochondrial proteins that function in the 
electron transport chain to generate ATP (199). However, the mechanism on how the synthesis 
of these mitochondrial proteins is regulated also remains to be elucidated. We have shown that 
synthesis of protein of members of oxidative phosphorylation is selectively upregulated during 
VACV infection. The short 5′ untranslated region with the less complex secondary structure of 
the oxidative phosphorylation mRNAs contributed to the translational upregulation (111). 
Additionally, mRNA encoding proteins for ribosomal subunits were also significantly enriched 
at 2 hpi, but higher TE was not significantly different at later times. These findings are discussed 
in detail in Chapter 5 of this dissertation. 
VACV mRNA translation 
 All the viruses inducing the shutoff of translation can continue to translate at least part of 
their mRNAs using non-canonical translation such as IRES, Ribosome shunting, CITE or VPG 
initiation. In many instances, the expression of viral proteins seems to occur through cap-
independent mechanisms. The 5’-poly(A) leader at the 5' end of the 5' UTR is the feature of all 
VACV post-replicative mRNAs.  5’-poly(A) leader conferred a selective translational advantage 
to post-replicative mRNA in poxvirus-infected cells (200,201). Post-translational modification of 
small ribosomal protein RACK1 by VACV kinase B1 is necessary for poly(A) leader mediated 
translational advantage (200). These poly(A)-headed mRNAs can be efficiently translated in 
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cells with impaired cap-dependent translation. Moreover, the 5’-poly(A) leader is not an IRES 
(201). Similar 5' leader sequence, Omega prime, found in tobacco mosaic virus (TMV) also 
enhances translation (202,203). Unlike VACV 5'-poly(A) leader, TMV omega prime enhances 
translation by promoting recruitment of eIF4F complex (201,204). The result of 5'-poly(A) 
leader mediated translational advantage during poxvirus infection is discussed in detail in 
Chapter 3 of this dissertation. We very recently, determined a cellular protein LARP4 is essential 
for poly(A) leader translation, and these results are discussed in detail in Chapter 4 of this 
dissertation. 
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 Summary  
We present a protocol to study mRNA translation regulation in poxvirus-infected cells 
using In-Vitro Transcribed RNA-based luciferase reporter assay. The assay can be used to study 
translation regulated by cis-elements of an mRNA, including 5’-untranslated region (UTR) and 
3’-UTR. Different translation initiation modes can also be examined using this method.  
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 Abstract 
Every poxvirus mRNA transcribed after viral DNA replication has an evolutionarily 
conserved, non-templated 5’-poly(A) leader in the 5’-UTR. To dissect the role of 5’-poly(A) 
leader in mRNA translation during poxvirus infection we developed an in-vitro transcribed 
RNA-based luciferase reporter assay. This reporter assay comprises four core steps: (1) PCR to 
amplify the DNA template for in-vitro transcription; (2) In-vitro transcription to generate mRNA 
using T7 RNA polymerase; (3) Transfection to introduce in-vitro transcribed mRNA into cells; 
(4) Detection of luciferase activity as the indicator of translation. The RNA-based luciferase 
reporter assay described here circumvents issues of plasmid replication in poxvirus-infected cells 
and cryptic transcription from the plasmid. This protocol can be used to determine translation 
regulation by cis-elements in an mRNA including 5’-UTR and 3’-UTR in systems other than 
poxvirus-infected cells. Moreover, different modes of translation initiation like cap-dependent, 
cap-independent, re-initiation, and internal initiation can be investigated using this method. 
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Introduction 
According to the central dogma, genetic information flows from DNA to RNA and then 
finally to protein (1,2). This flow of genetic information is highly regulated at many levels 
including mRNA translation (3,4). Development of reporter assays to measure regulation of gene 
expression will facilitate understanding of regulatory mechanisms involved in this process. Here 
we describe a protocol to study mRNA translation using an in-vitro transcribed RNA-based 
luciferase reporter assay in poxvirus-infected cells.  
 Poxviruses comprise many highly dangerous human and animal pathogens (5). Like all 
other viruses, poxviruses exclusively rely on host cell machinery for protein synthesis (6–8). To 
efficiently synthesize viral proteins, viruses evolved many strategies to hijack cellular 
translational machinery to redirect it for translation of viral mRNAs (7,8). One commonly 
employed mechanism by viruses is to use cis-acting elements in their transcripts. Notable 
examples include Internal Ribosome Entry Site (IRES) and cap‐independent translation enhancer 
(CITE) (9–11). These cis-elements render the viral transcripts a translational advantage by 
attracting translational machinery via diverse mechanisms (12–14). Over 100 poxvirus mRNAs 
have an evolutionarily conserved cis-acting element in the 5’-untranslated region (5’-UTR): a 5’-
poly(A) leader at the very 5’ ends of these mRNAs (15,16). The lengths of these 5’-poly(A) 
leaders are heterogeneous and are generated by slippage of the poxvirus-encoded RNA 
polymerase during transcription (17,18). We, and others, recently discovered that the 5’-poly(A) 
leader confers a translation advantage to an mRNA in cells infected with vaccinia virus (VACV), 
the prototypic member of poxviruses (19,20).   
 The in-vitro transcribed RNA-based luciferase reporter assay was initially developed to 
understand the role of 5’-poly(A) leader in mRNA translation during poxvirus infection (19,21). 
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Although plasmid DNA-based luciferase reporter assays have been widely used, there are several 
drawbacks that will complicate the result interpretation in poxvirus-infected cells. First, plasmids 
are able to replicate in VACV-infected cells (22). Second, cryptic transcription often occurs from 
plasmid DNA (18,23,24). Third, VACV promoter-driven transcription generates poly(A)-leader 
of heterogeneous lengths consequently making it difficult to control the poly(A)-leader length in 
some experiments (18). An in-vitro transcribed RNA-based luciferase reporter assay circumvents 
these issues and the data interpretation is straightforward.  
 There are four key steps in this method: (1) polymerase chain reaction (PCR) to generate 
the DNA template for in-vitro transcription; (2) in-vitro transcription to generate mRNA; (3) 
transfection to deliver mRNA into cells; and (4) detection of luciferase activity as indicator of 
translation (Figure 2-1). The resulting PCR amplicon contains the following elements in 5’ to 3’ 
direction: T7-Promoter, poly(A) leader or desired 5’-UTR sequence, firefly luciferase open 
reading frame (ORF) followed by a poly(A) tail. PCR amplicon is used as the template to 
synthesize mRNA by in-vitro transcription using T7 polymerase. During in-vitro transcription, 
m7G cap or other cap analog is incorporated in newly synthesized mRNA. The capped 
transcripts are transfected into uninfected or VACV-infected cells. Cell lysate is collected at 
desired time after transfection to measure luciferase activities that indicate protein production 
from transfected mRNA. This reporter assay can be used to study translation regulation by cis-
element present in 5’-UTR, 3’-UTR or other regions of an mRNA. Furthermore, the in-vitro 
transcribed RNA-based assay can be used to study different mechanisms of translation initiation 




Figure 2-1: Schematic of the experimental procedure. 
PCR is used to generate a DNA template with desired elements. mRNA encoding a luciferase 
reporter gene is synthesized in-vitro using a T7 RNA polymerase-based system. A Firefly 
luciferase (Fluc) mRNA is co-transfected with a Renilla luciferase (Rluc) mRNA into uninfected 




Note: Information about the Material/Equipment used in this protocol can be found in the Table 
of Materials. 
 
 1. Prepare DNA template by PCR for in-vitro transcription 
1.1. To prepare DNA template by PCR, design primers. When designing primers consider 
crucial characteristics like primer length, annealing temperature (Tm), GC content, 3’ end with G 
or C etc.  
 
Note: Discussed in detail in these literature (25–27).  
 
1.2. Design primers to generate PCR amplicon containing the following elements in 5’ to 3’ 
direction: T7-Promoter, poly(A) leader, firefly luciferase ORF and a poly(A) tail referred 
hereafter to as T7_12A-Fluc. Design primers (Forward and Reverse) to encompass all the 
additional elements not present in the template DNA (Figure 2-2A). 
 
Note: The sequence of all elements can be found in Table 2-1. 
 
Table 2-1: Sequences used in the method 
The table contains the sequences of T7 promoter, poly(A) leader, Kozak sequence, poly(A) tail. 
Elements Sequence 
T7 Promoter TAATACGACTCACTATAGGG 
Poly(A) leader AAAAAAAAAAAA, ranging from 3 to 51 As 
Kozak sequence GCCACC 
Poly(A) tail AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA…… 
 
1.3. Include several extra nucleotides in forward primer (5’-3’) (28), followed by T7-
promoter, poly(A) leader or desired 5’-UTR sequence and approximately 20 nucleotides, adjust 
based on Tm, corresponding to the 5’ end of the reporter gene’s ORF. Ensure the corresponding 
region in the primer is identical to the sense strand (+ strand) of the gene.  
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Note: For long 5’-UTR, synthesize two DNA fragments: one with T7 promoter followed by long 
5’-UTR and second with reporter gene’s ORF. Join these two fragments using overlap extension 
PCR (29). 
 
1.4. Design reverse primer (5’-3’) to include a poly(A) tail and approximately 20 nucleotides, 
adjust based on Tm, corresponding to the 3’ end of the reporter gene’s ORF. Ensure the 
corresponding region in the primer is identical to the anti-sense strand (- strand) of the gene and 
an in-frame stop codon is present before the poly(A) tail. 
 
Note: The desired length of A’s in a poly(A) leader or poly(A) tail can be customized in the 
primers. For example, to add 50 A’s in the poly(A) tail, the reverse primer should entail 50 T’s. 
Similarly, to add 20 A’s in the poly(A) leader, the forward primer should entail 20 A’s.  
 
1.5. For internal control, design another set of primers containing the following elements in 5’ 
to 3’ direction: T7 Promoter, a random 5’-UTR coding sequence containing Kozak sequence, 
renilla luciferase ORF and poly(A) tail referred hereafter to as T7_Kozak-Rluc. 
 
1.6. In a PCR tube, add the reagents in the following order: DNase free water, 2X high-
fidelity DNA polymerase, primers and sequence confirmed luciferase template DNA (Table 
2-2). 
 
Table 2-2: PCR reaction 
The order and the volume of components added in PCR reaction. 
Components Volume 
DNase free water: 38 µl 
2X High-fidelity DNA polymerase Master 
mix: 
50  µl 
Forward Primer (10 µM): 4 µl 
Reverse Primer (10 µM): 4 µl 
Luciferase DNA Template* (1-10 ng/µl): 4 µl 
Total: 100 µl 
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Note: Amounts of individual components in the mixture should be adjusted according to the 
reaction volume. 
*Source for Fluc DNA template is PTK-Fluc plasmid. 
*Source for Rluc DNA template is PTK-Rluc plasmid 
 
1.7. Use a standard 3-step (Denaturation, Annealing, Extension) PCR cycle to generate DNA 
template as shown in Table 2-3.  
 
Table 2-3: PCR Program 
The steps for PCR program along with temperature, time and cycle.  
Step Temperature Time  Cycle 
Initial denaturation 95 °C 2 minutes  (1X Cycle) 
Denaturation 95 °C:  15 seconds 
 
Annealing  X °C:  30 seconds   (25X Cycle) 
Extension  72 °C:  T minutes  
 
Final Extension  72 °C:  7 minutes   (1X Cycle) 
Hold 4 °C:  ∞ 
 
 
Note: Annealing temperature X °C depends on the primer set being used and extension time T 
minutes depend on the PCR amplicon size and DNA polymerase used. 
 
1.8. Detect the PCR product by running 5-10% of PCR reaction in 1% agarose Tris-acetate-
EDTA (TAE) gel electrophoresis (containing 0.1µg/ml ethidium bromide) along with 
commercially available molecular weight standard. Visualize the gel under a UV illuminator to 
determine the size of the PCR product.  
 
1.9. After determining the correct size of the PCR product as shown in Figure 2-2B, ~1.7 kb 
for T7_12A-Fluc and ~1.0 kb for T7_Kozak-Rluc, purify it using a commercially available PCR 
purification kit. Elute the DNA using 100 µl nuclease free water.  
 
1.10. Once purified, determine the concentration of the DNA and the A260/A280 ratio (~1.8-
2.0 is acceptable). 
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1.11. Store purified DNA at -20 °C or use for in-vitro transcription immediately. 
 
Figure 2-2: Primer design and PCR-based DNA amplification. 
(A) Forward primer is synthesized to include an 8nt random sequence, T7 promoter followed by 
a desired 5’-UTR and part of the 5’ end of the luciferase reporter gene, while the reverse primer 
includes a T-tract to generate a poly(A) tail and the 3’ end of the luciferase reporter gene. By 
overhang extension PCR using a plasmid template containing luciferase gene, a DNA template is 
generated. (B) DNA band of the desired size from PCR reaction was detected using 1% agarose 
TAE gel electrophoresis. 
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 2. Generate mRNA by in-vitro transcription 
2.1. Synthesize RNA from the PCR product in vitro, using an in-vitro transcription kit 
(Figure 2-3A). 
 
Note: T7_12A-Fluc and T7_Kozak-Rluc DNA templates are used to synthesize 12A-Fluc and 
Kozak-Rluc mRNAs, respectively.  
 
2.2. In a microcentrifuge tube, add the reagents in the following order: DNase-RNase free 
water, NTP Buffer Mix, Cap Analog, Template PCR Product, T7-RNA polymerase Mix (Table 
2-4).  
 
Table 2-4: In-vitro transcription reaction 
The order and the volume of components added for in-vitro transcription reaction. 
   
Components Volume 
 
DNase-RNase free water: up to 20 µl 
 
NTP Buffer Mix (20 mM of each rNTP): 2 µl 
 
Cap Analog (40 mM): 4 µl  
 
Template PCR Product (400 ng)*: X µl  (Concentration dependent) 
T7-RNA polymerase Mix: 2 µl 
 
Total: 20 µl 
 
 
Note: Other capping system can also be used to cap RNA sequentially after in-vitro transcription 
following manufacturer’s instruction. 
 
2.3. Mix thoroughly and incubate at 37 °C for 2 hours. 
 
2.4. Proceed to purification of the synthesized RNA using an RNA purification kit. 
 
2.5. Run purified RNA in 1.5% agarose Tris-borate-EDTA (TBE) gel (containing 0.5 µg/ml 
ethidium bromide) to check the RNA. Visualize the gel under a UV illuminator (Figure 2-3B).  
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2.6. Determine the concentration of the RNA and the A260/A280 ratio (~1.8-2.0 is 
acceptable). 
 
2.7. Aliquot the purified RNA and store at -80 °C.  
 
Figure 2-3: mRNA synthesis and transfection. 
(A) Schematic of in-vitro transcription. DNA amplified by PCR containing the luciferase gene 
downstream from the 5’-UTR of interest and the T7 promoter is used as the template. The T7 
RNA polymerase is recruited to the promoter and adds ribonucleotides, shown in white, from 5’ 
to 3’ direction. Once mRNA is 25-30nt long, m7G cap is added using an anti-reverse cap analog, 
ARCA. (B) RNA bands from in-vitro transcription was detected using 1.5% agarose TBE gel 
electrophoresis. (C) Schematic demonstrating the transfection of reporter mRNA into cells. 
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Medium containing either the reporter mRNA or cationic lipid transfection reagent in separate 
tubes is allowed to equilibrate at room temperature for 5 minutes. The solutions are then mixed 
followed by incubation at room temperature for 15 minutes after which the RNA/transfection 
reagent mixture is added into cells in culture plates. 
 3. Transfect mRNA to cells  
3.1. Seed HeLa cells in a 24-well plate (to be approx. ~80-90% confluent next day) and 
incubate overnight in an incubator at 37 °C with 5% CO2. 
 
3.2. Infect HeLa cells with vaccinia virus (VACV) at a Multiplicity of Infection (MOI) of 5 or 
keep uninfected HeLa cells for comparison. 
 
Note: MOI is number of infectious viral particles per cell. 
MOI of X= {[(Number of cells * X) / Virus Titer] * 1000} µl of virus per 1 ml medium. 
 
3.3. After desired hours post infection (hpi) (we often transfect at 10-12 hpi), transfect mRNA 
(500 ng of total mRNA per well of 24-well plates) using a cationic lipid transfection reagent as 
shown in Figure 2-3C.  
 
3.3.1. For one well of a 24-well plate, mix 480 ng of 12A sequence bearing firefly luciferase 
(12A-Fluc) mRNA and 20 ng of Kozak sequence bearing renilla luciferase (Kozak-Rluc) mRNA 
in one microcentrifuge tube. In another microcentrifuge tube add 1.1 µl of cationic lipid 
transfection reagent. 
 
3.3.2. Add 55 µl of reduced serum medium in both tubes. Mix and incubate at room 
temperature for 5 minutes. 
 
3.3.3. After 5 minutes of incubation, add 55 µl cationic lipid transfection reagent containing 
reduced serum medium in mRNA containing tube. 
  
3.3.4. Mix gently but thoroughly, and incubate at room temperature for 15 minutes. 
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3.3.5. During the incubation, remove the cell culture medium and add 400 µl of reduced serum 
medium per well of 24-well plates. 
 
3.3.6. After incubation, add 100 µl of the mixture dropwise and evenly to one well of 24-well 
plates.  
 
 4. Measure luciferase activities 
4.1. Five-hours post-co-transfection of 12A-Fluc and Kozak-Rluc mRNA, measure luciferase 
activity using a Dual-Luciferase Assay Kit (DLAK).  
 
4.2  Remove reduced serum medium and lyse the cells by adding 150 µl 1X Passive lysis 
buffer, a component of DLAK.  
 
4.3. After 10 minutes incubation at room temperature, collect the lysate by scrapping the cells 
and transfer to a microcentrifuge tube.  
 
4.4. Centrifuge the lysate at 12,000 X g for 10 minutes at 4 °C to pellet cell debris. 
 
4.5. Add 30 µl of supernatant in opaque-walled 96 well white assay plate with a solid bottom. 
 
4.6. Measure the dual luminescence using DLAK and a multimode plate reader luminometer.  
 
4.7. The measurement is taken using kinetics function (all steps on a per-well basis) using the 
settings described in Table 2-5.  
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Table 2-5: Luciferase Measurement Settings 
The steps for luciferase measurement with recommended volume or time.  
Steps Volume/Time 
Inject Luciferase Assay Substrate (Fluc): 30 µl 
Wait / Incubation time: 2 sec 
Luminescence Measurement (Fluc): 10 seconds 
Stop & Glo Substrate (Rluc): 30 µl 
Wait / Incubation time: 2 sec 
Luminescence Measurement (Rluc): 10 seconds 
 
Note: The reading can also be taken using manual luminometer. Add equal volume of lysate and 
substrate for Fluc in a cuvette. Wait for 2 seconds and measure for 10 seconds using 
luminometer. Following Fluc measurement, quickly take out cuvette from luminometer and add 
equal volume of substrate for Rluc manually.  Again, wait for 2 seconds and measure for 10 
seconds using luminometer.  
 
4.8. Export the luminescence reading data into desirable file format.   
 
4.9. Determine relative translation rate from 12A-Fluc mRNA in uninfected and VACV 














 Results  
The four steps of in-vitro transcribed RNA-based luciferase reporter assay:  PCR to 
generate DNA template for in-vitro transcription, in-vitro transcription to generate mRNA, 
mRNA transfection, and luciferase measurement, can be seen in the schematic diagram (Figure 
2-1). Designing of primers for both DNA templates (Fluc and Rluc) and the general scheme of 
overhang extension PCR is illustrated in the schematic (Figure 2-2A). After PCR, the correct 
sized PCR product was detected by TAE agarose gel electrophoresis (Figure 2-2B). 
Subsequently, the PCR product is used as the template to synthesize RNA in-vitro (Figure 2-
3A), which is purified and run in TBE gel electrophoresis to verify the size (Figure 2-3B). The 
purified and verified mRNA is transfected into cells using cationic lipid transfection reagent 
(Figure 2-3C). 
The in-vitro transcribed RNA-based luciferase reporter assay was developed to 
understand the role of 5’-poly(A) leader in mRNA translation during poxvirus infection. Using 
this assay, we tested the translation efficiency of a Fluc mRNA that contains a 5’-poly(A) leader 
(12nt) in uninfected and VACV-infected cells. The Fluc value was normalized using Rluc value 
in both uninfected and VACV-infected cells to determine the relative Fluc activity (i.e. Fluc 
activity/Rluc activity) (Figure 2-4A). The division of Fluc by Rluc normalized the transfection 
efficiency and RNA stability in a particular well. Using this analysis approach, we determined 
that a 5’-poly(A) leader containing mRNA has a translational advantage during VACV infection 
(Figure 2-4B). The advantage in infected cells was not due to differential transfection efficiency 
or mRNA stability as the RNA level was similar in uninfected and VACV infected cells 5 hours 
post mRNA transfection (19). 
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Figure 2-4: Increased translational efficiency of mRNA containing a 5’-poly(A) leader. 
(A) Fluc mRNA containing a poly(A) leader in the 5’-UTR and Rluc mRNA with the Kozak 
consensus sequence in the 5’-UTR are co-transfected into cells. (B) Fluc mRNA with 5’-poly(A) 
leader was transfected in uninfected and VACV-infected cells along with Rluc mRNA. Five-
hours post-transfection, luciferase activity was measured using a luminometer. Rluc normalized 
Fluc activity is represented in uninfected and VACV-infected cells. Error bars indicate the 
standard deviations (SD) of at least three repeats. Student’s t-test was used to determine P-
values; ***P value < 0.001. 
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 Discussion 
All four-core steps are critical to the success of the in-vitro transcribed RNA-based 
luciferase reporter assay. Special attention should be given to primer design, especially for the 
T7 promoter sequence. T7 RNA polymerase starts transcription from the underlined first G 
(GGG-5’-UTR-AUG-) in T7 promoter added before the 5’-UTR sequence. Although the 
transcription start site (TSS) starts from the first G at the 5’ end, decreasing the number of G’s 
less than three in T7 promoter region decreased the RNA yield/output from in-vitro transcription. 
During the experiment, we observed that gel purified DNA product was not the best for in-vitro 
transcription as both yield and quality of RNA were lower. We only ran 5-10% of the PCR 
reaction in 1% agarose gel electrophoresis to determine the size and purified the rest 90-95%, 
using a PCR purification kit, to be used for in-vitro transcription. In case of non-specific 
amplification from PCR, cutting the desired sized band from gel and using gel purified DNA 
fragment is recommended. As the yield might be low, we suggest increasing the reaction volume 
for in-vitro transcription reaction. Similar to other transfection-based methods, DNA/RNA may 
stimulate DNA/RNA sensing pathways that may globally or selectively suppress translation. 
Therefore, data should be interpreted with cautions, although we did not experience problems 
potentially caused by this issue in our experiments. 
The proposed method is suitable for use in different model systems with some 
modifications like the method of mRNA delivery, internal control to be used, a suitable time for 
translation, sample preparation and analysis of data. The main limitation of this method is that it 
is a reporter assay to quickly test translation regulation by cis elements that does not completely 
reflect physiological conditions. Therefore, this method should be corroborated by other 
complementary experiments, if possible.  
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Compared to DNA modification, the roles of RNA modifications are less well 
understood. However, with the discovery of enzymes that write, read and erase RNA 
modifications (30–35), it is now possible to study the influence of RNA modification in gene 
expression (31–35). The in-vitro transcribed RNA-based luciferase reporter assay may be 
modified to incorporate different RNA modifications and used to test their effects on RNA 
translation. For example, this method can incorporate different cap analogs that have various 
modifications (30,31). Additionally, supplementing an internal RNA modifying enzyme during 
or after in-vitro transcription can possibly incorporate internal RNA modification. Addition of a 
modification to cap 0, cap 1, and an internal RNA modification will provide a tool to study the 
roles of these RNA modifications in translation. 
The in-vitro transcribed RNA-based luciferase reporter assay has a great potential and 
broad application in understanding basic biology about RNA translation. Different mechanisms 
for the initiation of translation, including cap-dependent initiation, cap-independent initiation, re-
initiation and internal initiation such as IRES can be studied using this method. On top of these 
advantages, this assay can be employed to test translation regulation by cis-elements at 5’-UTR 
and 3’-UTR in an mRNA. The described protocol uses PCR product, which provides the 
advantage to avoid lengthy cloning and quickly examine the effects of RNA elements on 
translation. To minimize potential errors during PCR, high fidelity polymerase and low PCR 
cycle number should be used. Alternatively, if a template is used frequently, the desired 5-’UTR 
and luciferase ORF can be cloned into a plasmid as the template of in-vitro transcription. 
Together, the protocol consolidates transcription and mRNA capping in a single reaction and 
utilizes conventional transfection and analysis that make in-vitro transcribed RNA-based 
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luciferase reporter assay a user-friendly, quick, and straightforward method to study mechanisms 
of mRNA translation. 
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 Abstract 
 The poly(A) leader at the 5’-untranslated region (5’-UTR) is an unusually striking feature 
of all poxvirus mRNAs transcribed after viral DNA replication (post-replicative mRNAs). These 
poly(A) leaders are non-templated and of heterogeneous lengths; and their function during 
poxvirus infection remains a long-standing question. Here, we discovered that a 5’-poly(A) 
leader conferred a selective translational advantage to mRNA in poxvirus-infected cells. A 
constitutive and uninterrupted 5’-poly(A) leader with 12 residues was optimal. Because the most 
frequent lengths of the 5’-poly(A) leaders are 8–12 residues, the result suggests that the poly(A) 
leader has been evolutionarily optimized to boost poxvirus protein production. A 5’-poly(A) 
leader also could increase protein production in the bacteriophage T7 promoter- based expression 
system of vaccinia virus, the prototypic member of poxviruses. Interest- ingly, although vaccinia 
virus post-replicative mRNAs do have 5’- methylated guanosine caps and can use cap-dependent 
translation, in vaccinia virus-infected cells, mRNA with a 5’-poly(A) leader could also be 
efficiently translated in cells with impaired cap-dependent translation. However, the translation 
was not mediated through an internal ribosome entry site (IRES). These results point to a 
fundamental mechanism poxvirus uses to efficiently translate its post-replicative mRNAs.  
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 Author Summary 
 Poxviruses continue to impact public health significantly, despite the eradication of 
smallpox, the deadliest disease in human history. As a tool, poxviruses are being engineered to 
treat various infectious diseases and multiple cancers. All poxvirus mRNAs transcribed after 
viral DNA replication have a poly(A) leader in their 5’-untranslated regions, the function of 
which remains elusive and represents a major gap in our understanding of the mechanisms 
fundamental to controlling poxvirus gene expression. In poxvirus-infected cells, a 5’-poly(A) 
leader was found to confer on poxvirus mRNAs a translational advantage that could be achieved 
in cells with impaired cap-dependent translation, which is used for translation of most eukaryotic 
mRNAs. Furthermore, since viruses typically exploit existing cellular functions, it is highly 
likely that these results point to an unknown cellular mRNA translation mechanism. Thus, the 
findings should facilitate targeting of poxvirus post-replicative mRNA translation for the 
development of novel antiviral strategies. The poly(A) leader can also be used to increase foreign 
gene expression when using the bacteriophage T7 promoter-based poxvirus expression systems. 
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 Introduction 
 All viruses rely entirely on their infected host cells for protein synthesis. Not surprisingly, 
to boost production of viral proteins, many viral evolutionary strategies usurp the host translation 
machinery. In doing so they target every step of protein synthesis, from mRNA production and 
stability, to translation initiation, elongation, and termination (1–4). Such mechanisms include 
mRNA sequence elements that enhance translation. A striking and unusual feature is found in all 
vaccinia virus (VACV) mRNAs transcribed after viral DNA replication; all of these mRNAs 
have a 5’-poly(A) leader in their 5’-untranslated regions (5’-UTRs) (5–8). It is well established 
that the 5’-UTR of an mRNA plays an important role in regulating eukaryotic mRNA translation 
(9); for the VACV mRNAs, however, it is unclear whether the 5’-poly(A) leader contributes to 
efficient translation of these VACV mRNAs. This lack of knowledge represents a major gap in 
understanding the fundamental gene expression mechanism of poxviruses. 
 Poxviruses comprise a highly dangerous class of emerging and re-emerging pathogens of 
humans and other vertebrates (10). Their large double-stranded DNA genomes encode hundreds 
of genes that are expressed in cascade at early, intermediate, or late stages of infection (10). The 
early genes initiate expression soon after viral entry, without the need for viral DNA replication; 
in contrast, intermediate and late genes can only be expressed after viral DNA replication. The 
intermediate and late genes are collectively referred to as post-replicative genes, and mainly 
function to form virions. In VACV, the prototypic poxvirus, 53 genes initiate transcription in the 
intermediate stage and 38 genes initiate transcription in the late stage (11, 12). All the VACV 
post-replicative mRNAs contain a non-templated 5’-poly(A) leader that is likely formed during 
transcription initiation, when the viral RNA polymerase slips at the conserved promoter 
sequence containing three A residues (6–8, 13). The 5’-poly(A) leaders of these mRNAs are of 
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heterogeneous length ranging from 3 to 51 A residues, with most between 8 and 12 A residues 
(5). For most VACV post-replicative mRNAs, the 5’-poly(A) leaders comprise the entire 5’-
UTR because the 5’-poly(A) leader and the first A residue of the start codon AUG overlap (5). 
Similar to eukaryotic cellular mRNAs, VACV early mRNAs and post-replicative VACV 
mRNAs are capped by methylated guanosine (14, 15). The 5’ cap is required for launching cap-
dependent translation that is the dominant translation mode in eukaryotic cells (16). Therefore, 
like eukaryotic cellular mRNAs, these VACV mRNAs can be translated in a cap-dependent 
manner. 
 To examine the function of the VACV poly(A) leader, we first developed an in vitro 
transcribed RNA-based reporter assay. We used this assay to demonstrate that the 5’-poly(A) 
leader of an mRNA can confer a translational advantage in VACV-infected cells. Remarkably, 
the translational advantage can be achieved in cells with impaired cap-dependent translation, 




 The 5’-poly(A) leader of an mRNA confers a translational advantage during VACV 
infection 
 To understand how the 5’-poly(A) leader may facilitate mRNA translation during VACV 
infection, we intended to develop a convenient reporter system. Though DNA plasmid-based 
luciferase expression is usually used to develop reporter system, technical issues posed barriers 
of the utility of it in VACV-infected cells as plasmids are able to replicate in VACV-infected 
cells (17); such plasmid replication makes it difficult to compare uninfected and VACV-infected 
cells. In addition, VACV promoter-driven transcription would generate mRNAs that are 
heterogeneous with respect to poly(A)-leader length (5); and, with plasmid templates, cryptic 
transcription would likely further complicate interpretation of the data (5, 11, 18). 
 To work around these complications, we developed an RNA-based luciferase reporter 
assay (Fig 3-1A). Using PCR, we first generated a DNA fragment containing the following 
elements in 5’ to 3’ order: a T7 promoter, the desired 5’-UTR sequence, the firefly luciferase 
(Fluc) ORF, and sequence encoding a poly (A) tail. The mRNA was transcribed from a bacterial 
T7-phage-promoter-based, in vitro transcription system, during which an m7G cap or its analog 
was incorporated. The resulting Fluc reporter mRNA was transfected into cells, together with a 
renilla luciferase (Rluc) reporter mRNA as the control of transfection efficiency. The Rluc 
mRNA contained a 5’-UTR bearing the Kozak consensus sequence that is important in 
translation initiation of eukaryotic mRNA (19). The normalized firefly luciferase activity was 
used as the indicator of translational potential of mRNAs with different 5’-UTRs.  
 Using this approach, we tested the translational efficiency of an Fluc mRNA whose 5’-
UTR bears a 20-residue 5’-poly(A) leader. Translational efficiency was compared in uninfected 
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and VACV-infected HeLa cells. The transfection was carried out at approximately 12 hpi, during 
the VACV post-replicative stage of infection (11). We tested the luciferase activities at 1, 2.5, 5 
and 8 h post transfection. As expected, both firefly and renilla luciferase activities increased over 
time. At 5 h, the luciferase activities did not reach or just reached the highest value in both 
uninfected and infected cells. In the following experiments, the luciferase activities were 
measured at approximately 5 h post transfection. Notably, compared to uninfected cells, VACV-
infected cells showed a significant increase of the normalized Fluc activity (Fig 3-1B). The 
control 5’-UTR from the cellular RNF165 mRNA, which contains no poly(A) leader, did not 
confer a translational advantage in VACV-infected cells (Fig 3-2C). The Fluc mRNA with a 
poly(A) leader amounts in VACV-infected and uninfected cells at 5 h post transfection were 
similar, shown here by quantitative RT-PCR (Fig 3-1C), ruling out the possibility of difference 
in luciferase activities due to different amounts of transfected RNA in VACV-infected cells. 
Interestingly, the translational advantage was not observed during the early replication stage as 
evidenced by using an A23 gene-deleted VACV (A23Δ) that arrested viral replication at the 
DNA replication stage (Fig 3-1D) (20). Together, these results showed that, in VACV-infected 
HeLa cells, mRNA with a 5’-poly(A) leader was more efficiently translated during the post-
replicative stage of VACV replication. 
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Figure 3-1: The 5’ poly(A) leader confers an mRNA translational advantage during the 
post-replicative stage of VACV replication. 
(A) Schematic of experimental approach. Messenger RNA was synthesized by a T7 promoter-
based in vitro transcription system. The firefly luciferase (Fluc) reporter mRNA under a 5’-UTR 
to be tested was transfected into cells together with a renilla luciferase (Rluc) reporter mRNA 
under a 5’-UTR-containing Kozak sequence. Luciferase activities were measured at 5 h post 
transfection using a luminometer with a dual luciferase assay system. (B) Fluc mRNA with a 5’-
poly(A) leader of 20 residues was transfected into uninfected or wild-type VACV-infected HeLa 
cells (12 hpi) together with an Rluc mRNA. Luciferase activities were measured at 5 h post 
transfection. The Rluc-normalized Fluc activity was normalized as 1 in uninfected HeLa cells. 
(C) The relative levels of Fluc mRNA from uninfected and VACV-infected HeLa cells were 
quantitated at 5 h post transfection by quantitative RT-PCR (qRT-PCR). The amount of mRNA 
in uninfected cells was normalized as 1. (D) Fluc mRNA with a 5’-poly(A) leader of 20 residues 
was transfected into uninfected, or A23-deleted recombinant VACV-infected HeLa cells (12 hpi) 
together with an Rluc mRNA. Luciferase activities were measured at 5 h post transfection. The 
Rluc-normalized Fluc activity was normalized as 1 in uninfected HeLa cells. Error bars represent 
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standard deviation (SD) of at least three experiments. P-values were obtained using the Student’s 
t-test; **P value < 0.01, ns = Not Significant (i.e. P value > 0.05). 
  
 12 residues is the optimal length of the 5’-poly(A) leader for conferring a 
translational advantage during VACV infection 
 Among VACV post-replicative mRNAs, the length of the 5’-poly(A) leader varies from 3 
to 51 residues, with most leaders between 8 and 12 residues (5). To determine the optimal length 
for conferring the translational advantage, we generated Fluc mRNAs with different poly(A) 
leader lengths, ranging from 4 to 20 residues. In VACV-infected cells, our reporter assays 
showed the translational advantage of the Fluc mRNAs increased as the length of the 5’-poly(A) 
leader increased to 12 residues (approximately 8-fold), and then decreased when leaders became 
longer (Fig 3-2A). The absolute luciferase activity was also the highest for the Fluc mRNA with 
a 5’-poly(A) leader of 12 residues in VACV-infected cells, further indicating the optimal length 
for conferring a translational advantage during VACV infection was 12 residues. We also 
examined the translational advantage during the VACV post-replicative stage by transfecting the 
12A-headed RNA at 2.5, 5, 7.5, 10 and 15 hpi. The results showed translational advantage 
during all the times examined. 
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Figure 3-2: The optimal length of 5’-poly(A) leader in conferring translational advantage is 
12 residues. 
(A) The Fluc reporter mRNAs with different 5’-poly(A)-leaders lengths were transfected into 
uninfected and VACV-infected HeLa cells, together with an Rluc mRNA. Luciferase activities 
were measured at 5 h post transfection. (B) Fluc reporter mRNA containing the A2L mRNA 5’-
UTR with (w) or without (w/o) a poly(A) leader, was transfected into uninfected and VACV-
infected HeLa cells, together with an Rluc mRNA. Luciferase activities were measured at 5 h 
post transfection. The Rluc-normalized Fluc activity was normalized as 1 in uninfected cells. (C) 
Fluc reporter mRNA containing RNF165 5’-UTR with (w) or without (w/o) an A-tract addition 
at the 5’-end was transfected into uninfected and VACV-infected HeLa cells together with an 
Rluc mRNA. Luciferase activities were measured at 5 h post transfection. Error bars represent 
standard deviation (SD) of at least three experiments. P- values were determined using the 
Student’s t-test; *P value < 0.05.  
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 Addition of a 5’-poly(A) tract at the 5’ end of a non-poly(A) UTR confers mRNA a 
translational advantage in VACV-infected cells 
 Although most VACV post-replicative mRNAs have a 5’-poly(A) leader immediately 
upstream of the start codon, some also contain a non-poly(A) intervening sequence (5), e.g., the 
viral A2L mRNA has a 32-nucleotide, non-poly(A) sequence between the poly(A) leader and the 
start codon (5). In VACV-infected cells, we tested the A2L mRNA 5’-UTR lacking a 5’-poly(A) 
tract, and found that it offered only slight translational advantage (Fig 2B). Adding a 12-residue 
A-tract to this mRNA at the 5’ end of the 5’-UTR, however, significantly increased its 
expression (Fig 3-2B). 
 To test whether a poly(A) leader can enhance translation potential of non-viral 5’-UTR 
during VACV infection, we added 12 A residues to the 5’ end of the RNF165 5’-UTR, which on 
its own only slightly enhance translation in VACV-infected cells (Fig 3-2C). In VACV-infected 
cells, addition of a 5’-end, 12-nucleotide A-tract to the RNF165 5’-UTR greatly enhanced 
translation of a downstream Fluc reporter (Fig 3-2C). These results further demonstrated that a 
5’-poly(A) leader conferred a translational advantage in VACV-infected cells. 
 
 An uninterrupted 5’-poly(A) leader is essential for optimal translation in VACV-
infected cells 
 We next investigated which A, amid the 12 residues, was vital for the poly(A) leader-
mediated translational advantage. We generated Fluc mRNAs, with A to U point mutations at 
each of the 12 positions. The mutation was represented as 12A_mut_AN, where mutation A to U 
was at the position ‘N’ upstream of start codon AUG (Fig 3-3A). Any A to U change in the 
poly(A) leader affected the translational advantage (Fig 3-3B). We also mutated the A to G in 
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several positions and these mutations all impaired the translational advantage. This result 




Figure 3-3: An uninterrupted 5’-poly(A) leader is essential for optimal translation in 
VACV-infected cells. 
(A) Schematic of representation showing individual 5’-poly(A) residues mutated to U. (B) Fluc 
reporter mRNA containing each of the mutated 5’-poly(A) leaders were transfected into 
uninfected and VACV-infected HeLa cells, together with an Rluc mRNA. Luciferase activities 
were measured at 5 h post transfection. The Rluc normalized Fluc activity was normalized as 1 
in uninfected HeLa cells. Error bars represent standard deviation (SD) of at least three 
experiments.  
 
 A 5’-poly(A) leader confers a translational advantage in multiple cell types and in 
myxoma virus infection 
 We examined the effect of the 5’-poly(A) leader on translation in different cell lines 
infected with VACV. During VACV infection, the translational upregulation of mRNA with a 
poly(A) leader was also observed in human foreskin fibroblasts (HFFs), rabbit RK13, and 
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monkey BS-C-1, though the enhancement levels varied (Fig 3-4A). We also tested the effect of 
the 5’-poly (A) leader on translation in RK-13 cells infected with Myxoma virus, a 
leporipoxvirus, and it similarly enhanced translational efficiency (Fig 3-4B). 
 
 
Figure 3-4: A 5’-poly(A) leader confers a translational advantage in multiple cell types and 
in myxoma virus infection. 
(A) An Fluc reporter mRNA with a 12-residue 5’-poly(A) leader was transfected into uninfected 
or VACV-infected HeLa, HFF, BS-C-1 or RK13 cells, together with an Rluc mRNA, at 24 and 
48 hpi. Luciferase activities were measured at 5 h post transfection. The Rluc-normalized Fluc 
activity was normalized as 1 in uninfected cells. (B) An Fluc reporter mRNA with a 12-residue 
5’-poly(A) leader was transfected into uninfected or myxoma virus-infected RK13 cells, together 
with an Rluc mRNA. Luciferase activities were measured at 5 h post transfection. Error bars 
represent standard deviation (SD) of at least three experiments. P-values were determined using 
the Student’s t-test; **P value < 0.01, *P value < 0.05. 
 
 Messenger RNA with a 5’-poly(A) leader is more efficiently translated than mRNA 
without a 5’-poly(A) leader in VACV-infected cells 
 We investigated whether, in VACV-infected cells, mRNAs containing a 5’-poly(A) 
leader have a translational advantage over those without a 5’-poly(A) leader. In previous study, 
we monitored the levels of active mRNA translation in VACV-infected HeLa cells by 
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simultaneous mRNA sequencing (RNA-Seq) and ribosome profiling (21, 22). Here, we 
calculated the genome-wide, relative translation efficiency (TE) of all VACV post-replicative 
mRNAs by the ratio of ribosome-protected mRNA to total mRNA, mapped to each transcript 
during the post-replicative stage at 4 and 8 hpi. VACV replication had proceeded to the post-
replicative stage at 4 hpi under the experimental condition, when most viral mRNAs have 5’-
poly(A) leaders (21). Although this calculation likely underestimated VACV mRNA translation 
efficiency, due to extensive read-through of VACV post-replicative mRNAs (5, 12), the VACV 
mRNAs were translated significantly more efficiently than cellular mRNAs (both in mock and 
VACV-infected cells), in a genome-wide manner (Fig 3-5). In fact, although there was an overall 
decrease of mRNA translation efficiency at 8 hpi compared to 4 hpi in VACV-infected cells, the 
translation efficiency of viral post-replicative mRNAs was still significantly higher than that of 
cellular mRNAs in mock-infected cells. These results indicated that, during a VACV infection, 
the post-replicative mRNAs with 5’-poly(A) leaders were more efficiently loaded with 
ribosomes, indicating higher translation efficiency of viral post-replicative mRNAs than that of 
host mRNAs (without 5’-poly(A) leaders). 
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Figure 3-5: VACV post-replicative mRNAs are more efficiently translated than cellular 
mRNAs. 
Boxwhisker plots of relative translation efficiency of VACV post-replicative mRNAs and host 
mRNAs at 4 and 8 hpi. Relative translation efficiency of mRNAs from uninfected HeLa cells is 
also shown. The bottom and top of the box indicate the first and third quartiles, respectively, 
with the line in the middle representing the median. Cell-M, cellular mRNAs from mock-
infected cells. Cell-I, cellular mRNAs from VACV-infected cells. VACV-I, VACV mRNAs. The 
highest relative translation efficiency of VACV-I was off scale. ***indicates a P value < 0.001. 
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 To examine further the role of the 5’-poly(A) leader, we carried out two experiments. In 
the first we constructed two plasmids in which an eGFP gene was under the control of the T7 
promoter. An A-tract or a sequence containing a Kozak element was inserted between the ATG 
and the T7 promoter transcription start site, respectively. We transfected the plasmid into HeLa 
cells and then infected them with a recombinant VACV, vT7LacOi, which encodes a T7 
polymerase gene whose expression is induced by Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(23). Because both plasmids were transfected into VACV-infected cells, the effect of VACV 
infection on plasmid replication was similar. Nevertheless, when cells were treated with IPTG, 
significantly more GFP was expressed from the plasmid containing the A-tract (Fig 3-6A). Small 
amount of eGFP protein expression was observed without IPTG induction, suggesting highly 
efficient translation of residual amount of mRNA from leaky expression in this inducible system. 
We quantified the eGFP mRNA levels by qRT-PCR and found similar mRNA amounts from A-
tract-containing plasmid at 5 μM of IPTG induction to that from Kozak sequence-containing 
plasmid at 25 μM of IPTG (Fig 3-6B), while the protein level from A-tract-containing plasmid 
was much higher (Fig 3-6A). 
 To establish further the role of the 5’-poly(A) leader in enhancing the translational 
efficiency of VACV post-replicative mRNA, we made two recombinant viruses expressing IPTG 
inducible eGFP based on the parental virus vT7LacOi. In the recombinant viruses, the T7 
promoter was followed by a Kozak sequence (vT7LacOi_Kozak-GFP) or an A-tract containing 
12 residues (vT7LacOi_A12-GFP) driving the eGFP ORF. With increasing concentrations of 
IPTG, both recombinant viruses responded with increasing GFP expres- sion (Fig 3-6C). 
Notably, the levels of eGFP expression were strikingly higher in vT7La- cOi_A12-GFP-infected 
cells (Fig 3-6C). Again, small amount of eGFP protein expression was observed without IPTG 
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induction, suggesting efficient translation of mRNA from leaky transcription. qRT-PCR showed 
vT7LacOi_Kozak-GFP infected cells expressed more GFP mRNA, from at 100 and 1000 μM, 
compared to that from vT7LacOi_A12-GFP-infected cells at 5 μM IPTG induction; however, the 
protein level was much higher from the latter vT7LacOi_A12-GFP-infected cells at 5 μM (Fig 
3-6D). We further compared the ratio of ribosome-bound GFP mRNA to total GFP mRNA with 
or without a poly(A) leader in VACV- infected cells by taking advantage of the two recombinant 
viruses. The result indicated that the relative ratio of the GFP mRNA transcribed from the 
vT7LacOi_A12-GFP genome (with a poly(A) leader) was significant higher (~3-fold) than that 
from the vT7LacOi_Kozak-GFP genome (without a poly(A) leader) (Fig 3-6E). In contrast, the 
ratios were similar for F17 mRNA, a late viral transcript with 5’-poly(A) leader from both 
viruses (Fig 3-6E). Taken together, these data supported that a poly(A) leader rendered VACV 
post-replicative mRNAs a translational advantage. 
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Figure 3-6: Messenger RNA with a 5’-poly(A) leader is more efficiently translated than 
mRNA without a 5’-poly(A) leader in VACV- infected cells. 
(A) HeLa cells were transfected with plasmids expressing eGFP from a T7 promoter and 
containing an A-tract or a Kozak sequence between the ATG and the T7 promoter. Cells were 
infected with vT7LacOi 24 h post transfection and different concentrations of IPTG were added 
to the media as indicated. At 24 hpi, Western blotting tracked eGFP and GAPDH (loading 
control) expression levels; and eGFP intensity was normalized to GAPDH, shown below. (B) 
Levels of eGFP mRNA levels for (A) were measured by qRT-PCR, and normalized to 18S 
rRNA. (C) HeLa cells were infected with recombinant VACV vT7LacOi_Kozak-GFP or 
vT7LacOi_A12-GFP. Indicated concentrations of IPTG were added to the culture media. At 24 
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hpi Western blotting tracked eGFP and GAPDH (normalization and loading control) expression, 
shown below. (D) Levels of eGFP mRNA expression of (C) were measured by qRT-PCR, and 
normalized to 18S rRNA. (E) HeLa cells were infected with vT7LacOi_A12-GFP or 
vT7LacOi_Kozak-GFP. Total and ribosome/polysome-bound RNAs were isolated at 15 hpi. The 
GFP and F17 mRNAs were measured by qRT-PCR and normalized to 18S rRNA. The ratios of 
ribosome/polysome-bound mRNA to total mRNA were calculated for GFP and F17, 
respectively. The ratios from vT7LacOi_A12-GFP-infected cells were normalized to one. 
**indicates a P value < 0.01. ns = Not Significant (i.e. P value > 0.05). 
 
 Messenger RNA with a 5’-poly(A) leader capped by an ApppG cap analog can 
confer a translational advantage in VACV-infected cells 
 Only approximately 5 to 10% of the mRNA expressed from the bacteriophage T7 
promoter in the VACV expression system contains the m7G cap structure (24), suggesting a 
possibility that the VACV post-replicative mRNAs with 5’-poly(A) leaders can be translated in a 
cap-independent manner in the experiment of Fig 3-6C. An ApppG cap cannot initiate cap-
dependent translation but does protect mRNA from degradation and so is often used to test cap- 
independent mRNA translation (25, 26). We compared Fluc mRNA synthesized with an ApppG-
cap to those with an m7G-cap, both with a 5’-poly(A) leader. Equal amounts of the mRNAs were 
transfected into VACV-infected HeLa cells, together with an m7G-capped Rluc mRNA, and 
luciferase activities were measured at 5 h post transfection. As expected, in uninfected cells, a 
100-fold higher luciferase activity was produced from the m7G-capped mRNA compared to the 
ApppG-cap mRNA. Strikingly however, in VACV-infected cells, mRNAs capped with an 
ApppG were also efficiently translated (Fig 3-7A). The levels of ApppG-capped, as well as the 
m7G-capped mRNA were similar at 5 h post transfection in uninfected and VACV-infected cells 
(Fig 3-7B), ruling out the possibility of difference in mRNA levels as a source of different 
luciferase activities. The translational advantage of ApppG-capped mRNA in VACV-infected 
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cells was also observed in different cell types. We tested ApppG-capped mRNAs with different 
lengths of 5’-poly(A) leaders and observed much higher luciferase activity in VACV-infected 
cells compared to uninfected cells (Fig 3-7C). Interestingly, the length dependence in ApppG-
capped mRNA was different from m7G-capped mRNA, which is likely due to different 
translation factors used in ApppG-capped and m7G-capped mRNA translation. In addition, large 
variations of ApppG-capped RNA translation in uninfected cells also contributed to the 
difference. Nevertheless, the conclusion of length dependence should be based on the mRNAs 
with m7G- capped mRNAs as the viral mRNAs are capped in VACV infected cells. These 
results suggested that mRNA with a 5’-poly(A) leader capped by an ApppG cap analog could 
confer a translational advantage in VACV-infected cells. 
 
 
Figure 3-7: Messenger RNA with a 5’-poly(A) leader capped by ApppG cap analog can 
confer the translational advantage in VACV-infected cells. 
(A) Relative luciferase activity from Fluc mRNA with a 5’- poly(A) leader capped with ApppG 
or m7G was measured at 5 h after transfection into uninfected or VACV- infected HeLa cells. 
Fluc activity was normalized by a co-transfected Rluc mRNA. Fluc activity from m7G- capped 
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mRNA in uninfected cells was normalized as 1. (B) Quantitative RT-PCR (qRT-PCR) compared 
the relative levels of Fluc mRNA capped by ApppG or m7G from uninfected and VACV-
infected HeLa cells at 5 h post transfection. The amount of mRNA in uninfected cells was 
normalized as 1. (C) ApppG-capped Fluc reporter mRNAs, with different lengths of 5’-poly(A) 
leaders, were transfected into uninfected and VACV- infected HeLa cells together with an m7G 
Rluc mRNA. Luciferase activities were measured at 5 h post transfection. Error bars represent 
standard deviation (SD) of at least three experiments. P-values were determined using the 
Student’s t-test; ***P value < 0.001, **P value < 0.01, *P value < 0.05, ns = Not Significant (i.e. 
P value > 0.05). 
 
 Messenger RNA with a 5’-poly(A) leader can confer a translational advantage in 
cells with impaired cap-dependent translation 
 Cap-dependent translation depends on the eukaryotic translation initiation factor 4E 
(eIF4E), which binds the 5’ cap (m7G) and recruits other translation-initiation components. The 
eIF4E binding protein 1 (4E-BP1) can bind to eIF4E and inhibit translation initiation; and 4E-
BP1 hyperphosphorylation disassociates it from eIF4E, allowing translation to initiate (27). To 
inhibit 4E-BP1 hyperphosphorylation, we suppressed PI3-kinase with the small molecule, 
LY294002, at 1 hpi and 8 hpi (28) (Fig 3-8A). The treatment reduced luciferase activities from 
transfected Fluc mRNA (with a poly(A) leader) and Rluc mRNA (with a 5’-UTR containing a 
Kozak sequence) in uninfected cells. In VACV-infected cells, mRNA with a 5’-poly (A) leader 
was still more efficiently translated, although somewhat less than in untreated cells, indicated by 
the ratios (3–5 fold) of firefly luciferase activities from VACV-infected cells to that from mock-
infected cells (Fig 3-8B). In contrast, the corresponding ratios of renilla luciferase activities from 
co-transfected mRNA containing a Kozak element in its 5’-UTR were lower than one (Fig 3-
8B). It is worth noting that we did not use renilla luciferase activities to normalize the firefly 
luciferase activities as the impairment of cap-dependent translation presumably affected renilla 
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mRNA translation. Moreover, in VACV-infected HeLa cells treated with LY294002 from 8 hpi, 
nascent viral protein synthesis was only slightly inhibited by LY294002, whereas translation of 
cellular proteins in uninfected cells was noticeably lower (Fig 3-8C). The treatment at 8 hpi 
rather than at earlier time of infection was to reduce the impact of unphosphorylated 4E-BP1 on 
VACV replication as early treatment of cells with LY294002 could inhibit VACV replication 
(28). 
 We employed another approach to impair cap-dependent translation by using three 
specific siRNAs that knocked down eIF4E at various levels in HeLa cells (Fig 3-8D). The 
knockdown of eIF4E reduced luciferase activities from transfected Fluc mRNA (with a poly(A) 
leader) and Rluc mRNA (with a 5’-UTR containing a Kozak sequence) in uninfected cells, 
corresponding to the levels of eIF4E knockdown. In contrast, in VACV-infected cells with eIF4E 
knockdown, the mRNA containing a poly(A) leader was efficiently translated, indicated by the 
high ratios of firefly luciferase activities from VACV-infected cells to that from uninfected cells 
(Fig 3-8E). The corresponding ratios of renilla luciferase activities from co-transfected mRNA 
containing a Kozak element in its 5’-UTR were much lower (Fig 3-8E), suggesting selective 
translation of poly(A)-headed mRNA in eIF4E knockdown cells infected with VACV. 
Consequently, the knockdown of eIF4E only reduced VACV gene expression at late time by 
approximately 2-fold using a reporter VACV expression firefly luciferase gene under the control 
of an early/late promoter (29) (Fig 3-8F). Similarly, there was only less than 2-fold reduction of 
virion production by a plaque assay (Fig 3-8G). Together, these findings demonstrated that even 
if cap- dependent translation was inhibited, mRNA with a 5’-poly(A) leader was still efficiently 
translated during the post-replicative stage of VACV replication.  
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Figure 3-8: VACV post-replicative mRNAs are efficiently translated when eIF4E is 
inhibited. 
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(A) Hypophosphorylation of 4E-BP1 was induced by LY294002 in uninfected and VACV-
infected HeLa cells at 1 hpi or 8 hpi and the cells were harvested for Western blotting analysis 
probed using anti-4E-BP1 antibody. An asterisk indicates hyperphosphorylated 4E-BP1. The 
arrow indicates hypophosphorylated 4E-BP1. (B) HeLa cells were treated with LY294002 at 1 or 
8 hpi. An Fluc reporter mRNA with a 12A leader was transfected into uninfected and VACV-
infected cells together with an Rluc mRNA at 12 hpi. Luciferase activities were measured at 5 h 
post transfection. The ratios of Fluc and Rluc activities from VACV-infected to uninfected HeLa 
cells were calculated, respectively. (C) HeLa cells infected with VACV and treated with 
LY294002 at 8 hpi. Newly synthesized proteins were labeled by AHA at 20 hpi and detected 
using antibodies against biotin conjugated to AHA using the Click-IT chemistry-based 
technique. The blots of infected-cell lysates were from different lanes on the same gel. (D) HeLa 
cells were transfected with control (siNC) or siRNAs targeting eIF4E. The protein levels of 
eIF4E and GAPDH were detected using specific antibodies 48 h post transfection. (E) HeLa cells 
were transfected with control or eIF4E siRNAs as in (D). An Fluc reporter mRNA with a 12A 
leader was transfected into uninfected and VACV-infected cells together with an Rluc mRNA at 
12 hpi. Luciferase activities were measured at 5 h post transfection. The ratios of Fluc and Rluc 
activities from VACV-infected to uninfected HeLa cells were calculated, respectively. (F) HeLa 
cells were transfected with control or eIF4E siRNAs as in (D). 48 h post-transfection, the cells 
were infected with a recombinant VACV expressing firefly luciferase gene under a viral 
early/late promoter. Luciferase activities were detected at 8 hpi. (G) HeLa cells were transfected 
with control or eIF4E siRNAs as in (D). 48 h post-transfection, the cells were infected with 
VACV. The viral titers were determined at 24 hpi using a plaque assay. Error bars represent 
standard deviation (SD) of at least three experiments. P-values were determined using the 
Student’s t-test; **P value < 0.01. 
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 The 5’-poly(A) leader is not an internal ribosome entry site (IRES) 
 The IRES is the best-studied cap-independent mechanism and is used by many RNA 
viruses, e.g., poliovirus uses an IRES to initiate cap-independent translation (30, 31). To test 
whether an A-tract can function as an IRES, we synthesized a bicistronic mRNA in which renilla 
luciferase (Rluc) and firefly luciferase (Fluc) coding sequences are connected by a poliovirus 
IRES (polio IRES), an A-tract with 20 A residues, or a Kozak-containing 20-nt sequence (Fig 
3-9A). The synthetic mRNA had an m7G cap so Rluc translation was cap-dependent. The polio 
IRES should drive Fluc translation whereas the Kozak-containing sequence should not. Since our 
reporter system was based on mRNA rather than a plasmid we could rule out interference from 
unexpected Fluc transcripts driven by cap-dependent translation. Synthetic RNA was transfected 
into uninfected or VACV-infected HeLa cells and the Fluc and Rluc activities were measured. 
As expected, Fluc driven by a poliovirus IRES was translated considerably in both uninfected 
and VACV-infected cells (Fig 3-9B); however, Fluc expression driven by the A-tract was 
negligible in both uninfected and VACV-infected cells, and at a level similar to that from the 
Kozak-containing sequence (Fig 3-9B). Interestingly, a comparison of Fluc and Rluc activities in 
uninfected and VACV infected cells indicated that the poliovirus IRES-driven Fluc mRNA 
translation was enhanced in VACV-infected cells, as evidenced by the significantly higher 
Fluc/Rluc ratio of the poliovirus IRES bicistronic mRNA (Fig 3-9B). These data indicated that 
the poly(A) leader did not function as an IRES. 
105 
 
Figure 3-9: The 5’-poly(A) leader is not an internal ribosome entry site (IRES). 
(A) Schematic of the bicistronic reporter mRNAs flanked by a poliovirus IRES, 20 A residues, 
or a Kozak-containing sequence. (B) The in vitro transcribed bicistronic mRNA was transfected 
into uninfected and VACV-infected HeLa cells and luciferase activities were measured 5 h post 
transfection. The ratios of Fluc to Rluc activities were calculated and displayed. Error bars 
represent standard deviation (SD) of at least three experiments. P-values were determined using 




Conferring a translational advantage by the 5’-poly(A) leader during poxvirus infection 
 After infection, VACV takes over host cell machineries to synthesize viral proteins 
rapidly and shut off cellular protein synthesis globally (32, 33). This can be largely attributed to 
cellular mRNA depletion and production of a large amount of viral mRNAs (11, 22). Cellular 
mRNA decay is accelerated due to VACV-encoded decapping enzymes and cellular transcription 
is also inhibited (34–39). In the meantime, virus-encoded, DNA-dependent RNA polymerase 
efficiently transcribes VACV mRNAs. Several hours after infection of HeLa cells, 70% of total 
mRNA is viral (11, 12). In VACV-infected cells, although the role of mRNA manipulation in 
host protein synthesis shutoff seems clear, it remains largely elusive whether and how the 
translational control contributes. As the takeover of protein synthesis in infected cells occurs 
after VACV DNA replication, it is conceivable that the VACV post-replicative mRNAs exert a 
translational advantage. 
 The 5’-poly(A) leader in several post-replicative VACV mRNAs was initially discovered 
almost three decades ago (6–8, 13). Our genome-wide survey demonstrated that all viral post-
replicative mRNAs contain 5’-poly(A) leaders (5). The 5’-UTR can regulate translation 
efficiency of an mRNA (9). Nevertheless, it was unclear whether the 5’-poly(A) leader has a 
specific function or is simply because the VACV RNA polymerase “accidentally” slips during 
transcription at three T residues on the template strand. This study demonstrated that poxviruses 
use the 5’-poly(A) leader to efficiently synthesize viral post-replicative proteins, most of which 
are the viral building blocks. The finding here demonstrated the role of the 5’-poly(A) leader in 
efficient translation of VACV post-replicative mRNAs during VACV replication. However, our 
findings do not rule out other mechanisms that confer a translational advantage of VACV post-
replicative mRNAs. Interestingly, although the enhancement of poly(A)-headed mRNA in 
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VACV-infected cells in all experiments, the enhancement levels varied in different experiments. 
The variations were likely due to quick VACV replication that resulted in variations of cellular 
environments at the time of RNA transfection. Most of the 5’-poly(A) leaders of VACV post-
replicative mRNAs are between 8 and 12 A residues (5); this agrees with data showing 5’-
poly(A) leaders within that range confer the optimal translational advantage. Thus, the 5’-
poly(A) leader is convincingly an evolutionarily optimized, transcriptionally and translationally 
coordinated element that VACV utilizes to maximize its protein production. 
 A-rich tracts with various lengths are present in other eukaryotic mRNA 5’-UTRs. In 
yeast, A-rich tracts can be found in over 3,000 5’-UTRs. Interestingly in yeast, protein 
abundance correlates with the size of the A-rich tracts and mRNAs containing 5’-UTRs with 12 
consecutive A residues generate large amounts of protein. Although the number of A residues is 
similar to those in the 5’-poly(A) leaders of VACV mRNAs, the yeast A-tracts are usually 
embedded internally in the 5’-UTR (40). In contrast, poly(A) leaders of VACV mRNAs are 
located at the very 5’ end and usually are the only 5’-UTR sequence. An A-rich tract was also 
found in the 5’-UTRs of other viruses, such as crucifer-infecting tobamovirus and avian 
herpesvirus (41, 42); however, as in yeast, they are usually present inside of the 5’-UTRs rather 
than at the very 5’ end. Additionally, unlike many of the other A-rich tracts, the 5’-poly(A) 
leader of VACV mRNA is not an IRES, although it can be efficiently translated in cells with 
impaired cap-dependent translation. These differences suggest poxvirus mRNAs employ a 
distinct mechanism. 
 Although our findings strongly indicate higher translation efficiency of poly(A)-headed 
mRNA in VACV-infected cells, especially since there was no significant difference with 
transfected RNAs after 5 h, the possibility that poly(A)-headed mRNA transcribed from viral 
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genome is more stable in VACV-infected cells has not been ruled out. In fact, we observed 
higher levels of 12A-headed mRNA (IPTG at 5 μM) than Kozak sequence-headed mRNA (IPTG 
at 25 μM) transcribed from recombinant VACV genome (Fig 3-6D), which could be attributed to 
higher mRNA stability and/or more active transcription of the 12A-headed mRNA. 
 
Could the 5’-poly(A) leader mediate cap-independent translation during poxvirus 
infection? 
 Many RNA viruses, such as piconaviruses, crucifer-infecting tobamovirus, hepatitis C 
virus, and Foot-and-mouth disease virus can synthesize their proteins through a cap-independent 
translation mode (41, 43–45). The most studied mechanism is through viral IRESs, which 
usually bear highly complex structures to recruit 40S ribosome (46). Some RNA viruses use 
other cap-independent mechanism such as 3’ cap-independent translational enhancer (3’CITE) in 
their mRNAs to recruit ribosome subunits (47, 48). Cap-independent translation is less 
appreciated in DNA viruses. In this study, we show that a poly(A)-headed mRNA is efficiently 
translated in cells with impaired cap-dependent translation (Fig 3-8) as well as without an m7G 
cap (Fig 3-7), which strongly suggests that a short, unstructured 5’-poly(A) leader may mediate 
cap-independent translation in VACV-infected cells. In literature, Mulder et al. showed that 
VACV protein synthesis only requires a low level of intact translation initiation factor eIF4F 
(49). In another in vitro study, Shirokikh et al. showed that the translation initiation complex 
could be formed on a 5’-poly(A) leader mRNA without the need of eIF4E, a rate-limiting and 
cap binding translation factor (50). Additionally, in yeast, crucifer-infecting tobamovirus, and 
avian herpesvirus, an A-rich tract in some 5’-UTRs is suggested to function as an IRES (26, 41, 
42), an RNA element allowing for a form of 5’ cap-independent translation initiation. 
 Recruitment of poly(A) binding protein (PABP) through the A-rich tracts plays an 
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important role in IRES-mediated cap-independent translation initiation. During the review 
process of this manuscript, Jha et al. reported that a small ribosomal subunit protein, receptor for 
activated C kinase (RACK1), is important for efficient translation of VACV post-replicative 
mRNAs (51). RACK1 was previously found to be important for IRES-mediated cap-independent 
translation of several RNA viruses (52). These findings support the possibility that the poly(A) 
can mediate cap-independent translation although it does not serve as an IRES (Fig 3-9). 
 VACV encodes its own capping enzymes, which cap VACV mRNAs with methylated 
guanosine, including the post-replicative mRNAs (15). The mRNA translation occurs in the 
“viral factory”, the site of viral replication (53). Cap-dependent translation initiation factors are 
recruited to and concentrated within discrete subcellular compartments of the viral factory (54). 
VACV mRNAs can be translated in a cap-dependent manner. The possibility that a cap-
independent translation mode can be employed by the VACV post-replicative mRNAs to confer 
a translational advantage does not exclude cap-dependent translation used by these mRNAs. It is 
likely that VACV uses both cap-independent and cap-dependent translation modes to maximize 
the translation potential of viral post-replicative mRNAs in different cellular environments. 
VACV infection globally shuts off host protein synthesis after DNA replication, coinciding with 
viral post-replicative mRNA synthesis (32, 33). During this stage, it is conceivable that the 
ability to utilize cap-independent translation is important because the global protein synthesis 
shutoff downregulates expression of most host proteins, including cap-dependent translation 
initiation factors. Meanwhile, a large amount of viral mRNAs need to be translated. 
Cap-independent translation could also ensure efficient viral mRNA translation in other 
physiological conditions, such as during cell mitosis and various stress conditions (including 
poxvirus infection itself), in which cap-dependent translation is suppressed (55). In fact, under 
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different conditions, some eukaryotic cellular mRNAs can employ both translational modes to 
ensure synthesis of necessary corresponding proteins (46). Similar to these cellular mRNAs, the 
VACV post-replicative mRNAs may switch between cap-dependent and cap-independent 
translation according to the availability of eukaryotic translation initiation factors and cellular 
environments. 
 While the experiments using an ApppG-capped RNA strongly support a cap-independent 
translation mode during the post-replicative stage of VACV replication (Fig 3-7), a caveat of the 
experiments is that VACV encodes both decapping and recapping enzymes that may remove and 
recap the transfected ApppG-capped mRNA in VACV-infected cells (14, 34, 35, 56). We do not 
rule out the possibility that the poly(A)-headed mRNA employs an alternative cap-dependent 
translation mode that requires a minimal amount of cap-binding translation initiation factor 
eIF4E. In fact, a minimal requirement of the eIF4F translation initiation complex has also been 
observed during the late stage of cytomegalovirus infection (57). Future experiments will further 
investigate these aforementioned different possibilities. Recombinant VACVs with defective 
decapping or capping enzyme expression will be useful in such study. 
 As all viruses rely on host translation machinery to synthesize viral proteins, VACV 
likely employs and modulates an existing cellular mechanism for its mRNA translation. The data 
presented here is an important step in uncovering this novel cellular translation mechanism. The 
5’-poly(A) leader can also be used to increase foreign gene expression when using poxvirus-
based vectors, as demonstrated in this study. 
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 Materials and methods 
Cells and viruses 
HeLa cells (ATCC-CCL2) and human foreskin fibroblasts (HFFs, kindly provided by Dr. 
Nicholas Wallace) were cultured in Dulbecco’s modified eagle’s medium (DMEM, Quality 
Biological) with 10% fetal bovine serum (FBS, Peak Serum). BHK21 (C13) (ATCC CCL10), 
RK13 (ATCC CCL37) and BS-C-1 (ATCC CCL-26) cells were cultured in Eagle's Minimum 
Essential Medium (EMEM, Quality Biological) with 10% FBS (Peak Serum). All cells were 
incubated in a 5% CO2 atmosphere at 37°C. The recombinant VACV with a firefly luciferase 
gene under the control of a viral early/late promoter was a gift from Dr. Bernard Moss and 
described previously (29). The recombinant VACV with intermediate transcription factor gene 
A23 deletion (vA23Δ) was a gift from Dr. Bernard Moss and was described elsewhere (20). 
Preparation, infection and titration (by plaque assay) of the VACV Western Reserve (WR) strain 
(ATCC VR-1354) and recombinant VACVs derived from it were carried out as described 
elsewhere (58). Myxoma virus was kindly provided by Dr. Stefan Rothenburg. 
In vitro RNA synthesis 
Primers were designed to produce DNA fragment containing the T7 promoter followed by a 5’-
UTR sequence of interest, reporter gene (firefly or renilla Luciferase) and poly(A) tail coding 
sequence. These primers were used to synthesize DNA fragments by PCR using a Q5 High-
Fidelity 2X Master Mix (New England Biolabs). The synthesized DNA was used as template to 
generate RNA using a HiScribe T7 Quick High Yield RNA Synthesis Kit (New England 
Biolabs). The synthesized RNA was capped using m7G (Anti-Reverse Cap Analog (ARCA)) or 
ApppG cap analog (New England Biolabs) according to the manufacturer’s instructions. The 
resulting RNA was purified using a PureLink RNA Mini Kit (Thermo Fisher Scientific) and 
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quantified using a NanoDrop ND-2000 instrument (Thermo Fisher Scientific). The IRES reporter 
plasmid pcDNA3 RLUC POLIRES FLUC used for biscistronic mRNA production was a gift 
from Nahum Sonenberg (Addgene plasmid # 45642) (31). 
Transfection and luciferase assay 
Capped and polyadenylated firefly luciferase RNA (480 ng in one well of a 24-well plate) was 
transfected into cells using Lipofectamine 2000 Transfection Reagent (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. When necessary, renilla luciferase reporter RNA 
(20ng in one well of a 24-well plate) was co-transfected as an internal control. The luciferase 
activities were measured at 5 h post transfection using a dual-Luciferase Reporter Assay System 
(Promega), according to the manufacturer’s instructions, on a microplate luminometer 
(Promega). 
Knockdown of eIF4E using small interfering RNA (siRNA) 
The siRNAs were purchased from Integrated DNA technologies (IDTDNA). HeLa cells were 
transfected with sieIF4E or siNC (negative control) at the final concentration of 5 nM using 
Lipofectamine RNAiMax (Thermo Fisher Scientific) according to the manufacturer's 
instructions. The cells were harvested to examine the effects of siRNA knockdown by Western 
blotting analysis or infected with VACV for various assays 48 h post transfection. 
Western blotting analysis 
Cells were lysed and heated in sample buffer. The cell lysates were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred onto a 
polyvinylidene difluoride membrane, which was blocked with 5% bovine serum albumin (BSA) 
in TBST solution (50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 0.05% Tween 20) at room 
temperature for 1 h. The membrane was then incubated with primary antibody in TBST-BSA 
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buffer for 1 h at room temperature or overnight at 4°C, washed with TBST, incubated with 
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature, washed with 
TBST, and developed using a chemiluminescent substrate. The intensities of the bands were 
quantified using Image J. 
Antibodies and chemicals 
Anti-GFP, anti-eIF4E and anti-4E-BP1 antibodies were purchased from Cell Signaling 
Technology. Anti-GAPDH was purchased from Abcam. LY294002 was purchased from Cayman 
Chemical. 
Pulse-chase labeling and detection of newly synthesized proteins with AHA (L-
azidohomoalanine) 
The experiment was carried out using Click-iT AHA nascent protein kit (Thermo Fisher 
Scientific). Briefly, HeLa cells were cultured in a T-75 flask to a confluence of 95%. The cells 
were infected or mock infected with VACV at a MOI of 10. The cells were treated with DMSO 
or LY294002 (25 μM) at the desired times of infection. Cell culture medium was replaced with 
methionine-free medium at the indicated times. After incubation in methionine-free medium, 
AHA was added to the medium at 100 μM for 2 h. The cells were scraped off the flask and 
collected by centrifuging. Cell pellets were then suspended with 500 μl of lysis buffer containing 
500U of benzonase for 30 min. After centrifuging at 12,000 g at 4°C for 10 min. The proteins 
were precipitated with methanol and chloroform and resolubilized in 50 mM Tris-HCl containing 
1% SDS, pH 8.0. AHA-containing peptides were labeled with alkyne-biotin, by subjecting 200 
μg of proteins to the click reaction for 30 min using the Click-iT protein labeling kit according to 
the manufacturer’s instruction (Thermo Fisher Scientific). Proteins were re-precipitated with 
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methanol and chloroform, solubilized with 50mM Tris-HCl containing 1% SDS, pH 8.0, for 
Western blotting analysis. 
Recombinant VACV generation 
The recombinant viruses used in this study include vT7LacOi-Kozak-GFP and vT7LacOi-A12-
GFP. The vT7LacOi-Kozak-GFP and vT7LacOi-A12-GFP were derived from the parental virus 
vT7LacOi that is capable of isopropyl-beta-D-thiogalactopyranoside (IPTG)-inducible T7 
promoter-controlled expression of foreign genes (59). The eGFP-encoding sequence downstream 
of either a Kozak encoding sequence (A ATT GTG AGC GCT CAC AAT TCC CGC CGC CAC 
C; vT7LacOi-Kozak-GFP) or 12 A residues (vT7LacOi-A12-GFP), under the control of a T7 
Promoter, were inserted between the VACWR146 and 147 ORFs. 
Quantitative reverse transcription PCR (qRT-PCR) 
Total RNA was extracted using TRIzol reagent (Ambion) followed by purification using a 
PureLink RNA Mini Kit (Thermo Fisher Scientific). The RNA was used to synthesize cDNA 
using SuperScript III First-strand synthesis (Invitrogen) according to the manufacturer’s 
instructions using random hexamers. Quantitative RT-PCR was carried out using iTaq Universal 
SYBR Green Supermix (Bio-Rad) according to the manufacturer’s directions and specific 
primers of desired genes. 
Isolation of total RNA and ribosome- and polysome-bound RNA 
HeLa cells were treated with 100 μg/ml cycloheximide for 15 minutes at 37°C before harvesting. 
The harvested cells were processed to isolate total mRNAs or ribosome- and polysome-bound 
mRNAs as described with modifications (60). The total RNA was isolated using TRIzol reagent 
followed by purification using a PureLink RNA Mini Kit. For ribosome/polysome-bound RNA, 
the harvested cells were resuspended in ribosome homogenization buffer (50 mM Tris-HCl (pH 
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7.5), 5 mM MgCl2, 25 mM KCl, 1% Triton X-100, 100 μg/ml cycloheximide, 10 mM Vanadyl 
ribonucleoside complex and 0.2 M sucrose) and incubated for 20 min on ice. After centrifuging 
at 20,000 g for 10 min at 4°C, the supernatant was collected and gently layered over sucrose 
cushion buffer (50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 25 mM KCl, 100 μg/ml 
cycloheximide, 10 mM Vanadyl ribonucleoside complex and 2 M sucrose) and ribosome 
homogenization buffer (1:1 ratio). The sucrose cushion was centrifuged at 35,000 rpm using 
SW41 Ti rotor for 20 hrs. The ribosome and polysome-bound mRNA was isolated from the 
pellet using TRIzol reagent followed by purification using a PureLink RNA Mini Kit. DNA was 
removed using DNase I from RNA samples. 
Relative translation efficiency analysis 
Relative translation efficiency (TE) was defined as the ratio of ribosome-protected RNA reads to 
mRNA reads as described elsewhere (61, 62). The mRNA and ribosome-protected RNA reads 
were obtained from the studies described elsewhere (21, 22). 
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 Abstract 
The 5'-poly(A) leader, a unique feature among all poxvirus post-replicative mRNAs, confers a 
translational advantage to viral post-replicative mRNAs. The poly(A) leader present at the very 
5' end of the 5'UTR bestows a translation advantage in cells with impaired cap-dependent 
translation. In the present study, we identified a cellular RNA-binding protein, La-related protein 
4 (LARP4) that is required for 5'-poly(A) leader-mediated translational advantage. We carried 
out an immunofluorescence assay to determine the factors enriched in the virus factory, where 
poxvirus post-replicative mRNAs translate. During VACV infection, LARP4—unlike poly(A) 
binding protein (PABP)—is enriched in the virus factory. Depletion of LARP4 significantly 
reduced the VACV titer and blocked post-replicative protein expression. Despite the moderate 
decrease in VACV DNA replication and post-replicative gene transcription observed during 
LARP4 depletion, the major effect is observed on the translation of post-replicative mRNAs. In 
fact, a decrease in LARP4 protein level diminishes 5’-poly(A) leader-mediated translational 
advantage. Importantly, LARP4 is crucial for the cap-independent mode of translation from 
5’-poly(A) leader. Further studies showed that LARP4 is dispensable for mRNA stability during 
VACV infection. These results indicate that LARP4 is required for efficient VACV post-
replicative mRNA translation. 
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 Introduction 
 Viruses induce the global shutdown of host protein synthesis—termed host shutoff—that 
facilitates host immune evasion and the reapportion of cellular resources (1–4). To selectively 
synthesize viral proteins during host shutoff, viruses use numerous approaches to regulate 
translation machinery and/or possess a sophisticated evolutionary element in their mRNA (5–9). 
Intriguingly, poxvirus devised a dual and coordinated approach to selectively synthesize viral 
proteins: (I) by modulating factors of host translation machinery (10–12) and (II) by acquiring an 
evolutionarily optimized cis element in its post-replicative mRNA (13–16). The cis element 
present in all poxvirus post-replicative mRNAs is known as the 5'-poly(A) leader (13–16). 
Previous studies have shown that the 5'-poly(A) leader provides a translational advantage to viral 
post-replicative mRNAs during poxvirus-induced host shutoff (10,17). Remarkably, poxviral 
poly(A) leader-mediated translation advantage can be achieved using both cap-dependent and 
cap-independent modes to maximize their protein synthesis during an adverse condition of host 
shutoff (17,18). However, the mechanism and specific factors required for the poly(A) 
leader-mediated translational advantage remains elusive. 
 RNA-binding proteins play a crucial role in regulating the translation of mRNAs. One 
such family of RNA-binding proteins is the La protein family that comprises the La RNA-
binding motifs and the RNA recognition motif (19,20). As a member of the La protein family, 
La-related protein 4 (LARP4) is known to bind to poly(A) RNA sequences, the receptor for 
activated C kinase 1 (RACK1), and poly(A) binding protein (PABP) (19). LARP4 promotes 
mRNA stability by binding to the 3' poly(A) tail and preventing deadenylation (21). The RNA-
binding La motif, RNA recognition motif, and poly(A) binding protein-interacting domain in 
LARP4 are necessary for its mRNA stability function (21). Moreover, the predominantly 
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cytoplasmic LARP4 is also postulated to play a role in translation as it is associated with actively 
translating ribosomes (19).  
 Although LARP4 is suggested to be important in translation and known to bind to 
RACK1, which is required for poly(A) leader-mediated translational advantage, whether LARP4 
is imperative for poxvirus 5'-poly(A) leader bearing mRNA translation remains unknown. In the 
present study, using an immunofluorescence assay, we showed that LARP4 is enriched in the 
virus factory during infection with VACV, the prototypic poxvirus. Further experiments 
demonstrated that LARP4 depletion is unfavorable for VACV replication and negatively affects 
post-replicative gene expression. Moreover, LARP4 is essential for 5’-poly(A) leader-mediated 
translation, especially for the cap-independent translation mode. During VACV infection, 
LARP4 binding to 5'-poly(A) leader is dispensable for mRNA stability. Our results suggest that 
LARP4 promotes poly(A) leader translational advantage probably via direct binding to the 
5'-poly(A) leader cis element, thereby enhancing translation initiation. 
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 Results 
The RNA-binding protein La-related protein 4 (LARP4) is enriched in the virus 
factory during VACV infection  
 The unique 5’-poly(A) leader of poxvirus post-replicative mRNA provides a translational 
advantage to these viral mRNAs in cells with impaired cap-dependent translation (10,17). Since 
the 5’-poly(A) leader is at the 5'-UTR region that regulates translation, 5’-poly(A) 
leader-mediated translational advantage can be achieved through both cap-dependent and 
cap-independent translation, which supports the notion that certain trans-factors may bind 
directly to the 5’-poly(A) leader of an mRNA to initiate translation, thereby critically influencing 
VACV post-replicative gene expression (17,22). VACV replicates in the cytoplasm forming a 
cytoplasmic DNA foci known as a virus factory (23). Since VACV post-replicative mRNA 
translation occurs within the virus factory, trans-factor binding to the poly(A) leader must be 
enriched in the virus factory (11,24). To gain insight, we examined the sub-cellular localization 
of proteins that have been known to bind to the poly(A) sequence in RNA (19,25,26). Our first 
idea was to test for well recognized poly(A) RNA-binding protein, PABP (25). Determination of 
the sub-cellular localization of PABP in uninfected and VACV-infected primary human foreskin 
fibroblasts (HFFs) was determined by immunofluorescence assay. For this assay, uninfected and 
VACV-infected cells (MOI=2, 12 hpi) were fixed with formaldehyde and stained with antibodies 
for PABP and nuclear stain DAPI. On top of staining cellular nuclei, DAPI also stains the virus 
factory (indicated by V). As expected, PABP was localized in the cytoplasm in uninfected HFF 
(Fig 4-1A, top row). Notably, we observed that PABP was excluded from the virus factory 
during VACV infection (Fig 4-1A, bottom row). Although initially surprising, we discovered 
literature indicating that—unlike other translation initiation factors—PABP is not enriched in the 
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virus factory during VACV infection (11,27). These observations suggest that PABP might not 
be required for poly(A) leader-mediated function. 
 In pursuit of a potential poly(A) RNA sequence binding protein, we came across LARP4, 
a member of the La protein family that is known to bind to poly(A) sequence at the 3' end of an 
mRNA (19,21,28). Our immunofluorescence assay showed that endogenous LARP4 primarily 
localizes in the cytoplasm of uninfected HFFs (Fig 4-1B, top row). During VACV infection, 
LARP4 enrichment occurs in multiple regions of the cytoplasm. Notably, the LARP4 enrichment 
region co-localizes to the virus factory where VACV post-replicative mRNA translation occurs 
(Fig 4-1B, middle row). The LARP4 enrichment in virus factory was detected as early as 4 hpi 
and continued to a tested time of 24 hpi. Next, we sought to understand whether LARP4 
enhancement in the virus factory requires VACV DNA replication and/or post-replicative gene 
expression. To answer this question, we utilized the intermediate transcription factor gene A23 
deleted VACV (VACV-ΔA23), which undergoes DNA replication (forming virus factory); 
however, the post-replicative gene expression is blocked. HFFs were infected with VACV-
ΔA23, and sub-cellular localization of LARP4 was determined. At 12 hpi, we observed many 
virus factories. However, LARP4 was remarkably not enriched but excluded from these factories 
(Fig 4-1B, bottom row). These data demonstrate that LARP4 is enriched in the virus factory 




Figure 4-1: LARP4 is enriched in Virus factory during VACV infection. 
(A) Immunofluorescence assay of uninfected and WT-VACV infected HFF (MOI=2, 12 hpi). 
Anti-PABP was used to determine localization of PABP (red) and DAPI (blue) was used to stain 
cellular nuclei and virus factory (indicated by V). Panel shows representative image. Scale bars: 
5 µm. (B) Immunofluorescence assay of uninfected and WT-VACV or VACV-△A23 infected 
HFF (MOI=2, 12 hpi). At 12 hpi, HFFs were fixed and stained with respective antibodies. 
Anti-LARP4 was used to determine localization of LARP4 (red) and DAPI (blue) was used to 
stain cellular nuclei and virus factory (indicated by V).  Panel shows representative image. Scale 
bar: 5 µm. 
 
Reduction of LARP4 protein level reduces VACV replication 
 Most of the VACV post-replicative genes encode for structural proteins required for 
virion formation and is thus vital for viral replication (23). If LARP4 is necessary for the 
5'-poly(A) leader, a feature of VACV post-replicative genes—depletion of LARP4—would 
affect VACV replication. To test this, HFFs depleted with LARP4 were infected with VACV at 
the multiplicity of infection of three. At 1 hpi, culture media was changed with or without the 
DNA replication inhibitor cytosine arabinoside (AraC, 40 μg/mL). At 12 hpi, we tested the 
cytopathic effect (CPE) of VACV infection on HFFs. Basic light microscopy showed that 
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LARP4 depletion with two siRNAs (#1 and #2) protected the cells from VACV-induced CPE 
compared to negative control siRNAs (Fig 4-2A). AraC treatment prevents VACV DNA 
replication; however, early gene expression continues up to 12 hpi (29). In fact, certain VACV 
early gene can induce CPE regardless of the replication status of the virus (30). This indicates 
that the minor CPE observed in the AraC treatment was instigated by early gene expression (Fig 
4-2A). To determine VACV replication during LARP4 depletion in HFFs, we performed a 
plaque assay at 24 hpi. Compared to the control siRNAs, both siRNAs (#1 and #2) targeting 
LARP4 reduced VACV titer by 10-fold and 14-fold, respectively (Fig 4-2B). These results 
showed that a decrease in LARP4 leads to a concomitant reduction in VACV replication. 
Moreover, a previous study indicated that LARP4 depletion reduces cellular protein synthesis by 
10-15% (19). During siRNA-mediated depletion of LARP4 in HFFs, we did not observe any 
decrease in the puromycin-labeled nascent cellular protein synthesis (Fig 4-2C). This result rules 
out the possibility of decreased VACV titer due to the decline of nascent cellular protein 
synthesis during LARP4 knockdown. 
 
Figure 4-2: Decrease of LARP4 protein level reduces VACV Replication. 
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At 72 hours post siRNA transfection, HFFs were infected with VACV at a MOI of 3 (A and B). 
AraC (40 μg/mL) treatment was used as a positive control. (A) VACV infected cells were 
observed 12 hours post infection by microscopy. (B) At 24 hpi, HFFs were collected for plaque 
assay. Titer of the VACV during indicated treatment was determined by plaque assay using 
BSC-1 cells. (C) HFFs were transfected with negative control siRNA (si-NC) or siRNAs 
targeting LARP4. Nascent protein synthesis was determined by treating cells and labelling 
nascent protein with puromycin (10 µg/ml) for 20 minutes at 37°C. Level of LARP4, puromycin-
labelled nascent protein, and β-Tubulin proteins were detected using specific antibodies 72 hours 
post siRNA transfection. Error bars represent standard deviation (SD) of at least three 
experiments. P-values were obtained using the Student’s t-test; ***P value <0.001. 
 
LARP4 knockdown suppresses post-replicative gene expression  
 To determine whether the reduction of VACV replication during LARP4 depletion was 
due to impaired VACV protein synthesis, Western blotting analysis was performed under similar 
condition. VACV protein synthesis occurs in a temporal manner, where early genes are 
expressed before DNA replication, whereas intermediate and late genes are expressed after DNA 
replication (28–30). As a result, intermediate and late genes are collectively termed post-
replicative genes (34). Before infection, the control or LARP4 siRNAs were transfected into 
HFFs for 72 hours. The HFFs were then infected with VACV at MOI of 5 in presence or absence 
of AraC. Since VACV early, intermediate, and late proteins are synthesized at different times 
post infection, we collected lysate from VACV-infected HFFs at 4, 8, and 12 hpi. The samples 
were evaluated for LARP4, GAPDH, VACV early (E3L), intermediate (D13L), and late 
(A10L/P4a) proteins. During LARP4 depletion, synthesis of VACV early protein (E3L) was 
similar to control siRNA treated cells. Remarkably, the synthesis of VACV intermediate (D13L), 
and late (A10L/P4a) proteins was nearly undetectable until 12 hpi during LARP4 depletion (Fig 
4-3A). As expected, post-replicative gene expression was completely blocked in the AraC 
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treatment. Immunoblotting of GAPDH demonstrates equal loading (Fig 4-3A). During LARP4 
reduction, a block in viral post-replicative protein synthesis could be attributed to a change in 
post-replicative mRNA level. We performed qRT-PCR to determine VACV early (E3L), 
intermediate (Gaussian), and late (A10L/P4a) mRNAs level at 12 hpi. Compared to control 
siRNAs, LARP4 knockdown using siRNA #1 did not reduce VACV early and intermediate 
mRNA levels; however, a 30% reduction in late mRNA was observed (Fig 4-3B). LARP4 
knockdown using siRNA #2 showed marginal non-significant reduction of early genes, leading 
to a 34% and 80% reduction in intermediate and late mRNA level, respectively. Notably, AraC 
treatment that prevents post-replicative gene expression led to a 98% and 99.9% reduction in 
intermediate and late mRNA level, respectively (Fig 4-3B). These findings indicate that LARP4 
knockdown completely blocks post-replicative protein synthesis while instigating only a 
moderate decrease in intermediate mRNA level and a significant decrease in late mRNA level, 
which is expected in cascade gene regulation.  
 We subsequently investigated whether the drastic block in VACV post-replicative protein 
synthesis could be due to the inhibition of viral DNA replication, which is a pre-requisite for 
post-replicative gene transcription. To test this question, we collected total DNA from control 
and LARP4 si-RNA transfected VACV-infected HFFs at 1 hpi and 24 hpi. AraC treatment was 
used as a positive control. The amount of VACV DNA was determined using qRT-PCR using 
specific primers for the C11 gene. Since VACV DNA synthesis occurs around 2 hpi, we 
determined the fold change in VACV DNA at 24 hpi compared to the time where the DNA 
replication hasn't occurred at 1 hpi  (34,35). Compared to control siRNAs, LARP4 siRNAs #1, 
#2, and AraC induced 3-fold, 4.5-fold, and 450-fold decreases in DNA level, respectively (Fig 4-
3C). During LARP4 knockdown, a complete blockage of VACV post-replicative protein 
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synthesis occurs (Fig 4-3A), while minor decrease in VACV DNA replication (Fig 4-3C) and a 
significant yet modest post-replicative gene transcription (Fig 4-3B) was observed. Altogether, 
these data suggest that the major contributor to the impairment of VACV post-replicative gene 
expression during LARP4 depletion is the inhibition of post-replicative mRNA translation. 
 
Figure 4-3: Depletion of LARP4 negatively affects post-replicative gene expression. 
HFFs cells were transfected with control or LARP4 siRNAs. 72 hours post transfection, HFFs 
were infected with VACV (A) or gaussian luciferase-expressing recombinant VACV (B and C) 
at a MOI of 5. AraC (40 μg/mL) treatment was used as a positive control. (A) At indicated times 
the HFFs were lysed, and the lysates were analyzed by western blot to determine the levels of 
LARP4, VACV early (E3L), intermediate (D13L), late (A10L/P4a) and GAPDH proteins. (B) At 
12 hpi, levels of VACV early (E3L), intermediate (G8R driven Gaussian), late (A10L/P4a) 
mRNAs were measured by qRT-PCR, and 18S rRNA was used for normalization. (C) At 1 and 
24 hpi, total DNA was extracted from the infected HFFs with indicated treatment. Level of 
VACV DNA at 1 and 24 hpi was determined and represented as fold change of VACV DNA at 
24 hpi to 1 hpi. Error bars represent standard deviation (SD) of at least three experiments. P-
values were obtained using the Student’s t-test; *P value <0.05, **P value < 0.01, ***P value 
<0.001, ns = Not Significant (i.e. P value > 0.05). 
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LARP4 depletion decreases 5’-poly(A) leader-mediated translational advantage 
 Following VACV DNA replication, post-replicative mRNAs are transcribed. Although 
LARP4 depletion moderately altered DNA replication and intermediate mRNA transcription, the 
major block in post-replicative gene expression may occur at the translation level of post-
replicative mRNAs. All VACV post-replicative mRNAs have a 5’-poly(A) leader. We then 
examined whether LARP4 is required for poly(A) leader-mediated translational advantage (17). 
Following 72 hours of LARP4 depletion, HFFs were mock-infected or infected with VACV 
(MOI=5). The 5’-poly(A) leader-containing the Fluc reporter mRNA and Kozak-headed Rluc 
mRNA were co-transfected into uninfected and VACV-infected HFFs at 12 hpi. Both Fluc and 
Rluc reporter mRNAs were either m7G capped (Fig 4-4A) or ApppG capped (Fig 4-4B). 
Relative luciferase activities were measured 5 hours after reporter mRNA transfection by 
normalizing 5’-poly(A) leader-driven Fluc activity against co-transfected Kozak sequence-driven 
Rluc activity. LARP4 knockdown decreased translation from the m7G capped 5’-poly(A) leader 
in uninfected HFFs (Fig 4-4A, top) and VACV-infected HFFs (Fig 4-4A, bottom). Similarly, 
LARP4 depletion also significantly decreased translation from ApppG-capped 5’-poly(A) leader 
mRNA in VACV-infected cells (Fig 4-4B, bottom). A non-significant but small decrease in 
ApppG-capped 5’-poly(A) leader mRNA translation was observed in uninfected cells (Fig 4-4B, 
top). Unlike VACV-infected cells, AraC treatment did not alter poly(A) leader-mediated 
translation in uninfected HFFs (Fig 4-4A and B, top). Moreover, in uninfected cells, LARP4 
depletion decreased translation from m7G capped (significantly) and ApppG-capped (non-
significantly) 5’-poly(A) leaders, thereby supporting the notion that LARP4 is required for 




Figure 4-4: LARP4 is required for 5’poly(A) leader mediated translation. 
HFFs, after 72 hours post transfection of control or LARP4 siRNAs, were either infected with 
VACV (MOI=5) or kept uninfected (A and B). AraC (40 μg/mL) treatment was initiated after 1 
hour of infection or uninfected condition. 5’Poly(A) leader containing Fluc reporter mRNA and 
Kozak headed Rluc mRNA were transfected into uninfected and VACV infected HFFs at 12 hpi. 
Both Fluc and Rluc mRNAs were capped by either m7G (A) or ApppG (B). Relative luciferase 
activity was measured 5 hours after reporter mRNA transfection by normalizing 5’Poly(A) 
leader driven Fluc activity by co-transfected Kozak sequence driven Rluc activity. Error bars 
represent standard deviation (SD) of at least three experiments. P-values were obtained using the 
Student’s t-test; **P value < 0.01, ***P value <0.001, ns = Not Significant (i.e. P value > 0.05). 
 
 LARP4 is crucial for cap-independent translation from a 5’-poly(A) leader 
 During our study, we noticed that LARP4 depletion decreased the poly(A) leader bearing 
mRNA translation from ApppG-capped mRNAs more than m7G capped mRNAs in the VACV-
infected condition. In fact, compared to control siRNAs, the decrease in ApppG-capped poly(A) 
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translation by LARP4 siRNA #1 and #2 were 8.75-fold and 26.27-fold, respectively (Fig 4-4B, 
bottom). Whereas, compared to control siRNAs, the decrease in m7G capped poly(A) translation 
by LARP4 siRNA #1 and #2 were 2.15-fold and 2.75-fold, respectively (Fig 4-4A, bottom). To 
investigate further, we carried out the experiment as per Fig 4-4 in the presence or absence of 
cap-dependent translation initiation inhibitor LY294002. The chemical LY294002 inhibits 
hyper-phosphorylation of eIF4E-binding protein (4EBP-1). Notably, hypo-phosphorylated 
4EBP-1 does not release the cap-binding protein eIF4E, thus inhibiting the cap-dependent 
initiation of translation. In the absence of LY294002, the poly(A) leader translation from 
ApppG-capped mRNA decreased more (2.5-fold and 8.4-fold in LARP4 depletion using siRNA 
#1 and #2, respectively, compared to control siRNA) than m7G capped mRNA (1.6-fold and 
2.48-fold in LARP4 reduction using siRNA #1 and #2, respectively, compared to control siRNA) 
(black bars, Fig 4-5A, top and bottom). In the presence of LY294002, translation from the 
m7G capped poly(A) leader showed a minimal decrease (1.47-fold) in the negative control 
siRNA transfected cells, the level of which was still higher than that of LARP4-depleted cells. 
Intriguingly, during LY294002 treatment, translation from the m7G capped poly(A) leader 
mRNAs in LARP4-depleted cells decreased to a basal level of approximately 30% compared to 
the cells transfected with control siRNAs (white bars, Fig 4-5A, top). In LY294002-treated 
cells, poly(A) leader translation from ApppG-capped mRNA decreased 3-fold in the control 
siRNAs transfected condition. The poly(A) leader containing mRNAs capped with ApppG 
during LY294002 treatment exhibited a severe defect in translation in the LARP4-depleted 
condition, leading to 10-fold decrease compared to control siRNA transfected cells (White bars, 
Fig 4-5A, bottom). In these experiments, AraC treatment, which blocks the post-replicative gene 
expression and necessary for poly(A) leader-mediated translation, was thus used as a positive 
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control (17). These results suggest that LARP4 is required for the cap-independent mode of 
translation from the poly(A) leader. 
 To further establish the role of LARP4 in the poly(A) leader's cap-independent mode of 
translation, we carried out an immunofluorescence assay to determine the localization of LARP4 
in WT-VACV- and vD9muD10mu-infected cells. VACV decapping enzymes (D9 and D10) 
remove caps from both host and viral mRNAs. To test whether the cap status of mRNAs is 
necessary for LARP4 enrichment in the virus factory, we infected A549 cells with WT-VACV 
and DKO-A549 cells with vD9muD10mu that cannot decap the mRNAs (36). At 12 hpi, we 
determined the enrichment status of LARP4 in virus factory. We observed that LARP4 was 
highly enriched in virus factories during WT-VACV infection compared to vD9muD10mu 
infection (Fig 4-5B). The quantification of LARP4 and DAPI in the viral factory showed 
significantly higher (2.05-fold) LARP4 and similar (1.04-fold) DAPI intensity during WT-
VACV infection when compared to vD9muD10mu infection (Fig 4-5C). This result indicates 
that WT-VACV with a functional decapping enzyme enhances LARP4 level in the virus factory, 
whereas decapping incompetent vD9muD10mu virus does not enrich LARP4 in the virus 
factory. Collectively, these results (Fig 4-5 A, B and C) indicate that LARP4 is required for both 
the poly(A) leader's cap-dependent and cap-independent mode of translation, and is especially 
critical for the cap-independent translation mode from a poly(A) leader containing mRNAs.  
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Figure 4-5: LARP4 is crucial for cap-independent mode of translation from 5’Poly(A) 
leader. 
(A) Control or LARP4 siRNAs were transfected into HFFs. After 72 hours, HFFs with indicated 
siRNAs treatment were infected with VACV (MOI=5). HFFs were either mock-treated or treated 
with LY294002 (25 μM) and/or AraC (40 μg/mL) at 1 hpi. The 5’Poly(A) leader containing Fluc 
reporter mRNA and Kozak headed Rluc mRNA were transfected into HFFs with indicated 
treatment. Relative Luciferase activity was measured 5-hour post reporter mRNA transfection by 
dividing Fluc activity by Rluc activity. (B) Immunofluorescence assay of WT-VACV or VACV-
D9muD10mu infected A549 cells and DKO cells, respectively (MOI=2). At 12 hpi, cells were 
fixed and stained with respective antibodies. Anti-LARP4 was used to determine localization of 
LARP4 (red) and DAPI (blue) was used to stain cellular nuclei and virus factory.  Panel shows 
representative image. Scale bar: 5 µm. (C) Quantification of the intensity of LARP4 and DAPI in 
the virus factory during of WT-VACV or VACV-D9muD10mu infection. 
 
LARP4 is dispensable for mRNA stability during VACV infection 
 Previous studies have shown that LARP4 binds to the 3' poly(A) tail in mRNAs and 
enhance stability (19,21). To determine the possibility of LARP4 binding to the 3' poly(A) tail 
and/or 5' poly(A) leader during VACV infection, aids in mRNA stability we synthesized the 
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5'-poly(A) leader containing reporter mRNAs without poly(A) tail. These reporter mRNAs were 
used to determine translation and stability during LARP4 depletion (Fig 4-6A). Following 
LARP4 depletion, HFFs were infected with VACV (MOI=5, 12 hpi). At 12 hpi, m7G and 
ApppG-capped 5’-poly(A) leaders bearing mRNA without the 3' poly(A) tail were transfected in 
VACV-infected HFFs. After 5 hours following reporter mRNA transfection, the samples were 
prepared for analysis of translation (Fig 4-6B) and mRNA levels (Fig 4-6C). Despite lacking a 3' 
poly(A) tail, both m7G and ApppG-capped mRNAs bearing the 5' poly(A) leader exhibited a 
decrease in translation during LARP4 knockdown (Fig 4-6B). This observation indicates that 
LARP4's role in poly(A) leader-mediated translational advantage is through direct interaction 
with the 5' poly(A) leader, which is—to a major extent—independent of binding to the 3' 
poly(A) tail. However, LARP4 binding to the 5' poly(A) leader may enhance either translation 
initiation, mRNA stability, or both. To test this, we determined the mRNA level at 5 hours post-
transfection of reporter mRNAs without poly(A) tail. Interestingly, we observed no apparent 
difference in the mRNA level of transfected reporter mRNA and endogenous GAPDH mRNA 
during LARP4 depletion (Fig 4-6C). Altogether, our results suggest that LARP4 depletion 
decreases poly(A) leader-bearing mRNA translation without altering mRNA stability, which 
suggests that LARP4 probably by binding to the 5' poly(A) leader enhances translation initiation 
in VACV-infected cells. 
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Figure 4-6: LARP4 binding to 5’poly(A) leader is dispensable for mRNA stability during 
poxvirus infection. 
(A) Schematic showing LARP4 can bind either to poly(A) leader or poly(A) tail or both. To rule 
out the effect of LARP4 binding to poly(A) tail, reporter RNAs (12A-Fluc and Kozak-Rluc) 
were synthesized without poly(A) tail. (B and C) After transfecting HFFs with control or LARP4 
siRNAs for 72 hours, cells were infected with VACV (MOI=5). At 12 hpi, reporter RNA (12A-
Fluc and Kozak-Rluc) capped by either m7G or ApppG but without poly(A) tail were transfected 
into HFFs with indicated treatment. (B) Relative Luciferase activity was measured 5-hour post 
reporter mRNA transfection by dividing Fluc activity by Rluc activity. (C) Levels of transfected 
m7G or ApppG capped reporter RNAs (without poly(A) tail) and GAPDH mRNAs were 
measured by qRT-PCR and normalized using 18S rRNA. Error bars represent standard deviation 
(SD) of at least three experiments. P-values were obtained using the Student’s t-test; **P value < 




 Poxviruses induce global host protein synthesis shutoff to cause devastating diseases in 
humans and animals. During host shutoff, poxviruses such as VACV have evolved strategies to 
increase their protein synthesis. One such approach is to acquire an evolutionarily optimized 5'-
poly(A) leader in the translation regulatory 5'UTR region (13,15,16,22). The poly(A) leader 
provides a translational advantage to VACV post-replicative mRNAs that encode for highly 
critical VACV structural proteins (10,17,23). Since poly(A) leader-mediated translation is 
independent of mRNA cap status, we hypothesized the existence of a poly(A) RNA-binding 
protein linked directly to the 5'-poly(A) leader to promote VACV post-replicative mRNA 
translation.  
 For identification of the 5'-poly(A) leader binding protein, we evaluated for proteins 
known to bind to a poly(A) RNA sequence (19,25). Using immunofluorescence assay, we 
identified LARP4 as a cellular protein enriched in the virus factory, which is the site for VACV 
post-replicative mRNA translation. Since LARP4 is known to bind to poly(A) RNA sequences 
and RACK1, and is essential for poly(A) leader-mediated translational advantage, we further 
explored the role of LARP4 (10,19). Additional experiments indicated that a decrease in LARP4 
protein level reduced VACV titer and blocked post-replicative gene expression completely, with 
a modest decrease in VACV DNA replication and a significant yet small decrease in post-
replicative gene transcription. During VACV infection, depletion of LARP4 decreased 
translation from poly(A)-headed mRNAs, especially from ApppG-capped reporter mRNAs and 
during the inhibition of cap-dependent translation. Furthermore, LARP4 depletion decreased 
translation from 5'-poly(A)-bearing mRNA in uninfected cells and reporter mRNAs lacking the 
3' poly(A) tail, signifying its importance for poly(A)-headed mRNA translational advantage. 
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Moreover, we found that silencing LARP4 expression did not affect mRNA stability during 
VACV infection. These findings suggest that LARP4 is vital for both the cap-dependent and cap-
independent mode of translation initiation in mRNAs bearing a 5'-poly(A) leader.  
 VACV B1 kinase phosphorylates S278 of RACK1 STSS motif, and this post-translational 
modification is required for poly(A) leader-mediated translation advantage (10). However, 
RACK1 did not bind to the poly(A) leader and was not enriched in the viral factory in our study 
(data not shown), thus suggesting that RACK1 phosphorylation may have another function 
during poly(A)-headed mRNA translation. Since the STSS motif is present at the extended loop 
of RACK1 and is known to interact with ribosomal protein at the exit site (10), we suspect that 
RACK1 phosphorylation changes the conformation of the exit site in the ribosome, thus making 
a conducive environment for poly(A)-headed mRNA translation. In Jha et al. 2017, the reporter 
system contained 35 A's; so we do not rule out the possibility that heterogenous poly(A) leader 
length may recruit different proteins to enhance translation. 
 A recent study showed that LARP4-NTD (N-terminal domain) is essential for poly(A) 
RNA binding (28). LARP4-NTD also contains the PAM2w motif, which is necessary for the 
interaction between the MLLE domains of PABP and LARP4. Cruz-Gallardo et al. 2019, 
subsequently demonstrated that LARP4-NTD binding is mutually exclusive with a PABP or 
poly(A) RNA sequence (28). This supports our and others’ observations that PABP is excluded 
from the virus factory (11,27) and is nonessential for LARP4-facilitated poly(A) leader 
translation.  
 One interesting observation we observed in our study was that LARP4 enrichment in 
virus factory diminished during vD9muD10mu virus infection compared to WT-VACV infection 
(Fig 4-5B and C). This observation prompts two possibilities. First, in vD9muD10mu infection, 
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LARP4 is requisitioned by cellular mRNAs more than by VACV mRNAs, leading to a uniform 
distribution of LARP4 throughout the cytoplasm. Second, LARP4 recruitment to viral mRNAs 
and consequent enrichment in the virus factory depends on the decapping status of the VACV 
post-replicative mRNAs. Although both situations are possible, we view the possibility that 
LARP4 is recruited to decapped VACV post-replicative mRNAs as more probable since our data 
suggest that LARP4 is vital for a poly(A) leader bearing mRNA's cap-independent mode of 
translation (Fig 4-4B, 4-5A bottom and 4-6B). Future studies will attempt to shed light on 
exploring these possibilities.  
 The data presented in this study demonstrated that LARP4 is required for poly(A)-headed 
mRNAs translation in uninfected and VACV-infected HFFs. In uninfected cells, LARP4 may 
play a role in mRNA stability and translation initiation. In VACV-infected cells, LARP4 may 
have a minimal, if any, function in mRNA stability; however, LARP4 increases translation 
initiation by presumably binding to poly(A) leader. In uninfected cells, we propose that LARP4 
will recruit other translation initiation factors and this recruitment of unknown translation 
initiation factors is enhanced by one or more unidentified VACV/host proteins, thus allowing the 
5'-poly(A) leader to confer a translational advantage during VACV infection (Fig 7). Future 
studies will focus on identifying the VACV/host protein(s), and other eukaryotic translation 
initiation factors required for poly(A) leader-mediated translational advantage and on 
determining the unknown pre-existing eukaryotic translation mechanism.  
146 
 
Figure 4-7: Schematic summary of the findings and working model. 
LARP4 binds to both poly(A) leader (this report) and poly(A) tail (19). During VACV infection, 
we hypothesize that LARP4 binding to poly(A) leader enhances recruitment of 40S ribosome to 
initiate translation and provide poly(A) bearing mRNA a translational advantage. The 
recruitment of 40S via LARP4 can be mediated by unknown eukaryotic initiation factor in 
uninfected condition, however, during VACV infection enhancement in LARP4 mediated 40S 
recruitment to poly(A) leader is mediated by unidentified viral protein/s and/or repurposed 
unknown host factor/s. 
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 Materials and methods 
Cell culture and virus infection 
Human foreskin fibroblast (HFF, gift from Dr. Nicholas Wallace) were cultured in Dulbecco’s 
modified eagle’s medium (DMEM, Quality Biological) containing 10% fetal bovine serum 
(FBS, Peak Serum) and 2 mM L-Glutamine (Quality Biological). Cells were incubated in a 5% 
CO2 atmosphere at 37°C. VACV Western Reserve strain (ATCC VR-1354), vD9muD10mu 
double mutant and intermediate transcription factor gene A23 deleted VACV (VACV-ΔA23) 
were kindly provided by Dr. Bernard Moss and was reported earlier (37). Virus titer was 
determined by plaque assay using BSC-1 cells as described elsewhere (38).  
Antibodies and chemical inhibitors 
Anti-LARP4 (A5108), anti-PABPC1 (A14872) and anti-RPS6 (A6058) antibodies were 
purchased from ABclonal Inc. Anti-RPL5 (51345) antibody was purchased from Cell Signaling 
Technology. β-Tubulin and GAPDH (sc-365062 HRP) antibodies were purchased from Santa 
Cruz Biotechnology. Anti-Puromycin (MABE343) was purchased from Sigma Aldrich. Anti-
D13L and anti-A10L/P4a antibody was a gift from Dr. Bernard Moss. The anti-E3L antibody 
was a present from Dr. Yan Xiang. LY294002 was purchased from Cayman Chemical. DAPI 
(D1306) was purchased from Thermo Fisher Scientific. Cytosine arabinoside (AraC) was 
purchased from Sigma-Aldrich.  
Western blotting analysis and nascent protein synthesis analysis 
Protein level was evaluated by preparing sample as described before (39). The sample was 
resolved in the SDS-PAGE gel followed by transferring to a polyvinylidene difluoride (PVDF) 
membrane. For detection of protein, membranes were blocked in either 5% BSA or 3% Milk for 
1 hour at room temperature followed by incubation with primary antibody for 1 hour at room 
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temperature or overnight at 4°C and finally, incubation with secondary antibody added in 1X 
TBST (with either 3% Milk or 5% BSA). The image was developed as described elsewhere (40).  
Nascent protein synthesis was determined by treating the cells with puromycin (10 µg/ml, 
P8833, Sigma Aldrich) for 20 minutes at 37°C. Treatment was aborted by removing the cell 
culture media containing puromycin and washed once with 1X-PBS. NP-40 lysis buffer was 
added directly on the cells and the cells were subsequently scraped. Lysis was carried out by 
rotating the sample at 4°C for 30 minutes and centrifuged at 12000 X g at 4°C for 10 minutes. 
The supernatant was used for sample preparation and evaluated by western blot analysis as 
described previously (39).  
RNA extraction and quantitative RT-PCR 
At desired time cell culture media was removed, cells were washed with 1X-PBS, TRIzol 
reagent (Ambion) was added, and cells were collected for RNA purification. Total RNA was 
extracted using the PureLink RNA Mini Kit (Thermo Fisher Scientific). The purified RNA was 
next used to synthesize cDNA using SuperScript III First-strand synthesis (Invitrogen) with the 
addition of either random hexamer or oligo-dT primers. The cDNA was used to perform 
quantitative RT-PCR with iTaq Universal SYBR Green Supermix (Bio-Rad) using specific 
primers of desired genes. 
In vitro transcribed RNA-based Luciferase Assay 
The RNA-based luciferase assay was used to determine the translation of 5'-Poly(A) leader 
containing mRNA during LARP4 depletion using the protocol described previously (17). The 
RNA used in this study were capped with either m7G (Anti-Reverse Cap Analog [ARCA], 
S1411L) or ApppG cap analog (S1406S, New England Biolabs). To test LARP4 specificity for 
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5'-Poly(A) leader, we synthesized reporter mRNA with or without poly(A) tail by modulating 
poly(A) tail in DNA template.  
Knockdown using small interfering RNA (siRNA) 
The small interfering RNAs (siRNAs) used for this study were purchased from Integrated DNA 
technologies (IDT-DNA). Lipofectamine RNAiMax (Thermo Fisher Scientific) was used to 
transfect si-LARP4 or si-NC (Negative Control) to HFF. The si-RNAs were used at the final 
concentration of 12.5 nM. At 72-hours post-transfection, the cells were either collected for 
western blot analysis to determine siRNA mediated depletion of the target protein or infected for 
desired hours for further analysis (titration, cytopathic effect, western blot, qRT-PCT, luciferase 
assay, and mmunofluorescence assay).  
Immunofluorescence assay  
After desired treatment cells were fixed with 4% formaldehyde (28908, Thermo Fisher 
Scientific) in 1X-PBS for 20 minutes. The cells were then permeabilized with 0.1% Triton X-100 
(9002-93-1, Thermo Fisher Scientific) in 1X-PBS for 15 minutes. Cells were washed 3X with 
1X-PBS and blocked for 1 hour at room temperature with 2% BSA containing 1X-PBS. Then, 
cells were incubated with the desired primary antibody (1:100 dilution in 2% BSA containing 
1X-PBS) for 1 hour at room temperature. Again, after 3X washes, cells were incubated with 
secondary antibody conjugated with a fluorophore (1:500 dilution in 2% BSA containing 1X-
PBS) for 1 hour at room temperature. Following 2X washes with 0.1% Triton X-100 in 1X-PBS, 
DAPI stain (5µM) in 1X-PBS was added to the cells for 20 minutes at room temperature. 
Finally, 2X washes with 1X-PBS were done to remove any unbound DAPI stain. The image was 
taken using Carl Zeiss LSM 880 confocal microscope. ZEISS Efficient Navigation (ZEN) 
software was used for analysis of the images.  
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 Abstract 
Vaccinia virus infection causes a host shutoff that is marked by global inhibition of host protein 
synthesis. Though the host shutoff may facilitate reallocation of cellular resources for viral 
replication and evasion of host antiviral immune responses, it poses a challenge for continuous 
synthesis of cellular proteins that are important for viral replication. It is, however, unclear 
whether and how certain cellular proteins may be selectively synthesized during the vaccinia 
virus-induced host shutoff. Using simultaneous RNA sequencing and ribosome profiling, two 
techniques quantifying genome-wide levels of mRNA and active protein translation, 
respectively, we analyzed the responses of host cells to vaccinia virus infection at both the 
transcriptional and translational levels. The analyses showed that cellular mRNA depletion 
played a dominant role in the shutoff of host protein synthesis. Though the cellular mRNAs were 
significantly reduced, the relative translation efficiency of a subset of cellular mRNAs increased, 
particularly those involved in oxidative phosphorylation that are responsible for cellular energy 
production. Further experiments demonstrated that the protein levels and activities of oxidative 
phosphorylation increased during vaccinia virus infection, while inhibition of the cellular 
oxidative phosphorylation function significantly suppressed vaccinia virus replication. Moreover, 
the short 5' untranslated region of the oxidative phosphorylation mRNAs contributed to the 
translational upregulation. These results provide evidence of a mechanism that couples 
translational control and energy metabolism, two processes that all viruses depend on host cells 
to provide, to support vaccinia virus replication during a host shutoff. 
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 Importance 
 Many viral infections cause global host protein synthesis shutoff. While host protein 
synthesis shutoff benefits the virus by relocating cellular resources to viral replication, it also 
poses a challenge to the maintenance of cellular functions necessary for viral replication if 
continuous protein synthesis is required. Here we measured the host mRNA translation rate 
during a vaccinia virus-induced host shutoff by analyzing total and actively translating mRNAs 
in a genome-wide manner. This study revealed that oxidative phosphorylation mRNAs were 
translationally upregulated during vaccinia virus-induced host protein synthesis shutoff. 
Oxidative phosphorylation is the major cellular energy-producing pathway, and we further 
showed that maintenance of its function is important for vaccinia virus replication. This study 
highlights the fact that vaccinia virus infection can enhance cellular energy production through 




 All viruses depend on infected host cells for protein synthesis. Many viruses, for 
example, poxviruses, influenza virus, picornavirus, and herpesviruses, cause a host shutoff after 
infection that is marked by global cellular protein synthesis inhibition (1–8). While this host 
shutoff conserves cellular resources and blunts host antiviral responses that benefit viral 
replication, it also presents a challenge to maintenance of the integrity of cellular functions 
necessary for viral replication, as continuous synthesis of certain host proteins may be needed. 
However, knowledge is scarce about selectively synthesized cellular proteins and their biological 
relevance during a virus-induced host shutoff. Determination of selectively synthesized proteins 
in this process will facilitate the identification of cellular functions that are important for viral 
replication.  
 Ribosome profiling is a technique based on deep sequencing of ribosome-protected 
mRNA fragments, providing genome-wide information of mRNAs that are actively translated 
(9–12). We have previously identified many unexpected translation products of vaccinia virus 
(VACV) by using ribosome profiling (13). Several other studies also identified large numbers of 
unexpected translation products from human cytomegalovirus (HCMV), coronavirus, and 
Kaposi’s sarcoma-associated herpesvirus by using ribosome profiling (14–16). Importantly, 
ribosome profiling can also simultaneously reveal the translation of host mRNAs during a viral 
infection. In a recent study, translational changes in host genes upon HCMV infection were 
studied by simultaneous transcriptome sequencing (RNA-Seq) and ribosome profiling (17). That 
study revealed many host genes translationally activated or repressed by HCMV, which does not 
induce a host shutoff. Given its great sensitivity and resolution, we reasoned that ribosome 
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profiling is a powerful tool for the study of selectively translated cellular mRNAs by analyzing 
actively translating and total mRNAs of individual genes during a virus-induced host shutoff.  
 Poxviruses are a family of large DNA viruses that include highly pathogenic members 
that infect humans and economically important animals and are exemplified by the variola virus 
that causes the deadly human disease smallpox (18). Poxviruses are also developed as agents for 
cancer therapy and as vaccine vectors (19, 20). VACV, the prototypic poxvirus, was the vaccine 
strain used to eradicate smallpox. However, vaccination with VACV may also cause 
complications such as keratitis, conjunctival disease, and iritis in immunocompromised 
individuals (21). It has long been known that VACV rapidly takes over the host translational 
machinery for viral protein synthesis and causes a global host protein synthesis shutoff (4, 5, 22). 
This shutoff is at least partially attributed to VACV-encoded decapping enzymes D9 and D10. 
These decapping enzymes efficiently remove 7-methylguanosine caps on the 5' termini of 
mRNAs (23–28). This decapping renders the mRNAs sensitive to degradation by exonucleases 
and results in a rapid depletion of mRNAs (24, 25, 29, 30). In addition to mRNA degradation, 
transcription inhibition may also play a role in this process (31). The global depletion of cellular 
mRNAs is assumed to contribute to the host shutoff. However, it is largely unknown whether 
cellular proteins are selectively translated and, if so, whether those selectively synthesized 
proteins are important for VACV replication.  
 In this study, we analyzed dynamic transcriptional and translational landscapes of host 
cells over the course of VACV infection by simultaneous RNA-Seq and ribosome profiling of 
VACV- and mock-infected cells. Our study indicates that cellular mRNA depletion plays a 
dominant role in the shutoff of host protein synthesis. Though the cellular mRNA amounts were 
significantly reduced, the relative translation efficiency (TE) of a subset of cellular mRNAs 
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increased, particularly for those involved in oxidative phosphorylation that are responsible for 
cellular energy production. We further demonstrated that the protein levels and activities of 
oxidative phosphorylation increased during VACV infection, while inhibition of oxidative 
phosphorylation suppressed VACV replication. A short 5' untranslated region (UTR) of the 
oxidative phosphorylation mRNAs contributed to the translational upregulation. This study 
revealed that a viral infection enhanced oxidative phosphorylation through translational 
upregulation in the context of an overall host shutoff.  
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 Results 
 Simultaneous RNA-Seq and ribosome profiling of VACV-infected cells. 
 To understand translational regulation and identify selectively translated cellular mRNAs 
during a VACV-induced host shutoff, we carried out simultaneous RNA-Seq and ribosome 
profiling of VACV- and mock-infected HeLa cells at 2, 4, and 8 h postinfection (hpi) (Fig. 5-
1A). Under these conditions, VACV replication was in the early stage when viral DNA 
replication did not occur yet at 2 hpi, whereas at 4 hpi and later times, VACV replication had 
proceeded to the post-DNA replication stage (28). RNA-Seq and ribosome profiling 
quantitatively measured the levels of total and actively translating mRNAs, respectively (9, 10). 
We obtained 114.6 to 135.8 million reads from individual RNA-Seq samples and 38.0 to 98.7 
million ribosome-protected fragments (RPFs) from individual ribosome profiling samples that 
were mapped to human and VACV genomes, providing sufficient depth of sequencing reads for 
further analyses. The analysis of viral mRNA translation from part of the sequencing data was 
reported previously (13). 
 Analysis of the cellular RPFs indicated that the ribosome profiling experiments were 
highly reproducible, as evidenced by the very strong correlation coefficient (r, >0.98) of two sets 
of completely independent ribosome profiling experiments (biological replicates) under the same 
infection conditions at each time point (Fig. 5-1B). The high reproducibility of the RNA-Seq and 
ribosome profiling experiments was also evidenced by the strong correlation of the reads of 
mock-infected cells at 2, 4, and 8 h, where the cells were under the same culture conditions 
without VACV infection. The correlation coefficients were >0.98 in all of the pairwise 
comparisons of experiments from the three time points (data not shown). The high quality of 
cellular ribosome-protected RNA fragment (RPF) reads was evidenced by the expected high 
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mapping rates in coding DNA sequences (CDSs) and 5′ UTRs and low mapping rates of 3′ UTRs 
and introns of cellular genes for both mock infection (Fig. 5-1C) and VACV infection (Fig. 5-





Figure 5-1: Experimental approach for simultaneous RNA-Seq and ribosome profiling 
during VACV infection. 
(A) Overall experimental design. HeLa S3 cells were mock or VACV infected; harvested at 2, 4, 
and 8 hpi; and subjected to RNA-Seq and ribosome profiling. (B) High reproducibility of 
ribosome profiling experiments. Correlation analysis of cellular reads between ribosome 
profiling experiments with two biological replicates under VACV-infected condition at 2, 4, and 
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8 hpi is shown along with Pearson's correlation coefficient. (C, D) Read densities (number of 
mapped reads divided by length) of genomic regions of 5′ UTRs, CDSs, 3′ UTRs, and introns of 
cellular mRNAs are shown. mRNAs are green and RPFs are red under mock-infected (C) and 
VACV-infected (D) conditions.  
 
 mRNA depletion plays a dominant role in VACV-induced host shutoff. 
 We first evaluated the contribution of mRNA depletion to VACV-induced host protein 
synthesis shutoff by analyzing the proportions of cellular RNA reads and RPFs in the total reads. 
The multidimensional scaling (MDS) plot showed a dramatic overall change in cellular mRNA 
and RPFs at 4 and 8 hpi (Fig. 5-2A), whereas the change at 2 hpi was subtle compared to that in 
mock-infected cells. This finding is consistent with the fact that VACV replication had 
proceeded to the postreplicative stage at 4 hpi, when the host shutoff occurred. During the host 
shutoff, the proportion of cellular mRNA reads decreased significantly at 4 and 8 hpi. The 
cellular RPFs also decreased significantly at 4 and 8 hpi (Fig. 5-2B). We next characterized the 
global changes in cellular mRNAs and RPFs in VACV-infected cells versus mock-infected cells 
at 2, 4, and 8 hpi. Figure 5-2C shows that the distribution of RPKMs (reads per kilobase of 
transcript per million reads) of mRNA and RPF reads virtually overlapped in the mock infection 
experiments at 2, 4, and 8 hpi. In contrast, the overall RPKMs in VACV-infected cells decreased 
dramatically after infection, indicating a host shutoff at both the transcriptional and translational 
levels. Because the total cellular and viral mRNA amounts extracted from mock- and VACV-
infected cells were similar, these results suggested that cellular mRNA depletion was the major 
contributor to VACV-induced host protein synthesis shutoff. 
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Figure 5-2: Global analysis of mRNA and RPF reads reveals the characteristics of VACV-
induced host shutoff. 
(A) MDS plot of ribosome profiling and RNA-seq data sets used to plot the sample relationship. 
The log2-fold changes in the 500 most variable genes between samples of ribosome profiling and 
RNA-seq data sets were approximated. Dimensions 1 and 2 of the MDS plot are presented, 
where dimension 1 explains 87.45% of the variability and dimension 2 explains 6.83% of the 
variability. (B) Mapping efficiency of mRNA/RPF reads of the human (black) and VACV 
(white) genomes at 2, 4, and 8 hpi. (C) Cumulative distribution of gene expression at mRNA 
(top) and RPF (bottom) levels, with time points shown in different colors. 
 
 Relative TE of host mRNAs during VACV-induced host shutoff. 
 While only a limited number of cellular genes are differentially expressed at 2 hpi, a large 
number of cellular genes are differentially expressed at 4 and 8 hpi at both the mRNA and 
translation (RPF) levels (Fig. 5-3A). The differentially expressed genes also overlapped 
considerably at the mRNA and RPF levels, particularly at 4 and 8 hpi (Fig. 5-3A). Though large 
numbers of cellular genes are differentially expressed at 4 and 8 hpi, the majority of them were 
downregulated, with only a small number of genes upregulated (Fig. 5-3B and C). Since the host 
cells underwent a global shutoff at both mRNA and RPF levels, almost all of the cellular 
functions were downregulated. Here we focused on the genes with increased levels of mRNAs 
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and RPFs because they are the candidates for selectively synthesized genes that are resistant to 
the general trend of host shutoff. However, gene set enrichment analysis (GSEA) showed no 
significantly enriched pathways at both the mRNA and RPF levels when using a cutoff with an 
adjusted P value of <0.05 by Benjamini and Hochberg's false discovery rate (FDR), which was 
not a surprise because of the global shutoff and only a very limited number of genes being 
upregulated. 
 We then employed a relative TE analysis, which is defined as the ratio of normalized 
RPFs to mRNA reads (Fig. 5-3D). It has been shown to be an effective way to identify 
differentially translated mRNAs in HCMV infection (32). Though the mRNA levels decreased 
significantly, we observed extensive TE regulation of cellular mRNAs responding to VACV 
infection revealed by a large number of mRNAs with differential TE (DTE) in VACV- versus 
mock-infected cells, particularly at 4 and 8 hpi (Fig. 5-3E). We hypothesized that the 
upregulation of the relative TE of mRNAs can serve as a compensating mechanism to maintain 
or increase protein levels in the context of decreased mRNA levels. The functions of the genes 
involved may be important for VACV replication or cell survival. The genes with upregulated 
relative TE (>2-fold) are listed in Data Set S1 in the supplemental material. 
 To examine this hypothesis, we carried out a GSEA of the host genes that responded to 
VACV infection with differential relative TE. Using the same cutoff, an adjusted P value of 
<0.05 by FDR, the GSEA of the genes yielded several enriched pathways with elevated relative 
TE, where oxidative phosphorylation was the only enriched function at all three time points (Fig. 





Figure 5-3: Differential mRNA, RPF, and relative TE analyses of cellular genes during 
VACV infection. 
(A) Venn diagram of numbers of differentially expressed genes (DEGs; adjusted P value, ≤0.05; 
absolute value of log2-fold change, ≥2) present at the mRNA and RPF levels at 2, 4, and 8 hpi. 
(B, C) Volcano plots of mRNA (B) and RPF (C) levels with DEGs in red and mitochondrial 
(MT) genes in blue. (D) Relative TE is defined as the ratio of normalized RPFs to the normalized 
mRNA read density in the CDS region. (E) Scatterplot of the mean log2 RPKM (μ) under mock- 
and VACV-infected conditions of mRNA/RPF reads versus the logarithmic TE difference value 
under the VACV-infected condition to that under the mock-infected condition (log2 DTE). 
Translationally upregulated cellular genes (log2 DTE, ≥1; μ, −1 or greater) are red, and 
downregulated genes (log2 DTE, −1 or greater; μ, −1 or greater) are blue. Mitochondrial genes 
are green. Numbers of up/down-regulated genes are also shown. (F) GSEA of genes with 
upregulated TE based on the KEGG pathway data set. P values were adjusted for multiple testing 
with FDR. NS, not significant, where the adjusted P value is >0.05. 
 
Oxidative phosphorylation capacity is enhanced during VACV infection, while 
inhibition of oxidative phosphorylation suppresses VACV replication. 
 Oxidative phosphorylation is the metabolic pathway in which ATP is produced through a 
series of biochemical reactions in mitochondria. The oxidative phosphorylation genes include 
>100 genes that are encoded in both the nuclear and mitochondrial genomes of mammalian cells. 
In human cells, the mitochondrial genome encodes 13 proteins that are subunits of oxidative 
phosphorylation (33, 34). The relative TE of mRNAs involved in oxidative phosphorylation was 
increased significantly, while the mRNA levels were decreased at 4 and 8 hpi of VACV infection 
(Fig. 5-4A and B). A heat map of the DTE of oxidative phosphorylation mRNAs clearly 
illustrates the translational upregulation of almost all of the oxidative phosphorylation genes 
(Fig. 5-4C). The RPF levels of a limited number of genes were even increased >2-fold after 
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VACV infection, which includes 9 of the 13 protein-encoding genes in the human mitochondrial 
genome (Fig. 5-4D and 5-2C). 
 
Figure 5-4: Oxidative phosphorylation genes are enriched in mRNAs with enhanced 
relative TE. 
(A, B) Box plots of oxidative phosphorylation genes (red) and other cellular genes (white) at the 
DTE (A) and mRNA (B) levels. ***, P < 0.001 (Mann-Whitney U test). (C) Heat map of DTE of 
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oxidative phosphorylation genes at 2, 4, and 8 hpi. (D) Heat map of cellular genes with increased 
RPFs (>4-fold) at 2, 4 or 8 h after VACV infection. FC, fold change. 
 
 The downregulation of mRNA levels and upregulation of protein levels involved in 
oxidative phosphorylation were verified by quantitative reverse transcription (RT)-PCR and 
Western blotting of nuclear genome-encoded SDHB and mitochondrial genome-encoded MT-
CO1 and MT-CO2, which are subunits of the oxidative phosphorylation complexes (Fig. 5-5A 
and B). To further examine whether oxidative phosphorylation proteins continued to be 
synthesized during the shutoff after VACV infection, we examined newly synthesized proteins in 
VACV-infected cells by labeling with AHA (l-azidohomoalanine) by a Click-iT chemistry 
technique. The newly synthesized proteins were then precipitated and detected with a total 
oxidative phosphorylation human antibody cocktail that recognizes five proteins of the oxidative 
phosphorylation complexes. The results indicated higher levels of UQCRC2, SDHB, and MT-
CO2 in VACV-infected cells than in mock-infected cells, while the ATP5A level remained 
stable (or slightly increased) and the NDUFB8 level decreased. The newly synthesized ATP5A, 
SDHB, and MT-CO2 could be clearly detected in VACV-infected cells at higher levels than in 
mock-infected cells (Fig. 5-5C). Interestingly, NDUFB8 was one of the few oxidative 
phosphorylation mRNAs with decreased relative TE at 4 or 8 hpi (Fig. 5-4C). These findings 
suggested that some of the mRNAs involved in oxidative phosphorylation were translationally 
upregulated, which resulted in continuous protein synthesis under the condition of VACV-
induced host shutoff. 
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Figure 5-5: Increased synthesis of oxidative phosphorylation proteins during VACV-
induced host shutoff. 
(A) Western blotting analyses of SDHB, MT-CO1, and MT-CO2 levels during the course of 
VACV infection (MOI of 5). Beta-tubulin and GAPDH were used as loading controls. Results 
representative of at least three independent experiments are shown. (B) Quantitative RT-PCR 
analyses of SDHB, MT-CO1, and MT-CO2 gene mRNA levels. The mRNA levels were 
normalized to 18S rRNA levels at different time points. Each result is an average of at least three 
independent experiments. The error bars indicate the standard deviation of three experiments. (C) 
HeLa cells infected with VACV (MOI of 5) or mock infected were starved in methionine-free 
medium and then incubated in medium containing AHA between 3 and 7 hpi. Total proteins 
(left) and newly synthesized proteins labeled with AHA-containing peptides with alkyne-biotin 
(right) that were precipitated with streptavidin beads were subjected to Western blotting analyses 
with a total oxidative phosphorylation human antibody cocktail. M, mock infection; I, infection. 
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 VACV infection has been reported to enhance the oxygen consumption rate (35), an 
indicator of cellular respiration, suggesting that VACV infection may increase oxidative 
phosphorylation-based ATP production. In fact, we observed that the ATP synthase activity and 
ATP level increased significantly in VACV-infected HeLa cells (Fig. 5-6A and E). Moreover, 
we tested the effects on VACV replication of carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), an uncoupler of oxidative phosphorylation, and antimycin A, an inhibitor of oxidative 
phosphorylation complex III, at concentrations that did not affect cell viability (Fig. 5-6B). The 
addition of both drugs to the culture medium significantly suppressed VACV replication by >10-
fold (Fig. 5-6C). Interestingly, CCCP inhibited VACV replication in a dose-dependent manner 
(Fig. 5-6D), which was correlated with a dose-dependent decrease in ATP levels by the CCCP 
treatment of VACV-infected cells (Fig. 5-6E). The block of VACV replication by CCCP and 
antimycin A was at or before late viral protein expression, as evidenced by a much lower VACV 
late protein expression level in cells treated with CCCP or antimycin A (Fig. 5-6F). Further 
experimentation with a reporter VACV containing a firefly luciferase gene under the control of a 
VACV early/late promoter indicated that the expression of both early and late VACV genes was 
affected by CCCP or antimycin A treatment (Fig. 5-6G and H). Because the chemicals were 
added at 1 hpi, this suggested that the impairment of oxidative phosphorylation started to affect 
VACV replication at the stage of early gene expression after entry. These results demonstrated 
that the oxidative phosphorylation function is important for VACV replication and its ATP 
generation capacity is enhanced during VACV infection. 
173 
 
Figure 5-6: Oxidative phosphorylation activity plays an important role in VACV infection. 
(A) ATP synthase activity is enhanced in VACV-infected HeLa cells. HeLa cells were infected 
with VACV at an MOI of 3, and ATP synthase activity was determined at 2, 8, and 24 hpi. ATP 
synthase activity was measured with an ATP synthase enzyme activity microplate assay kit. 
Significant differences, defined by a P value of <0.05, are indicated by asterisks. (B) HeLa cells 
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were treated with the chemicals indicated (CCCP (1 μM) and antimycin A (20 μM)), and cell 
viability was determined at 24 h posttreatment. (C) Inhibition of VACV replication by the 
mitochondrial function inhibitors CCCP (1 μM) and antimycin A (20 μM). HeLa cells were 
infected with VACV at an MOI of 3. The chemicals indicated were added to the medium at 1 
hpi. VACV titers were determined at 24 hpi by a plaque assay. Significant differences, defined 
by a P value of <0.05, are indicated by asterisks. (D) HeLa cells infected with VACV were 
treated with CCCP at the concentrations indicated, which did not significantly affect cell 
viability (not shown). VACV titers were determined by a plaque assay at 24 hpi. Significant 
differences from the titer with no CCCP treatment, defined by a P value of <0.05, are indicated 
by asterisks. (E) ATP levels of uninfected HeLa cells (Un) or HeLa cells infected with VACV 
were treated with CCCP at the concentrations indicated. ATP levels were determined 16 hpi with 
an ATP determination kit. Significant differences from the ATP level in VACV-infected cells 
without CCCP treatment, defined by a P value of <0.05, are indicated by asterisks. (F) Western 
blotting of VACV protein expression with the anti-VACV serum treatment indicated at 16 hpi. 
The vertical lines in the VACV protein expression blot were generated because of a limitation of 
the Western blot imaging system when processing strong signals. (G and H) HeLa cells were 
infected with WRvFire VACV that contained a firefly luciferase gene under the control of a viral 
early/late promoter with the treatment indicated. Luciferase activity was measured at 2 hpi in the 
presence of AraC (G) or at 8 hpi without AraC treatment (H). AraC is a DNA replication 
inhibitor that arrests VACV replication at the early gene expression stage. Significant differences 
from vehicle treatment, defined by a P value of <0.05, are indicated by asterisks. 
 
Short 5′ UTRs of oxidative phosphorylation mRNAs can confer a translational 
advantage on VACV-infected cells. 
 The 5′ UTR plays an important role in the regulation of mRNA translation (36). We 
therefore examined whether 5′ UTRs may contribute to the upregulation of oxidative 
phosphorylation mRNA TE. We did not observe apparent consensus sequences in the 5′ UTRs of 
oxidative phosphorylation mRNAs. Interestingly, we observed instead that the 5′ UTRs of 
human oxidative phosphorylation mRNAs are shorter than the overall mRNAs. The median 
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length of the longest forms of individual 5′ UTRs is 102 nucleotides (nt) for oxidative 
phosphorylation mRNAs and 161 nt for the overall mRNAs (Fig. 5-7A). The minimum free 
energy (MFE) for RNA folding of the oxidative phosphorylation mRNA 5′ UTRs is also 
significantly higher than that of the overall cellular mRNA 5′ UTRs (Fig. 5-7B), indicating a less 
complex secondary structure. A shorter 5′ UTR with a less complex secondary structure may 
contribute to the higher TE of the corresponding mRNAs in VACV-infected cells (37). To test 
this possibility, we selected four short 5′ UTRs from nucleus-derived oxidative phosphorylation 
mRNAs and generated mRNAs containing individual 5′ UTRs upstream of a firefly luciferase 
reporter gene by in vitro transcription. Each of the mRNAs was transfected into uninfected or 
VACV-infected HeLa cells at 2 hpi together with an RNA containing a Renilla luciferase 
reporter gene as a transfection efficiency control. Luciferase activity was measured as an 
indicator of mRNA translation. The use of RNA rather than DNA reporters in this assay ruled 
out the possibility of a difference in luciferase activities attributable to transcription. All of the 5′ 
UTRs tested exhibited higher luciferase activities in VACV-infected cells, though the 
enhancement does not correspond linearly to the length of the 5′ UTRs (Fig. 5-7C). As a control, 
a longer 5′ UTR (119 nt) of TRIM73 mRNA, which is not an oxidative phosphorylation gene 
product, did not confer higher luciferase activity on VACV-infected cells (Fig. 5-7C). These 
results suggested that short oxidative phosphorylation mRNA 5′ UTRs can be one mechanism 
that confers a translational advantage on VACV-infected cells.  
 To further test whether a shorter 5′ UTR may have a translational advantage in VACV-
infected cells, we generated another firefly luciferase reporter mRNA containing three tandem 
COX6A1 5′ UTR copies. The use of multiple 5′ UTR copies rather than a longer 5′ UTR from a 
different mRNA was to rule out the contribution of different sequence elements other than length 
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as much as possible. The mRNA with three 5′ UTR copies did not give VACV-infected cells a 
translational advantage over uninfected cells (Fig. 5-7D). Interestingly, the luciferase activity of 
the reporter with the tandem 5′ UTR copies was higher than that with one copy of the COX6A1 
5′- UTR in uninfected cells (data not shown), suggesting that the tandem 5′-UTR copies did not 
downregulate the translation of the reporter mRNA in uninfected cells. These experimental 
results, together with the global analysis, suggested that a short 5′ UTR could confer a 
translational advantage of oxidative phosphorylation mRNAs on VACV-infected cells during 
host shutoff. However, it is worth noting that various elements in a 5′ UTR can regulate mRNA 




Figure 5-7: Short 5′ UTRs of oxidative phosphorylation mRNAs can confer a translational 
advantage on VACV-infected cells. 
(A, B) Box plots of the lengths (A) and normalized MFE (B) of oxidative phosphorylation and 
whole cellular mRNAs. ***, P < 0.001 (Mann-Whitney U test). (C) Relative firefly luciferase 
activities of reporter mRNAs under the control of various oxidative phosphorylation mRNA 5′ 
UTRs in mock- and VACV-infected cells. Transfection was carried out at 2 hpi, and luciferase 
activity was measured at 7 hpi. The number following the gene name indicates the length of the 
5′ UTR. The firefly luciferase activity was normalized to a cotransfected Renilla luciferase 
mRNA (transfection control). For each reporter mRNA, the luciferase activity in mock-infected 
cells was normalized as 1. Each result is an average of at least three independent experiments. 
The error bars indicate the standard deviation. (D) Relative luciferase activities of firefly reporter 
mRNAs under the control of one copy or three tandem copies of the Cox6A1 5′ UTR in mock- 
and VACV-infected cells. The experiment was carried out as described for panel C. 
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 Discussion 
 VACV infection causes cellular mRNA degradation. This degradation occurs through a 
combined action of VACV-encoded decapping enzymes D9 and D10 and cellular nuclease 
XRN1 (23–25, 30). VACV infection also inhibits host cell transcription (31). Our analyses 
showed that mRNA depletion plays a major role during the VACV-induced host shutoff that 
results in similar reductions of ribosome-associated cellular mRNAs. The result is consistent 
with several previous studies that showed the cellular mRNAs are globally downregulated after 
poxvirus infections (22, 28, 38–40). However, this does not rule out the possibility that cellular 
mRNA translation is also suppressed during VACV infection. In fact, a recent study showed that 
the gene product of VACV open reading frame 169 (ORF169) suppresses general cellular 
protein translation (41). An important question is how some of the cellular mRNAs can escape 
from mRNA depletion and translational repression to maintain the integrity of infected cells at a 
level sufficient for viral replication. Since the cellular mRNAs and nascent cellular proteins are 
dramatically downregulated during VACV infection (4, 5, 22, 28), measurement of steady-state 
levels of mRNA and protein during VACV-induced host shutoff may not be able to sensitively 
identify those selectively expressed genes. Global TE analysis by simultaneous RNA-Seq and 
ribosome profiling provides a highly sensitive approach to the identification of selectively 
translated mRNAs during virus-induced host shutoff (11, 32). 
 Oxidative phosphorylation in the mitochondrion is the major source of cellular energy 
production in the form of ATP (42). Even in cancer cells or rapidly dividing cells, in which a 
larger portion of ATP is produced by substrate phosphorylation during glycolysis in the 
cytoplasm, oxidative phosphorylation is still a major source of ATP production (43). Like the 
replication of all other viruses, that of VACV depends entirely on host cells to provide energy. 
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Interestingly, in the context of a host shutoff, the oxygen consumption rate, an indicator of 
energy metabolism, increases in VACV-infected cells (35), which may require increased 
expression of proteins involved in oxidative phosphorylation through selective protein synthesis. 
In fact, our analysis of mRNAs with elevated TE identified oxidative phosphorylation as the 
primary and consistent target of translation upregulation during VACV infection. Experimental 
evidence further demonstrated that oxidative phosphorylation activity is important for VACV 
replication. Therefore, these data support a model in which oxidative phosphorylation mRNA 
translation is selectively upregulated to meet the energy expenditure when mRNA levels are 
reduced during a VACV-induced host shutoff. Our finding is in concert with the notion from 
several recent publications that VACV infection can reprogram the cellular metabolism to favor 
viral replication. A study by Fontaine et al. showed that VACV depends more on glutamine than 
on glucose for efficient replication (44). While it is possible to produce ATP energy through 
glycolysis by using glucose, a pathway that does not need oxidative phosphorylation, oxidative 
phosphorylation is required when using glutamine as cellular fuel. Studies by Mazzon et al. 
showed that VACV infection increases the synthesis of some precursors of cellular energy 
metabolism utilized in viral replication, which may also require an elevated oxidative 
phosphorylation capacity (45, 46). Interestingly, a study of protein abundance in VACV-infected 
cells by mass spectrometry showed that several oxidative phosphorylation proteins and proton-
transporting ATP synthase were among the overabundant proteins, supporting the conclusion of 
this study (47). 
 Mitochondrial functions are damaged in many viral infections. For example, herpes 
simplex virus 1 infection causes the degradation of host mitochondrial DNA (48), while 
enterovirus 71 and dengue virus infections cause an oxidative phosphorylation dysfunction in 
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infected cells (49, 50). On the one hand, the disruption of mitochondrial functions may help 
viruses to avoid eliciting innate immune responses. On the other hand, this impairment can hurt 
the energy production function of mitochondria, on which both viral replication and cellular 
survival depend. Impaired oxidative phosphorylation may be able to provide sufficient energy 
for some viruses. However, for viruses that need a large amount of energy, the impaired 
oxidative phosphorylation function could be a factor that restricts viral replication. VACV is a 
large DNA virus that has been annotated to encode >200 ORFs, with the potential to have an 
additional >500 nonclassical ORFs from our recent analysis of VACV mRNA translation (13, 
51). Protein translation is one of the most energy-consuming processes; it uses 30 to 40% of all 
cellular energy (52–54). Compared to many small viruses that encode only one or a few ORFs, 
translation of a large number of proteins at high levels may need an increased rate of energy 
production. In fact, it has been shown that the oxygen consumption rate increases during VACV 
infection (35). The increased ATP synthase activity observed in the present study suggests that at 
least part of the increased oxygen consumption contributed to the production of ATP, which is 
the usable cellular energy source. 
 We have, in fact, analyzed upstream ORFs (uORFs), internal ribosome entry site 
elements, and potential conserved sequences in the oxidative phosphorylation mRNA 5′ UTRs. 
However, we did not observe significant differences from overall cellular mRNAs. Rather, our 
analyses suggest that a short, less complex 5′ UTR is at least partially responsible for the 
translational upregulation of some oxidative phosphorylation mRNAs in VACV-infected cells. A 
short, less complex 5′ UTR in Drosophila is responsible for the higher TE of some oxidative 
phosphorylation mRNAs under the condition of dietary restriction (55). Interestingly, the lengths 
of the VACV 5′ UTRs are also short. The 5′ UTRs of early mRNAs vary from 3 to 601 nt, with a 
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median length of 21 nt, while the 5′ UTRs of intermediate and late mRNAs all have a poly(A) 
leader with a length of up to 51 nt (56, 57). As the poly(A) leaders are also short, less complex 5′ 
UTRs, it is possible that both the viral mRNAs and some of the host cellular mRNAs utilize this 
feature and some common factors for efficient protein synthesis during VACV-induced host 
shutoff. However, it is unlikely that a short 5′ UTR is the only mechanism employed to elevate 
the translation of oxidative phosphorylation mRNAs during VACV-induced host shutoff. Other 
sequence characteristics of 5′ UTRs, CDSs, or 3′ UTRs may contribute to the difference. In fact, 
the CDSs, 3′ UTRs, and full-length transcripts of oxidative phosphorylation mRNAs are also 
significantly shorter than total human cellular mRNAs (data not shown). These features may also 
affect other steps of mRNA translation, such as elongation. Again, VACV ORFs encode shorter 
CDSs than cellular ORFs (data not shown). The 3′ UTRs of VACV early mRNAs are generally 
short, while the 3′ UTRs of intermediate and late VACV mRNAs are heterogeneous (56–59). 
Again, the resemblance of short 5′ UTRs, CDSs, and full-length transcripts of VACV and 
oxidative phosphorylation mRNAs suggests that they may employ some common strategies for 
efficient translation during a VACV-induced host shutoff, though the advantages of a shorter 5′ 
UTR, CDS, or 3′ UTR may provide during this process remain elusive. 
 While this study showed translation upregulation as a mechanism to enhance oxidative 
phosphorylation capability during VACV infection, future studies will be devoted to further 
understanding the viral and cellular mechanisms involved in this process. Oxidative 
phosphorylation in mammals involves >100 genes encoded in both the nuclear and mitochondrial 
genomes. Translation of oxidative phosphorylation mRNAs occurs in both the cytoplasm and 
mitochondria by using two distinct translation systems. A recent study has suggested that 
translation in the two organelles is synchronized and that coordination is controlled and initiated 
182 
by cytosolic translation (60). The elevation of the relative TE of both mitochondrion- and 
nucleus-encoded oxidative phosphorylation mRNAs that occurs during VACV infection supports 
this notion. However, the translational control of oxidative phosphorylation mRNAs is complex 
and the mechanism that coordinates their translation in mammalian cells is largely unknown. It 
has been suggested that mTORC1 can selectively promote the translation of mitochondrion-
related mRNAs via inhibition of the eukaryotic translation initiation factor 4E-binding proteins 
(4E-BPs) (61). VACV infection can inhibit 4E-BP1 by stimulating the hyperphosphorylation of 
4E-BP1 (62). It is possible that inhibition of 4E-BP1 is partially responsible for the enhancement 
of oxidative phosphorylation mRNA translation during VACV infection. In addition, while this 
study addressed the role of protein synthesis in the host cell response to VACV infection, we do 
not exclude other posttranslational mechanisms, for example, protein stability regulation, in this 
process. 
 As host protein synthesis shutoff is caused by infections with many different viruses, 
selective protein synthesis through translational upregulation during virus-induced host shutoff 
may be a common mechanism to continuously translate proteins that are important for cells to 
survive for a period of time sufficient to support viral replication. In fact, while this report was 
under review, another study revealed that the mRNAs important in cell maintenance processes 
such as oxidative phosphorylation are less affected during influenza virus-induced host shutoff, 
and that is important for viral replication (63). Identification of these selectively translated 
proteins is important to elucidate the functional relevance of and mechanism involved during a 
virus-induced host shutoff. 
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 Materials and Methods 
Cell culture and virus infection. 
Suspension HeLa S3 (ATCC CCL2.2) cells were cultured in minimum essential medium (MEM) 
with spinner modification and 5% equine serum in a 5% CO2 atmosphere at 37°C. Infection of 
HeLa S3 cells was carried out as described elsewhere (28). Adhesion HeLa (ATCC CCL2) cells 
were cultured in Eagle's MEM supplemented with 10% fetal bovine serum. The VACV Western 
Reserve strain (ATCC VR-1354) and WRvFire expressing luciferase under the control of a 
VACV synthetic early/late promoter were gifts from Bernard Moss (64). Preparation, titration, 
and infection of VACV were performed as described previously (65). 
Antibodies and chemical inhibitors. 
Anti-MT-CO2, anti-MT-CO1, anti-SDHB, total oxidative phosphorylation human antibody 
cocktail, and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) antibodies were 
purchased from Abcam (Cambridge, MA). Anti-tubulin antibody was purchased from Santa 
Cruz Biotechnology (Dallas, TX). Anti-VACV serum was a gift from Bernard Moss. The 
oxidative phosphorylation inhibitors CCCP and antimycin A were purchased from Sigma-
Aldrich (St. Louis, MO). The VACV DNA replication inhibitor cytosine arabinoside (AraC) was 
also purchased from Sigma-Aldrich. 
Ribosome profiling and RNA-Seq. 
The experimental procedures for ribosome profiling and RNA-Seq were described previously 
(13). Briefly, ribosome profiling was carried out as described elsewhere, with minor 
modifications (10). VACV-infected (at a multiplicity of infection (MOI) of 10) and mock-
infected HeLa S3 cells pretreated with the translational inhibitor cycloheximide were lysed and 
treated with DNase (Thermo Fisher Scientific, MA), and the lysate was clarified. mRNA was 
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isolated from a portion of the lysate with oligo(dT) and fragmented with RNase III (New 
England BioLabs, MA). The mRNA fragments between 50 and 80 nt were extracted. The RPFs 
were separated by electrophoresis after the lysate was digested with RNase I (Thermo Fisher 
Scientific), the ribosomes were then isolated by sucrose cushion centrifugation, and the RPFs 
between 28 and 34 nt were isolated. The purified mRNA and RPFs were used to generate 
libraries for deep sequencing as described previously (10). The purified libraries were sequenced 
with a HiSeq 2000 system. 
Mapping, quantification, and differential gene expression analysis. 
The adaptors of RNA-Seq and ribosome profiling reads were trimmed with FASTX Toolkit 
(v0.0.13.2, fastx_clipper: -l 25 –n –v –Q33; fastx_trimmer: -f 1 –Q33). The tRNA and rRNA 
were removed by Bowtie (v1.0.1, -l 20) (66). The DNA reference sequences encoding tRNAs 
were obtained from the Genomic tRNA Database (http://gtrnadb2009.ucsc.edu/download.html) 
(67). The DNA reference sequences encoding rRNAs were obtained from iGenomes (Illumina, 
Inc., San Diego, CA). The reads were mapped to both the human genome (Ensembl, GRCh37) 
and the VACV genome (NC_006998.1) with Tophat (v2.0.11, –library-type fr-firststrand) (68). 
Raw counts of protein-encoding genes were quantified by HTSeq (v0.6.1p2) (69). Raw counts of 
the host genes and the VACV genes were combined, and RPKMs were calculated by edgeR (70). 
The raw read numbers were normalized to the effective library sizes of total reads of the host and 
VACV. Genes with mean RPKMs of <1 were not included for further analysis. The RPKMs of 
the host genes were used to calculate differentially expressed genes at both the mRNA and RPF 
levels by comparing expression levels in VACV-infected cells to those in mock-infected cells. P 
values from multiple testing were adjusted by the Benjamini-Hochberg procedure. Genes with an 
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adjusted P value of ≤0.05 and a ≥2-fold absolute logarithmic change value were identified as 
differentially expressed. 
Relative TE and GSEA.Relative TE was defined as the ratio of normalized RPF density to 
normalized mRNA density (17, 32). DTE was calculated as the ratio of TE under VACV-
infected conditions to TE under mock-infected conditions. Among genes with a mean log2 
RPKM of four related samples (mRNA and RPF from mock- and VACV-infected cells at each 
time point) larger than −1, those with a logarithmic DTE value of >1 were defined as 
translationally upregulated genes, and those with a logarithmic DTE value of less than −1 were 
defined as translationally downregulated genes. GSEA was carried out with the Bioconductor 
package piano (71). 
5′ UTR, 3′ UTR, CDS, and transcript length analysis. 
Sequences of protein-encoding transcripts were obtained from Gencode (v19, 
http://www.gencodegenes.org/releases/19.html). 5′ UTR, CDS, 3′ UTR, and transcript sequences 
were extracted from the aforementioned sequences, and only the longest isoforms were used for 
length and MFE analyses. MFE was calculated by the ViennaRNA package (v2.1.8), followed 
by normalization to sequence length. 
Western blotting. 
Cell lysates were denatured by heating, separated by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride membrane for 
Western blotting as described previously (72). 
RNA extraction and quantitative RT-PCR. 
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Total cellular RNA was prepared with TRIzol (Thermo Fisher Scientific, MA) according to the 
manufacturer's procedure. Total RNA (1 μg) was used for RT with a random hexamer. The 
reverse-transcribed products were used for quantitative PCR of specific genes. 
ATP synthase activity assay and ATP level determination. ATP synthase activity was measured 
with an ATP synthase enzyme activity microplate assay kit (Abcam). Briefly, samples of mock- 
or VACV-infected HeLa cells (MOI of 5) were collected at different times postinfection. ATP 
synthase from these samples was immunocaptured within the wells, and its enzyme activity was 
measured by determining the production of ADP, which is coupled with oxidation of NADH to 
NAD+ and monitored as a decrease in absorbance at 340 nm. ATP levels were measured with 
the ATP determination kit (Molecular Probes) by a bioluminescence assay with a recombinant 
firefly luciferase and its substrate luciferin in accordance with the manufacturer's protocol. 
Cell viability assay. 
HeLa cells were treated with chemicals or solvent vesicle at the concentrations indicated. The 
cells were then trypsinized and resuspended with DMEM after 24 h of treatment, the cell 
suspension was mixed with trypan blue at a ratio of 1:1, and cell viability was measured with a 
LUNA II automated cell counter. The data from at least three independent experiments were 
collected and averaged. 
In vitro transcription. 
RNAs were generated with the HiScribe T7 High Yield RNA synthesis kit (New England 
BioLabs). Briefly, template DNA containing the T7 promoter sequence, 5′ UTR, firefly or 
Renilla luciferase, and poly(A) tail coding sequences was generated by PCR. In vitro 
transcription and 5′ capping of the RNAs with methylated guanine were carried out in 
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accordance with the manufacturer's instructions. The resulting RNAs were purified with the 
PureLink RNA minikit (Thermo Fisher Scientific) and quantified for transfection. 
RNA transfection and luciferase activity measurement. 
Equal amounts of firefly luciferase reporter RNA were transfected into mock- or VACV-infected 
HeLa cells at 2 h after VACV infection with Lipofectamine 2000 (Thermo Fisher Scientific). 
Renilla luciferase reporter RNA was cotransfected as an internal control for experimental 
variation. Luciferase activity was measured at 7 h after VACV infection. A luminometer was 
used to measure luciferase activities with appropriate reporter assay reagents (Promega, WI) 
according to the manufacturer's instructions. Each result was an average of at least three 
independent experiments. 
Detection of newly synthesized proteins. 
Newly synthesized proteins were detected with the Click-iT AHA nascent protein kit (Thermo 
Fisher Scientific) combined with immunoprecipitation of the AHA-labeled proteins. Briefly, 
culture medium was replaced with methionine-free medium and incubated for 2 h. AHA was 
then added to the medium at 100 μM and incubated for 4 h to label nascent proteins. The cells 
were collected by centrifugation at 1,000 × g for 5 min and lysed with radioimmunoprecipitation 
assay lysis buffer at 4°C for 30 min. Cell lysates were collected by centrifugation at 12,000 × g 
for 10 min at 4°C, and the proteins in the supernatant were precipitated with methanol and 
chloroform and resolubilized in 50 mM Tris-Cl containing 1% SDS. A total of 200 μg of protein 
was subjected to click reaction for 30 min to label the AHA-containing peptides with alkyne-
biotin with the Click-iT Protein Reaction Buffer kit according to the manufacture's instructions. 
The proteins were then precipitated with methanol and chloroform and resolubilized in 50 mM 
Tris-Cl containing 1% SDS, and then an equal volume of 50 mM Tris-Cl containing 6% NP-40 
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was added. The AHA-labeled nascent proteins were precipitated with streptavidin beads, eluted, 
and detected with specific antibodies. 
Data availability. 
The sequencing data obtained in this study have been deposited at the National Center for 
Biotechnology Information Sequence Read Archive (accession no. SRP056975 and 
SRP093314). 
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Chapter 6 - Conclusion  
 The findings of this dissertation improved our understanding of selective cellular and 
viral protein synthesis during poxvirus-induced global inhibition of host protein synthesis. The 
results presented herein have aided in advancing our understanding of how certain cellular 
proteins are selectively synthesized, and the strategies that poxviruses have evolved to boost viral 
protein synthesis during poxvirus-induced host shutoff.  
 During infection, poxvirus makes host cells conducive for viral replication by inhibiting 
host cell cytopathic effect, altering cellular metabolism, and causing a host shutoff that is marked 
by global inhibition of host protein synthesis. Although this host shutoff may facilitate the 
reallocation of cellular resources for viral replication and the evasion of host antiviral immune 
responses, it poses a challenge to maintain viral replication if continuous synthesis of crucial 
cellular proteins and viral proteins is vital for the viral replication. However, it remains unclear 
whether and how certain cellular and viral proteins may be selectively synthesized during 
poxvirus-induced host shutoff. 
 Chapters 3, and 4 of this this dissertation present the strategy that VACV uses to boost 
viral protein synthesis during host shutoff. Through a literature review, we identified an 
unusually striking feature of all poxvirus mRNAs transcribed after viral DNA replication 
(post-replicative mRNAs) at the 5’-untranslated region (5’-UTR), which is known as the poly(A) 
leader. These 5'-poly(A) leaders are non-templated and of heterogeneous length, and their 
function during poxvirus infection remained a long-standing question. To dissect the role of the 
5’-poly(A) leader in mRNA translation during poxvirus infection, we developed an in-vitro 
transcribed RNA-based luciferase reporter assay (Chapter 2). The RNA-based luciferase 
reporter assay described here circumvents issues of plasmid replication in poxvirus-infected cells 
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and cryptic transcription from the plasmid. This protocol can be used to determine translation 
regulation by cis-elements in an mRNA including 5’-UTR and 3’-UTR in systems other than 
poxvirus-infected cells. Moreover, different modes of translation initiation such as cap-
dependent, cap-independent, re-initiation, and internal initiation can be investigated using this 
method. 
 Using in-vitro transcribed RNA-based luciferase reporter assay and other experiments, 
we determined that a 5’-poly(A) leader conferred a selective translational advantage to mRNA in 
poxvirus-infected cells (Chapter 3). A constitutive and uninterrupted 5’-poly(A) leader with 12 
residues was optimal. Since 5’-poly(A) leaders were frequently 8–12 residues in length, the 
result suggests that the poly(A) leader has been evolutionarily optimized to enhance poxvirus 
protein production. A 5’-poly(A) leader also could increase protein production in the 
bacteriophage T7 promoter-based expression system of VACV. Interestingly, although VACV 
post-replicative mRNAs do have 5’- methylated guanosine caps and can use cap-dependent 
translation, in vaccinia virus-infected cells, mRNA with a 5’-poly(A) leader could also be 
efficiently translated in cells with impaired cap-dependent translation. However, translation was 
not mediated through an IRES. These results point to a fundamental mechanism that poxvirus 
uses to efficiently translate its post-replicative mRNAs.  
 The 5'-poly(A) leader is present at the 5'UTR region associated with translation 
regulation, and poly(A) leader-mediated translational advantage does not depend on the status of 
the mRNA cap. This supports the notion that translation initiation factors may bind directly to 
5'-poly(A) leader of an mRNA to initiate translation, thereby critically influencing VACV 
post-replicative gene expression. We performed immunofluorescence assays to determine the 
trans-factors enriched in the virus factory, where viral post-replicative mRNAs translate and are 
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thus required for translational advantage. During VACV infection, poly(A) RNA sequence 
binding protein La-related protein 4 (LARP4)—unlike poly(A) binding protein (PABP)—is 
enriched in the virus factory (Chapter 4). A decrease in LARP4 protein level reduces VACV 
replication, blocks post-replicative protein expression, and decreases 5’poly(A) leader-mediated 
translational advantage. Further studies have suggested that LARP4 is crucial for the 
cap-dependent and cap-independent mode of translation from the 5’-Poly(A) leader. LARP4 
binding to the 5’-poly(A) leader is dispensable for mRNA stability during poxvirus infection. 
These results suggest that LARP4 by presumably binding to the 5'-poly(A) leader augments the 
post-replicative mRNA translation of VACV. 
 In Chapter 5 of this dissertation, we performed simultaneous RNA sequencing and 
ribosome profiling (quantifying genome-wide levels of mRNA and actively translating mRNA, 
respectively) to measure the host mRNA translation rate during a VACV-prototypic poxvirus-
induced host shutoff. This allowed us to analyze the responses of host cells to VACV infection at 
both the transcriptional and translational levels. The analyses showed that cellular mRNA 
depletion played a dominant role in the shutoff of host protein synthesis. Though the cellular 
mRNAs were significantly reduced, the relative translation efficiency of a subset of cellular 
mRNAs increased, particularly those involved in oxidative phosphorylation that are responsible 
for cellular energy production. Further experiments demonstrated that the protein levels and 
activities of oxidative phosphorylation increased during VACV infection, while the inhibition of 
cellular oxidative phosphorylation function significantly suppressed VACV replication. 
Moreover, the short 5' untranslated region and less complex secondary structure of the oxidative 
phosphorylation mRNAs contributed to translational upregulation. These results provide 
evidence of a mechanism that couples translational control and energy metabolism, which are 
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two processes that all viruses depend on host cells to offer in order to support VACV replication 
during host shutoff.  
 In this dissertation, we have addressed the major gap in understanding the fundamental 
gene expression mechanism of poxviruses during host shutoff. An improved understanding of 
this mechanism will help us design better poxvirus vectors to treat various infectious and non-
infectious disease such as cancers. Another, more significant impact will be in the poxvirus-
based vaccine field. Scientists have been using poxvirus-based vaccines since these can induce 
both innate and adaptive immunity, which has shown to have higher protection. The findings of 
this dissertation will aid in achieving higher and more efficient production of antigens that are 
difficult to express to elicit effective immune response and will help overcome this limiting 
factor for vaccine development. To address this limitation, our research has shown that having a 
5’-poly(A) leader in the 5’UTR of any foreign gene can significantly enhance protein production 
(antigen) using poxvirus as a vector. Furthermore, identification of the 5'-poly(A) leader binding 
protein required for translational advantage will facilitate in the development of new target for 
anti-poxviral therapy. Like other viruses, VACV exploits a pre-existing cellular translation 
mechanism, and identification of the poly(A) leader binding protein could lead to the discovery 
of unknown cellular translation mechanisms. Additionally, in poxvirus-based expression 
systems, the use of poly(A) leader upstream of any foreign gene followed by incorporation the 
poly(A) leader binding protein will make the expression system more self-sufficient. 
 Another important contribution in pursuit of determining the selectively synthesized 
cellular proteins during poxvirus-induced host shutoff, was revealing that proteins involved in 
oxidative phosphorylation were synthesized at the same or higher-level during shutoff. Since 
mRNAs for oxidative phosphorylation decreased over time during infection, translational 
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efficiency was higher from the low quantity of enduring mRNA-maintained protein level. 
Interestingly, our results suggest a mechanism hijacked by the virus to facilitate poxvirus 
replication during shutoff by enhancing energy metabolism via the coupling of translational 
control and energy metabolism—two processes that all viruses depend on host cells to provide.  
 Future studies will focus on determining the specific translation initiation factors 
required for 5'-poly(A) leader-mediated translational advantage and for translation from short 
5'UTR-bearing oxidative phosphorylation mRNAs during poxvirus infection. Since the poly(A) 
leader has a translation advantage during poxvirus infection, future studies will emphasize on 
identifying the viral or cellular protein/s required for poly(A) leader-mediated enhanced 
translation. We will also determine the roles that LARP4, RACK1, and decapping enzymes (D9 
and D10) play in the overall advantage from the poly(A) leader. All these avenues may lead to an 
unidentified translational mechanism that would contribute greatly to the existing knowledge on 
this important step of gene regulation at the mRNA translation level. 
 The summary of this dissertation that increased our understanding of the selectively 
synthesized cellular proteins and VACV post-replicative proteins during VACV-induced host 
protein synthesis shutoff is shown in Fig 6-1. 
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Figure 6-1: Selective protein synthesis during VACV-induced host shutoff 
During VACV-induced host shutoff, viral and specific cellular proteins are selectively 
synthesized to drive efficient viral replication. The viral post-replicative mRNAs use 
evolutionary optimized 5'-Poly(A) leader at the 5'-UTR region to mediate translation advantage 
to VACV post-replicative mRNAs. The 5'-poly(A) leader recruits RNA binding protein LARP4 
and potentially other initiation factors to mediate translation in both uninfected and VACV 
infected cells. During VACV infection, however, viral protein/s augments the translational 
initiation to provide translational advantage to 5'-poly(A) leader bearing VACV post-replicative 
mRNAs. The crucial cellular protein necessary for VACV replication are proteins encoding for 
different complexes of oxidative phosphorylation (OXPHOS). The mRNAs encoding for 
proteins of OXPHOS have shorter and less complex secondary structure bearing 5'-UTR that 
provides higher translation efficiency during VACV infection. These findings advanced our 
understanding on selectively synthesized proteins during poxvirus-induced host shutoff.  
 
  
 
 
